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ABSTRACT 
 
Human histidyl-tRNA synthetase (HARS) is an aminoacyl-tRNA synthetase 
(AARS) that catalyzes the attachment of the amino acid histidine to histidyl-tRNA 
(tRNAHis) in a two-step reaction that is essential for protein translation. Currently, two 
human diseases, Usher Syndrome IIIB (USH3B) and an inherited peripheral neuropathy, 
Charcot Marie Tooth Syndrome (CMT), have been linked genetically to single point 
mutations in the HARS gene. The recessive HARS USH3B mutation encodes an Y454S 
substitution localized at the interface between the anticodon-binding domain and the 
catalytic domain of the opposing subunit. Patients with Usher Syndrome IIIB lose their 
sight and hearing during their second decade of life, and clinicians have observed that the 
onset of deafness and blindness may be episodic and correlate with febrile illness. 
Furthermore, some young USH3B patients present with a fatal form of acute respiratory 
distress. In addition to the single HARS mutation linked to Usher Syndrome, eight other 
mutations in the HARS gene are associated with CMT, an inherited peripheral 
neuropathy. Peripheral neuropathies are associated with progressive and length-
dependent damage of the motor and sensory neurons that transmit information to the 
spinal cord. The age of onset and phenotypic severity of CMT linked to HARS is highly 
variable. When expressed in a yeast model system, the HARS variants are dominantly 
lethal, and confer defects in axonal guidance and locomotor deficiencies when expressed 
in C.elegans. Here, the biochemical characterization of the HARS USH3B and three 
peripheral neuropathy variants are described. The approaches included enzyme kinetic 
analysis with purified HARS enzymes to monitor catalytic deficiencies, differential 
scanning fluorimetry (DSF) to evaluate structural instability, and cellular models to detect 
physiological effects of axonal outgrowth by CMT variants. The results suggest that 
Usher Syndrome IIIB is unlikely to be a consequence of a simple loss of aminoacylation 
function, while HARS-linked peripheral neuropathy variants all share common catalytic 
defects in aminoacylation. The HARS system represents a notable example in which two 
different complex human diseases arise from distinct mutations in the same parent gene. 
By understanding the biochemical basis of these inherited mutations and their link to 
Usher Syndrome and CMT, it may be possible to develop mechanism-based therapies to 
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 CHAPTER 1: INTRODUCTION 
1.1 Histidyl-tRNA synthetase as a Class II Aminoacyl-tRNA synthetase  
Aminoacyl-tRNA synthetases (aaRS) are essential for protein synthesis, providing 
aminoacylated-tRNA for incorporation of amino acids into a growing polypeptide chain 
by the ribosome. Aminoacyl-tRNA synthetases are classified as ligases and use high energy 
ATP to catalyze the attachment of amino acids to cognate tRNA, a key reaction that 
contributes to the accuracy of protein synthesis. A typical animal cell contains 37 
cytoplasmic and mitochondrial synthetase genes, all of which are encoded on nuclear 
chromosomes. Mitochondrial synthetases are given the same name as cytosolic 
synthetases, appended with the numeral 2 (e.g. HARS and HARS2). Collectively, they 
ensure accurate and efficient protein synthesis under a broad range of conditions, in 
multiple cellular compartments.  
This family of enzymes has been partitioned into two classes, containing 10 
members, on the basis of sequence comparisons [1-3] [4]. Class I and class II enzymes 
differ mainly with respect to the topology of the catalytic fold and site of esterification on 
cognate tRNA [1]. Class I enzymes are, with the exception of TyrRS and TrpRS, 
principally monomeric, contain a Rossman fold catalytic domain, and aminoacylate the 2´ 
hydroxyl of the A76 of their cognate tRNAs during catalysis. Class II aaRSs typically form 
dimers or tetramers and have a catalytic domain composed of anti-parallel β-sheets and 
flanked by α-helices (residues 1-325). The class II enzymes couple the amino acid moiety 
to the 3´ hydroxyl of the tRNA’s terminal adenosine. The anticodon binding domain further 
divides the aaRS enzymes into three sub-classes a, b and c. Class IIa, distinguished by an 
N-terminal catalytic domain and C-terminal accessory domain (later shown to be the 
  2 
anticodon binding domain); class IIb, whose anticodon binding domain is located in the N-
terminal region; and class IIc, encompassing the tetrameric PheRS and GlyRS class II 
synthetases [5].  
In higher eukaryotes from flies to humans nine of the synthetases from both class I 
and class II assemble in to the Multi-synthetase complex (MSC). The MSC includes 
AspRS, ArgRS, MetRS, Glu-ProRS, GlnRS, IleRS, LeuRS, LysRS, and three auxiliary 
proteins p43, p38, and p18 to aid in assembly of the MSC [6].    
 
1.2 Structure of human Histidyl-tRNA Synthetase 
Figure 1.1 Human histidyl-tRNA synthetase APO dimer. 
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Histidyl tRNA Synthetase (HARS) is a 114 kDa homodimer (Figure 1.1) that 
belongs to the class II group of aaRS. The overall secondary structure of a HARS monomer 
consists of 20% beta strands/37% 𝛼 helices and is structurally classified as an α-β layered 
sandwich. Each 57 kDa monomer contains a N-terminal catalytic domain, an insertion 
domain, and a C-terminal anticodon binding domain (Figure 1.1). HARS also contains 
three class II conserved motifs (I, II, and III). 
The C-terminal anti-codon binding domain of HARS is shared with GARS, TARS, 
and PARS [7]. Eukaryotic HARS enzymes contain an additional 50 amino acid helix-turn-
helix domain called the WHEP domain. The WHEP domain is named after the first three 
aaRS enzymes that contain at least one or more copies of the domain within their structure 
tryptophanyl, histidyl, and glutamyl-prolyl tRNA synthetases (W, H, and EP) (Figure 1.2). 
Additionally, glycyl and methionyl-tRNA synthetase enzyme structures also contain a 
WHEP domain.  
 
Figure 1.2. NMR structure of human Histidyl-tRNA synthease WHEP domain.  
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Figure 1.3. Multiple species alignment of histidly-tRNA synthese with family 
conserved domains and motifs annotated. 
Stricly conserved residues are white highlighted in red, semi-conserved residues are red.  
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MOUSE                      G   I  P  E         GE      K  Y   D  G    LR   T    R   AVR V I F R   DT VF LKE L GKY  D  LI L  QG ELLS  YDL VPFA YLAQM EK FDV IRC K H AEV T T ... .S D K
WORM                       G   I  P  E         GE      K  Y   D  G    LR   T    R   ALR V V F R   DT VF LRD L GKY  E  LV L  QG ELLS  YDL VPFA YLAQS NS LQT TET N Y AET V M ... GG D Q
YEAST                      G   I  P  E         GE      K  Y   D  G    LR   T    R   VIR I L F K   DT VF LRE L GKY  D  LI L  QG EL S  YDL VPFA YVADM EA FST SGL K H GVT I A ... .S N E C
BACTERIA                    G   I  P  E         GE      K  Y   D  G    LR   T    R   AI I L    I     M   D LT  E  AG V IET WQR EGT KNVLGSY YSE RL V QTPLFKRAI VTDVVE E TFE RN S P G C AG
                                                                       .    PDB 4PHC  
          150       160       170       180       190       200        210  
HUMAN                 I    R   P    GR R F Q      G         E           L I        NMN LTNIKRY  AKVY RDN AMTR  Y E Y CDFDIA NFD MIPDA CL IM E LS   DF V V K... H P K C I S Q G L. K
MOUSE                 I    R   P    GR R F Q      G         E           L I        NMN LTNIKRY  AKVY RDN AMTR  Y E Y CDFDIA QFD MIPDA CL IM E LS   F V V K... H P K C I S Q GN L. K
WORM                  I    R   P    GR R F Q      G         E           L I        NMN ITNI RY  AKVY RDQ VMSR  Y E Y CDFDIA QYD MLPEA CL IV E LT   EF I L K... T Q L G D L K E G F. N
YEAST                 I    R   P    GR R F Q      G         E           L I        NMN IQSIKRY  AKVY RDQ AMTK   E Y CDFDVA TFE MVPD  CL IL E LT   DF I L N... H M S S S V G S G K K. K
BACTERIA               I    R   P    GR R F Q      G         E           L I        NQ R W  MF HE  QK  Y   EV  I A I L   E L L EHGLLYN EQ L Y GP R .. Q H LGC F LQGPD D. L M TARWWRA G S HVT E
                                                                            PDB 4PHC  
     220       230       240       250       260       270             280  
HUMAN       L                      KLD    E     M                                   R I DGMF I GV D R I S VD   K W EVK E EK E RIGD V LD R A C S SKF T C S VS N VG GLAP VAD Y QQ......HGGVS VEQ
MOUSE       L                      KLD    E     M                                   R I DGMF V GV D R I S VD   K W EVK E EK E RIGD V LD R A C P SKF T C S VS N VG GLAP VAD Y QQ......HGGVS VEQ
WORM        L                      KLD    E     M                                   R I EGMF V GI K I S VD   K W DV E EK E KLGE V LH L A S PAKDF T C S TP EQ IN FLTK QTG L RFRELNSDLNNLE LEK
YEAST       L                      KLD    E     M                                   R I DGIF I GV D R I S VD   K W VK E EK E KIGE V IH K Q A K EDV K S A SP A K TE GQSE TAD Y KLNGSLK.....E HAV
BACTERIA     L                      KLD    E     M                                    E D L Q E    D K  VSIGS A...RANYR ALVAF E HK .... C RR YTNPLR.................VLDSKNPE QAL
                                       TT     TT                            PDB 4PHC   
     290       300       310       320       330       340                  
HUMAN                         L                  L RGLDYY     E V                   L P L QN GL DL  YL L GI ISFD S A      TGVIY A LQD K S KQALE G KL FE T F DDK L LLQ..............TP
MOUSE                         L                  L RGLDYY     E V                   L P L QN GL DL  YL L GI ISFD S A      TGVIY A LQD K S KQAVE G KL FE I F DDK L LLQ..............MP
WORM                          L                  L RGLDYY     E V                   M P L QN GA EL  YL V GV V YE S A      TGAIY A SQL D G DKFKK E KV IE N D T.T R P APKALEGT......AVENS
YEAST                         L                  L RGLDYY     E V                   L I SN GL DI  Y A I ISFD S A      TGLIY V SADAN T EKAKQ D AT MK TE FD DSF L TSASAPPENASELKKKAKS
BACTERIA                       L                  L RGLDYY     E V                   L P L  L GI T  V      N VF  NDA A GDYL.DEESREHFAG CKL ESA A..Y VNQR RT W TNS................
                                                                            PDB 4PHC   
   350       360       370           380       390       400       410      
HUMAN             G   AGGRYD LV              P  G   G ER                            LGV SVA      G  MF K V CV LS  V  IF IV R IR T T V VAAQAGEEP G DP.... GRK I S EQ LEALEEK T E Q L SA
MOUSE             G   AGGRYD LV              P  G   G ER                            LGV SIA      G  MF K V CV LS  V  IF IV R VR T T V VATQAGEEP G DP.... GRK I S EQ LEASEEK T E Q L SA
WORM              G   AGGRYD LV              P  G   G ER                            VGV SVA      G  MF K V C  VS  I  LF IM R IR T T V VAEDTAGQP K DS.... A.N C F A EA QK...VA T Q E Y SA
YEAST             G   AGGRYD LV              P  G   G ER                            VGV SIA        MF K I CV IS  V  IF LI R IK T T V VMAEDASEF N N SEASGK STQ F S KQ INSS.TT P A Q F AF
BACTERIA           G   AGGRYD LV              P  G   G ER                             TV       G   V  L  L LV A I LV......LGSQ C EQLG......GRAT A FAM VL QAVNPEF..K DP.VVD Y AS
                                                                      TTT   PDB 4PHC   
      420       430        440       450       460       470       480      
HUMAN                      L                    Q               G  E   G            Q L ERLKLV  DAGI ELL K P  E GI LVAII EQ L D IKLR V S E..... KKL E SE W K.A Y KN KLLN LQYC EA P K V S T R E
MOUSE                      L                    Q               G  E   G            Q L ERLKLV  DAGI ELL K P  E GI LVAII EQ L D IKLR V S E..... KKL E SE W K.A Y KN KLLN LQYC EA P K V S A R E
WORM                       L                    Q               G  E   G            Q V DR KLV  AGI EMA K P  E I LAIVI EQ L D VKLR V T D..... KNL R K KM RS K.T L AN KLLT FQYA ERR P K V N V R E
YEAST                      L                    Q               G  E   G            L ERMKV  DAGI E V K  E G IAVIL  E LRVK L QGGGKDWTGY P TKQ W E.A Y Y AKANPRK FDAA KA CH KE YL K R G EFA
BACTERIA                    L                    Q               G  E   G            Q M LA  D M H G  D GA VAVVL ES V  A VK L S EGADT. SA....A A ER R ELPGVKL TN GG NFKK FARA KW R AN T V D R G Q
....                                                                        PDB 4PHC   
     490       500                                                       
HUMAN         V  E LV  IK                                                           ....VD RR D  EE  RRTGQPLCIC...........
MOUSE         V  E LV  IR                                                           ....VD RR D  EE  RRTNQPLSTC...........
WORM          I  D LI  VR                                                           ....QT KL Q  TA  DTLAAL...............
YEAST         V    IV  V                                                            DDDGEL SAAD  PI QEKLSQIHEDGLNEVTRLIKGL
BACTERIA          D VA  LR                                                           TAVAQ.... S  AH  TLLG.................
α1 β1 β2 α2 η1 β3 α3 
β4 β5 α4 β6 
α5 η2 α6 η3 α7 α8 β7 α9 
η4 α10 η5 β8 β9 
β10 α11 β11 α12 β12 
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Human HARS has three unique structural elements that are found across all species of 
HARS enzymes: HisA, HisB motifs, and the insertion domain (Figure 1.3). These motifs 
and domains play a role in catalytic activity of HARS and will be discussed in detail 
throughout this introduction. 
The first crystal structures of E.coli HARS complexed with ATP, AMP, histidine, 
histidinol, histidyladenylate (HAM), and 5’-O-[(L-histidinylamino)sulfonyl] adenosine 
provided structural insight of active site residues involved in substrate specificity and 
catalysis. Most recently tRNAHis bound to bacterial Thermus thermophilus HARS was 
crystallized [8]. 
The first crystal structures for eukaryotic Trypanosomal brucei and Trypanosomal 
cruzi HARS highlighted a key difference between eukaryotic and prokaryotic HARS [9] 
in the insertion domain. In eukaryotes the insertion domain is much larger than what is 
observed in the bacterial HARS structures [9]. To date there are four deposited crystal 
structures of human HARS in the Protein Data Bank (PDB) not including two NMR 
structures of the isolated WHEP domain and HARS splice variant. However, the only 
substrate bound to the human HARS enzyme to date is histidine [10]. While, not as many 
human HARS:substrate complexes have been resolved, many of the key residues 
previously identified for bacterial HARS enzymes are conserved in human (Table 1.1). 
Therefore some basic aspects and chemistry in the HARS active site can be inferred from 
what is known about E.coli HARS. These structural elements and residues are essential in 
assisting the two step mechanism carried out to aminoacylate tRNAHis with high fidelity. 
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Table 1.1: Amino acid residues involved in substrate specificity and 
binding  
















   
Arg9 Lys60 




1.2.1 Histidine Binding Pocket  
Histidine binding prepares HARS for catalysis via an induced-fit model [11]. These 
conformational changes in the active site of HARS are initiated by the histidine binding 
pocket composed of highly conserved residues found in distinct sequences motifs. First, 
the LV/AAGGGLDYY loop (or HisA Loop) forms one wall of the binding pocket. This 
HisA loop is highly conserved and extends over a part of the active site [12]. Second, the 
glycine-rich β-strand (sequence AGGRYDGL preceding motif III) comprises the histidine 
binding pocket floor and wall.  
Histidine forms hydrogen bonds (H-bonds) with eight amino acids residues within 
the binding pocket (Figure 1.4) of the human HARS enzyme. The Asp 177 and Tyr331 
residues form H-bonds with the Nδ and Nε of the imidazole ring, respectively [10]. The 
nature of these interactions are conserved in E.coli HARS as Glu131 (motif II) and Tyr264 
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[12]. The α-amino functional group of histidine forms H-bonds with the side chains of 
Asp130, Thr132, and Tyr330 while the α-carbonyl functional group forms hydrogen bonds 
with Arg157, Gln173 and Arg326. In the E.coli structure conserved side chains that make 
direct contact with histidine are Glu83 and Gln127 (motif II), which contact the α-amino 
and α-carbonyl functional groups [12].  
 
Figure 1.4. Human HARS histidine binding. 
Active site residues that are essential for histidine binding are shown as yellow sticks 
while the substrate histidine is shown as gray sticks. Hydrogen bond and electrostatic 
interactions are shown as black dotted lines.  
  
1.2.2. ATP Cofactor Binding  
Many interactions are required to prepare adenosine triphosphate (ATP) for attack 
by a bound histidine molecule and encourage the magnesium pyrophosphate moiety to act 
as a leaving group. Bound ATP in the active site of E.coli HARS forms a “fishhook” 
conformation that is evidently unique to class II aaRS [13]. Interestingly, these residues 
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are seemingly pre-positioned upon large structural rearrangements made by histidine 
binding [9]. Residues in the β strands and the loop portion of motif 2 are important in ATP 
contacts for HARS [14]. Generally, residues involved in ATP binding are among the most 
highly conserved in the HARS family and for the most part shared by all members in class 
II. In the E.coli HARS structure the π-stacking interaction between the adenine ring of ATP 
and Phe125 provides specificity in the binding of ATP. The recognition of the N6 amino 
group of ATP involves the main chain carbonyl of Tyr122. The ATP ribose 2’ OH forms 
an additional contact with HARS by hydrogen bonding with the main chain carbonyl of 
Thr281. There are four arginine residues that mediate interactions with the triphosphate 
group of ATP. First, the conserved Arg113 forms a bridging interaction with the α and β 
phosphates of ATP in the crystal structure of E.coli HARS complexed with histidinol [14]. 
Also, the γ phosphate forms salt bridges with conserved Arg121 and Arg311 in a complex 
with ATP. However, when HARS is complexed with the adenylate, the Arg121 and 
Arg311 interactions are absent and adopt different conformations [14, 15]. Furthermore, 
Glu115 also assists in the stabilization of the triphosphate group of ATP in a position such 
that it points back towards the adenine base. The α phosphate of ATP interacts with 
conserved residue Arg113. The β and γ phosphates are neutralized by two coordinated 
magnesium ions that are positioned by water molecules and conserved Glu115 [12]. The γ 
phosphate also forms interactions with conserved Arg121 and Arg311. 
While to date there is currently no human HARS structure bound to ATP, key 
residues are highly conserved (Figure 1.3 and Table 1.1). Modeling the structural alignment 
of human HARS bound to histidine with the E.coli ATP bound structure reveals that many 
of these interactions are preserved (Figure 1.5).   
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Figure 1.5. Alignment of E.coli and human amino acid active site residues involved 
in histidyl-adenylate binding.   
Modeling human residues critical for ATP and adenylate binding. Residues identified as 
essential for adenylation recognition from the E.coli structure are shown as green sticks 
while identical residues in human are shown as blue sticks. Histidyl-adenylate from the 
E.coli structure is shown as gray sticks. 
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1.2.3 Histidyl-tRNA Recognition  
Accuracy of protein synthesis is dependent upon the ability of aaRS enzymes to 
specifically recognize identity elements of cognate tRNA molecules. These nucleotides are 
primarily concentrated in the anticodon region and acceptor stems and provide functional 
groups that can be recognized by specific amino acid side chains of the aaRS enzymes [16, 
17]. tRNA identity and recognition can emerge from the presence of modified bases such 
as those commonly seen in the dihydrourdine (D-arm) of tRNA molecules, or from less 
common modifications such as C5-methylation of uracil [18]. Key identity elements for 
E.coli HARS recognition of histidyl-tRNA (tRNAHis), primarily concentrated in the 
acceptor stem, include an additional 5’ guanosine residue at the -1 position (G-1) and its 
monophosphate, the G-1:C73 base pair, and the GUG anticodon. Mutations of these E.coli 
tRNAHis identity elements diminishe aminoacylation in vitro [19-21] while inclusion of 
these acceptor stem identity elements on micro helices confer recognition by E.coli and 
yeast HARS [22-24]. The G-1 base is unique to tRNAHis and a critical identity element that 
is present in Bacteria, Eukarya, and Archaea, with few exceptions. The G-1 base can be 
either encoded in the tRNAHis gene for most Bacteria and Archea [25, 26] but in Eukarya 
is added post-transcriptionally upon 5’ end processing by the enzyme, tRNAHis 
guanylyltransferase (Thg1)[27]. Additionally, the 5’ monophosphate of E.coli tRNAHis G-
1 is also important in recognition and aminoacylation by HARS [19, 20].  
The prokaryotic discriminator base C73 diverges in eukaryotes to form a non-
Watson-Crick base pair G-1:A73 (Figure 1.6). Substitutions of this base pair impaired 
recognition by eukaryotic yeast HARS, although the base requirements at this position 
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were less stringent for yeast compared with E.coli [28]. Additionally, a RNA 
methyltransferase Bicoid-interacting protein 3 (BCDIN3) was shown to specifically bind 
cytoplasmic tRNAHis and monomethylate the G-1 monophosphate in vivo and in vitro [29]. 
The 5’G -1 monomethylation of cytoplasmic tRNAHis by BCDIN3 molecules was shown 
to increase stability while not disrupting aminoacylation.  
Previously, E.coli family conserved HARS residues involved in discriminator base 
G-1:C73 tRNAHis recognition included motif loop 2 residues Arg123, Arg116, and Gln118. 
A substitution of Arg123 as a putative contact to the 5’phosphate produced a 200-fold 
decrease in aminoacyl-transfer [30]. Similar kinetic defects in aminoacyl-transfer were also 
observed for Arg116 and Gln118 [30]. Consistent with their role in selectivity of tRNAHis 
residues, these are moderately conserved in the human HARS structure (Table 1.1). 
Interestingly, eukaryotic A73 tRNAHis recognition by yeast HARS relies on a specific tri-
peptide sequence (Ala-Thr-Met) located in motif loop 2 [31]. 
 
Figure 1.6: Cloverleaf representation of E.coli and human tRNAHis molecules.  
Clover leaf structure of E.coli and human histidyl tRNA. Key recognition elements are 
shown in red. 
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Recent crystal structures of Thermus thermophilus HARS-tRNA complexes have 
illuminated the conformational changes necessary to accommodate tRNAHis upon binding 
[8]. Only slight structural changes occur throughout the protein with tRNAHis binding 
(Figure 1.7) and are primarily limited to the insertion domain [8]. Interestingly, the 
anticodon of the tRNA molecule becomes more flexible upon HARS binding.   
 
 
Figure 1.7. Structural model of tRNAHis binding of HARS. 
Thermus thermophilus HARS-tRNAHis complex is aligned to human HARS-histidine 
bound complex. Human HARS is shown as a yellow cartoon with histidine in green 
spheres. T. Thermophilus cartoon structure is shown in purple with tRNAHis as gray 
sticks. 
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1.2.4 A Role for Coordinated Metal Ions  
HisRS requires two magnesium ions to carry out catalysis. Arnez et al. defined the 
locations of magnesium ions by taking a crystal of HisRS:histidinol:ATP complex and 
soaking it in manganese(II) chloride (MnCl2). These data showed that two Mn2+ ions 
coordinate the β and γ phosphates of ATP. The β and γ phosphates of ATP are neutralized 
by two coordinated magnesium ions that are positioned by water molecules and conserved 
Glu115. Weak electron density, consistent with a bound Mg2+ ion, was observed in an 
electron density map for the HisRS:histidinol:ATP complex [14]. This particular Mg2+ ion 
coordinates the β and γ phosphates of ATP. Furthermore, interatomic distances between 
the Mn2+ principal ion and the β phosphate oxygen is approximately 0.5 Å, which would 
be expected to contribute to catalysis by weakening the bond between the α and β 
phosphates of ATP. In similar manganese soaking experiments with class IIa, Seryl-tRNA 
synthetase (SerRS), the principal metal ion was shown to coordinate the α and β phosphates 
[32]. The functional role for the metal ion coordination between the α and β phosphates for 
SerRS is a metal-catalyzed mechanism for the adenylation reaction. Arg259 in the 
HisRS:ATP complex resides in the position occupied by the metal catalyst Mg2+ in class 
IIa SerRS. However, Arg259 and Arg113 serving in place of a Mg2+ ion is unique to HisRS 
compared to other class II aaRS. Other class II aaRS enzymes have conserved carboxylate 
groups to assist coordination of metal ions to carry out catalysis, while HisRS has in place 
residues Glu270 and Thr281 that have poor geometry for metal coordination but participate 
in the arginine salt bridge switch [14]. 
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1.3 Function of Histidyl-tRNA Synthetase 
As HARS is a class II aaRS enzyme it attaches the amino acid histidine to the 3’OH 
of the terminal ribose of tRNAHis [12]. HARS catalyzes the transfer of histidine to a 
histidine transfer RNA molecule (tRNAHis) in a two-step reaction: 𝐻𝐴𝑅𝑆 + 𝐴𝑇𝑃 + 𝐻𝑖𝑠	 ⇌ 𝐻𝐴𝑅𝑆 ∙ 𝐴𝑀𝑃 − 𝐻𝑖𝑠 + 𝑃𝑃𝑖   (1) 𝐻𝐴𝑅𝑆 ∙ 𝐴𝑀𝑃~𝐻𝑖𝑠 + 𝑡𝑅𝑁𝐴345 ⇌ 𝐻𝑖𝑠~𝑡𝑅𝑁𝐴345 + 𝐴𝑀𝑃 (2) 
This two-step mechanism is facilitated by critical residues in the active site of 
HARS, many of which are also involved in substrate binding as described above. However, 
the mechanistic role of active site residues was judiciously evaluated by our group and is 
described below.   
 
1.3.1 Electrophilic Catalysis is Required to Facilitate HARS Amino Acid 
Activation Reaction  
The adenylation reaction requires both histidine and ATP binding to the HARS 
active site and involves a highly conserved residue Arg259. This HARS family arginine is 
not present in other aaRS class II enzymes and takes part in the adenylation reaction. 
Utilizing Arg259 for catalysis is unique to HARS, as other class II aaRS enzymes 
AspRS[33] and SerRS[32] use a divalent magnesium metal ion to coordinate the α-
phosphate of ATP and serve as an electrophilic catalyst. Arg259 is positioned on the HisA 
loop to fix the α-carboxylate group of the histidine substrate as the attacking nucleophile 
by supporting amino acid residues within the active site [34]. The ηN of the guanidinium 
group of Arg259 is positioned approximately 3Å from the α-phosphate of ATP while the 
ηN hydrogen bonds with phenolic group of Tyr264. Thus, stabilization by Tyr264 enhances 
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substrate binding allowing for the formation of a hydrogen bond to the δN of the histidine 
[12]. In the HARS:histidinol complex a water-mediated interaction exists between Glu270 
and εN of Arg259. However, in the HARS:adenylate complex Glu270 moves to form a salt 
bridge with the guanidinium group excluding the water molecule. This movement serves 
as a salt bridge switch that weakens the ionic interaction between Arg259 and the α-
phosphate [14] and stabilizes adenylate formation in the active site. Arg113 as well as 
Arg259 are arranged to interact with α-phosphate of the histidyl-adenylate intermediate 
which stabilizes negative charge developed on the non-bridging oxygens α-phosphate 
during the transition state [12]. Evidence for Arg259 as a critical residue in catalysis is 
further supported by mutational studies where a two or three log decrease in activity is 
observed when Arg259 is substituted with histidine [14] or other amino acids [35].  
 
1.3.2 HARS Aminoacylation Reaction involves Substrate Assisted Catalysis  
Once the histidyl-adenylate is formed, the second reaction carried out by HARS, 
aminoacylation, requires the decomposition of a mixed anhydride (the histidyl-adenylate) 
to form an aminoacyl ester on the 3’OH of tRNAHis. While Glu83 in the active site is in a 
favorable location to function as a base it is also poised to neutralize the α-amino group of 
the histidine substrate. Mutational analysis of Glu83 [36] suggests that it does not act as a 
base but forms a salt bridge with the α-amino group of histidine, neutralizing the charge, 
and satisfying a critical electrostatic interaction.  
The HARS mechanism for transfer of the aminoacyl-adenylate intermediate onto 
its cognate tRNAHis is described as substrate assisted catalysis (SAC). During the substrate 
assisted catalysis bond formation between the 3’OH of tRNAHis and the α-carboxylate 
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carbon of the aminoacyl-adenylate occurs prior to the cleavage of the bond joining the α-
carboxylate carbon to the axial oxygen of the α-phosphate. In the SAC mechanism the pro-
S non-bridging oxygen acts as the base to abstract a proton from the 3' hydroxyl of the A76 
ribose on the histidyl-tRNA [36]. Then the A76 3’oxygen facilitates a nucleophilic attack 
on the carboxyl carbon of the histidyl-adenylate and breaks the mixed anhydride to release 
AMP.  
 
1.3.3 Alternating Site Catalysis Model  
As E.coli HARS is a dimer the active site of one monomer has the potential to affect 
catalytic events in the second. A model to explain the coordination of catalysis between 
the two active sites of the HARS dimer has been described by Guth and Francklyn in 2007 
as “Alternating Site Catalysis”[30]. In this model histidine and ATP bind to one active site 
of the dimer to form the histidyl-adenylate intermediate. Following adenylate formation, 
tRNAHis will then bind to this same subunit. A single round of aminoacyl transfer takes 
place in this active site, producing a “primed complex” with one aminoacylated tRNAHis 
per dimer. Instead of disassociating from the HARS dimer the aminoacylated tRNAHis 
molecule remains bound while histidine and cofactor ATP are recruited into the second 
active site. The second active site will form the histidyl-adenylate and recruit another 
tRNAHis molecule. Finally, the aminoacylated tRNAHis from site one is released while the 
catalytic transfer of histidine onto tRNAHis occurs in the second site. Evidence for this 
model include single turnover and stoichiometry studies that have indicated that one mole 
of adenylate is formed per active site and adenylate production is influenced by the 
presence of tRNAHis [30, 36]. Generating a fluorescent version of E.coli HARS enabled 
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detection of the adenylation reaction in real time [37]. These assays demonstrated that the 
rates in the active sites are also different and defined by a double exponential [37].  
1.3.4 Evolutionary Conservation and Structural Homology  
During the course of evolution, the catalytic domain is the most preserved between 
prokaryotic and eukaryotic HARS enzymes. Overall the sequence homology shared 
between prokaryotic, E.coli, HARS and eukaryotic, S.cerevisiae, HARS is only 28.5% in 
the catalytic domain, encompassing 235 residues [14]. However, overall sequence 
homology shared between eukaryotic and prokaryotic C-terminal anticodon binding 
domain is minimal but they share a conserved GExExxxG motif in the C-terminal domain. 
The eukaryotic HARS enzymes share much greater overall sequence homology, for 
example S.cerevisiae and H.sapiens HARS have 43.5% shared sequence homology. 
However, while both the human and trypanosomal HARS sequences are part of the same 
eukaryotic branch on the phylogenetic tree [38] there is less than 30% sequence identity 
shared between them. Similarly, the sequence identity between trypanosomal HARS and 
bacterial HARS is less than 30% [9].  
The evolutionary addition of the appended WHEP domain occurred at the time of 
insects. This helix-turn helix structure is found in five other aaRS enzymes. The WHEP 
domain facilitates noncanonical function of glutamyl-prolyl-tRNA synthetase (EPRS) [39] 
and mediates protein complex formation for other aaRS enzymes [40]. For HARS the 
WHEP domain supports aminoacylation function [41]. Additionally, a short sequence of 
the WHEP domain is an epitope for Jo-1 anti-synthetase antibodies [42]. While the WHEP 
domain mediates noncanonical activities of the EPRS complex, a similar role for HARS is 
not known.    
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1.4 Non-canonical function of aminoacyl-tRNA synthetases 
It is now appreciated that many of the aaRS enzymes have evolved to perform 
secondary non-canonical functions (Table 1.2). Known “moonlighting” activities of aaRS 
enzymes include; cytokine activity, regulation of inflammatory response, cell migration, 
pro and anti-angiogenic activity, and even transcriptional regulation [43]. aaRS enzymes 
that have moonlighting activities include EPRS, Tyrosyl-tRNA synthetase (YARS), 
tryptophanyl-tRNA synthetase (WARS), SARS and TARS [43, 44].  
Table 1.2: Non-canonical functions of aminoacyl-tRNA synthetases  
 
Methionyl-tRNA synthetase (MARS) after UV exposure can globally reduce 
translation[54]. This noncanonical function is mediated by a phosphorylation on MARS 
that reduces the affinity for tRNAiMet, thereby reducing available initiator methionyl-












of inflammatory mRNAs [45] 
MARS 




SARS Repress translation and inhibits angiogenesis [47] 




and immune cell 
migration 
[49] 
GARS Anti-tumorigenic [50] 






KARS Transcriptional control and pro-migratory   [53] 
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is observed by EPRS[55]. EPRS is a bifunctional enzyme with the two aaRS active sites 
linked in function by a WHEP domain and attaches both glutamate and proline to the 
respective tRNA molecules (linked by a WHEP domain). As a resident MSC protein, EPRS 
is released by phosphorylation to form the GAIT (gamma interferon activated inhibition of 
translation) complex after stimulation with interferon (IFN)-g in myeloid cells [56]. It 
subsequently binds the 3’-UTRs of select mRNAs to repress translation and production of 
toxic proteins during the immune response, after acute inflammation[57]. 
Furthermore, SARS, YARS, WARS, and TARS all have secondary functions that 
are thought to regulate blood vessel growth and development[58]. SARS is capable of 
regulating transcription of VEGF-A during vascular development by translocating into the 
nucleus [47]. There is published evidence to indicate that the non-canonical functions of 
YARS, WARS and TARS in regulating blood vascular biology are mediated 
extracellularly. YARS is secreted and cleaved by extracellular polymorphonuclear 
leukocyte (PMN) elastase to form two fragments that have cytokine activity and pro-
angiogenic properties [49] [59]. Extracellular fragments of WARS have an anti-angiogenic 
effect inhibiting both proliferation and migration of endothelial cells [52]. TARS pro-
angiogenic properties are also mediated extracellularly and its catalytic activity is likely 
necessary for this activity [51, 60].  
Glycyl-tRNA synthetase (GARS) is yet another example of another synthetase that 
when secreted has non-canonical functions. GARS can reduce tumor growth in a mouse 
model in vivo via inhibition of ERK and induction of apoptosis [50]. This non-canonical 
function of GARS is thought to be mediated by intracellular ERK signaling.   
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To date the only identified non-canonical function of HARS is its cytokine activity 
associated with the autoimmune disease idiopathic inflammatory myositis. The WHEP 
domain of HARS serves as the epitope for the auto antibody anti-Jo-1 as the precipitating 
factor of the disease. Interestingly, transcript analysis from skeletal muscle biopsies have 
revealed evidence for two splice variants [61, 62]. One splice variant completely lacks the 
core catalytic domain linking the WHEP and C-terminal anticodon binding domain[61], 
while the second splice variant entails only the WHEP domain (Figure 1.8) [62]. 
Consequently, anti-Jo-1 antibodies cross react with both HARS splice variants. Of note, a 
pharmaceutical company ATyr currently utilizes HARS as a therapeutic for limb griddle 
muscular dystrophy [63]. However, the mechanism of secretion from skeletal muscle tissue 
and biological function of extracellular HARS splice variants remain unknown. 
Figure 1.8. Human HARS splice variant.  
HARS splice variant shown as cartoon model completely lacks the core catalytic domain. 
A disordered linker connects the WHEP domain to the anti-codon binding domain. 
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1.5 Link between aminoacyl-tRNA synthetases and neurobiological disease 
Currently, pathological mutations associated with human diseases have been 
identified in genes that encode both cytoplasmic and mitochondrial aaRS enzymes. The 
first of these was mitochondrial DARS2 gene, which encodes mitochondrial aspartyl-
tRNA synthetase [64] while the first cytoplasmic ARS mutation associated with a human 
disease, Charcot Marie Tooth (CMT), was discovered in GARS [65]. 
Interestingly mutations in GARS and other aaRS genes can specifically affect the 
central, sensorineural, and peripheral nervous system (Table 1.3). To date, pathological 
mutations in ten of the genes encoding mt-ARSs [66] have been identified. Of the known 
pathological aaRS mutations, many have shared characteristics but some also lead to tissue 
specific phenotypes (Table 1.3). 
1.5.1 Aminoacyl-tRNA synthetases and central nervous system diseases  
There are few reports linking aaRSs to central nervous system diseases, which often 
affect specific brain regions. The autosomal recessive monogenetic disease 
Leukoencephalopathy with Brain stem and Spinal cord involvement and elevated Lactate 
(LBSL) represents the first well-characterized CNS disease associated with an aaRS. 
Genetic analysis of some 30 different families helped link the disease to mutations in the 
DARS2 gene encoding mitochondrial AspRS [64]. Hallmarks of the disease defined by 
MRI imaging include abnormalities of the white matter in the cerebellum, spinal cord, and 
brainstem. While the mutant substitutions in LBSL are predicted to impair dimer formation 
and decrease DARS2 catalytic function, mitochondrial respiratory chain complex activity 
in these LBSL patients was normal [64].  
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Table 1.3: Aminoacyl-tRNA Synthetases associated with neurological 
diseases 
 
Mutations in the DARS gene encoding cytoplasmic AspRS were also identified in 
patients with hypomyelination with brain stem and spinal cord involvement and leg 
spasticity (HBSL), an inherited white matter disease [67]. These DARS coding changes 
may affect enzyme activity by either disrupting tRNA binding or reducing protein 
  
 
Table abbreviations:  NC- not confirmed   ONA-OMIM not assigned   Na-not applicable Charcot-Marie-
Tooth disease (CMT), distal spinal muscular atrophy type V (dSMA-V), autosomal recessive non-
syndromic hearing impairment (ARNHI), Brain stem and Spinal cord involvement and elevated Lactate 
(LBSL), leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL), 
hypomyelination with brain stem and spinal cord involvement and leg spasticity (HBSL), pontocerebellar 






Location of Mutation(s) 
in Protein Structure Phenotype Reference 
KARS_601421 613641 Anti-codon binding domain Active site CMTRIB 
(McLaughlin, Sakaguchi 
et al. 2010) 
GARS_600287 601472 600794 Dimer interface 
CMT2D 
DHMN5A 
(Antonellis, Ellsworth et 
al. 2003) 
AARS_601065 613287 Editing domain CMT2N (Latour, Thauvin-Robinet et al. 2010) 
YARS_603623 608323 Catalytic domain DI-CMTC (Jordanova, Irobi et al. 2006) 
HARS_142810 NC* Dimer interface CMT (Vester, Velez-Ruiz et al. 2013) 
HARS2_600783 614926 Catalytic domain Perrault Syndrome (Pierce, Chisholm et al. 2011) 
LARS2_604544 615300 Catalytic domain C-terminal domain Perrault Syndrome 
(Pierce, Gersak et al. 
2013) 
HARS_142810 614504 Anti-codon binding domain Usher Syndrome IIIB (Puffenberger, Jinks et al. 2012) 
KARS_601421 613916 Anti-codon binding domain NSHL (Santos-Cortez, Lee et al. 2013) 
DARS_603084 615281 Catalytic domain HBSL (Taft, Vanderver et al. 2013) 
DARS2_610956 611105 Multiple LBSL (Scheper, van der Klok et al. 2007) 
RARS2_611524 611523 Lacking exon 2 PCH (Edvardson, Shaag et al. 2007) 
QARS_603727 ONA* Catalytic domain N-terminal domain MCPH (Zhang, Ling et al. 2014) 
MARS_156560 NC* C-terminal domain N-terminal domain HSP 
(Novarino, Fenstermaker 
et al. 2014) 
EARS2_612799 614924 Multiple LTBL (Steenweg, Ghezzi et al. 2012) 
AIMP2_600859 168600 na Parkinson’s Disease (Lee, Karuppagounder et al. 2013) 
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expression [68, 69]. Interestingly, patients with the DARS-linked white matter disease 
exhibited the same types of white matter abnormalities in brain stem and spinal cord 
regions by MRI imaging that were observed in patients with the DARS2 mutations linked 
to LBSL. Cases of white matter disease associated with aaRSs are not exclusively restricted 
to AspRS. A recent report described a disease called leukoencephalopathy with thalamus 
and brainstem involvement and high lactate (LTBL) linked to mutations encoding 
mitochondrial glutamyl-tRNA synthetase (EARS2) [70]. In an attempt to generate a HBSL 
mouse model, halpoinsufficiency was not sufficient enough to explain the tissue specific 
phenotype observed in patients [71]. Heterozygous mice had normal CNS morphology and 
myelination suggesting that pathological mechanisms of DARS2 mutations are likely due 
to be a gain of toxic function and not simple loss of aminoacylation function. The 
pathological role of aaRS proteins in these diseases is at an early stage, and it is too soon 
to conclude that they are entirely explained by the sensitivity of neurons to decreased 
output in translation. 
Several other reports highlight the potential association of mutations in aaRS genes 
with neurodegenerative diseases. For example, the lethal heterogeneous neurodegenerative 
disease pontocerebellar hypoplasia (PCH6) was linked to the RARS2 (mitochondrial 
arginyl-tRNA synthetase) gene in a patient with a homozygous frameshift mutation 
predicted to generate a truncated protein [72]. Other case studies of PCH6 subjects 
subsequently identified additional RARS2 mutations [73]. In the zebrafish model, RARS2 
is highly expressed in the brain 24 hours post fertilization. Of further interest, zebrafish 
knockdown models of TSEN54 (subunit associated with RNA splicing previously 
described) and RARS2 produce comparable phenotypes characterized by brain hypoplasia 
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and increased cell death, but little effect on brain patterning. These interesting results 
suggest there may be a common pathological PCH phenotype associated with loss of 
function of the TSEN and RARS2 alleles, as well as a demand for specific spliced tRNA 
products at specified times during neuronal development [74]. Recently, whole-exome 
sequencing identified that QARS is a causative gene in affected individuals of the two 
families with children affected by autosomal-recessive primary microcephaly (MCPH) 
[75]. Symptoms of this disease are associated with intellectual disability, seizures during 
infancy, and atrophying in brain regions of the cerebellar vermis and cerebral cortex. This 
disease phenotype is similar to the PCH caused by mutations in RARS and TSEN complex 
previously described.  However, specific brain regions are differentially affected for each 
disease. Four variants were identified, two of which were localized to the catalytic domain 
and the remaining two to the tRNA binding N-terminal domain. Activity studies showed 
that all mutations caused a loss of functional protein.  
MARS was identified by an exome sequencing study as one of 15 genes linked to 
hereditary spastic paraplegias (HSP) [76]. HSP is characterized by the degeneration and 
progressive loss of corticospinal motor neuron tract function; patients typically present 
with lower limb spasticity, seizures, ataxia, peripheral neuropathy, intellectual disability, 
skin, and visual defects. The potential roles of many of the genes reported in this study in 
HSP were validated in the zebrafish model; the MARS mutation was too severe to be fully 
evaluated.  
Another important connection between aaRS function and neurodegenerative 
disease is the linkage between the aminoacyl-tRNA synthetase complex interacting 
multifunctional protein-2 (AIMP2, also referred to as p38) and familial Parkinson’s 
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disease. Initially, AIMP2 was reported to be deposited in Lewy bodies, and its 
accumulation had been noted in some familial cases of Parkinson’s disease [77, 78]. Later, 
AIMP2 was determined to be a substrate of the E3 ligase PARKIN. Multiple loss of 
function mutations in the gene encoding PARKIN are a common cause of familial 
Parkinson’s disease. While the complete basis of AIMP2-linked neurological 
pathophysiology is not yet clear, it is possible that an important secondary role of AIMP2 
is modulating neuronal protein turnover; when this process is dysfunctional, particular cell 
death pathways may become activated. 
1.5.2 Aminoacyl-tRNA synthetases and sensorineural diseases   
Sensorineural deafness is characterized by defects in either the inner ear or the 
connecting auditory neural circuitry. Perrault Syndrome is described clinically as an 
ovarian dysgenesis with sensory hearing loss. Genetic studies indicate that mutations in 
mitochondrial HARS2 and mitochondrial (leucyl-tRNA synthetase) LARS2 are both 
linked to Perrault Syndrome [79, 80]. Similarly, the LARS2 mutation associated with 
Perrault Syndrome, T522N, also targets a highly conserved residue located in the catalytic 
domain. By contrast, the frame shift mutation at codon 360 (c.1077delT) and T629M 
compound heterozygous mutations found in another Perrault syndrome patient localizes to 
the poorly conserved leucine-specific C-terminal domain. Yeast complementation assays 
showed that T522N LARS2 did not support growth, while T629M LARS2 did. Notably, 
C. elegans models carrying the mutations were completely sterile, recapitulating at least 
one component of the disease phenotype. 
Hearing loss phenotypes have been linked to a number of aaRSs in addition to 
HARS. Patients in three unrelated consanguineous Pakistani families suffered from an 
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autosomal recessive non-syndromic hearing impairment (ARNHI) linked to mutations in 
the known ARNHI-associated locus in (lysyl-tRNA synthease) KARS, DFNB89 [81]. One 
of the mutations is predicted to encode an Y173H substitution in a residue located in the 
oligomer-binding (OB) fold motif of the KARS anticodon binding domain. In this location, 
the substitution could negatively affect tRNA binding and/or catalysis. Significantly, the 
mouse organ of Corti and vestibular system features many cell types, including inner/outer 
hair cells spiral ligament, and sulcus and spiral limbus cells of the vestibular membrane 
epithelium where KARS is prominently expressed.  
1.5.3 Aminoacyl-tRNA synthetases and inherited peripheral neuropathies   
Charcot-Marie-Tooth disease (CMT) is a hereditary peripheral neuropathy that 
manifests as progressive degeneration of distal motor and sensory neurons, leading 
ultimately to muscle weakness and atrophy of the legs and hands/arms. The various forms 
of CMT can be further categorized into either demyelinating type 1, which features defects 
in the myelin sheath surrounding peripheral nerves, and axonal type 2, which results in 
abnormalities in the axon of the peripheral nerve. Nerve conduction studies and 
electromyography (EMG) examination of patients with CMT are typically abnormal. 
While more than 80 genes have been linked to CMT [82], 30 gene mutations in aaRS genes 
are associated with the intermediate and axonal autosomal dominant and intermediate 
autosomal recessive forms of the disease [43]. The first cytoplasmic aaRS to be linked to 
CMT was glycyl-tRNA synthetase (GARS) [65]. Since that initial report, mutations in the 
genes encoding four additional aminoacyl-tRNA synthetases have been linked to CMT 
[83]. The cytoplasmic YARS, bifunctional (cytoplasmic and mitochondrial) KARS, and 
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cytosolic alanyl-tRNA synthetase ARS and HARS have all been implicated in CMT. 
Mutations in aaRS genes have also been linked to non-CMT peripheral neuropathies.  
1.6 HARS mutations associated with disease 
1.6.1 Association of HARS with idiopathic inflammatory myopathy Anti-
Synthetase Syndrome  
Idiopathic inflammatory myopathy (IIM) is a heterogeneous connective tissue 
disease characterized by inflammation of skeletal muscle [84]. While clinically muscle 
weakness, wasting, and elevated serum creatine kinase (CK) are helpful in diagnosis the 
hallmark of this disease is revealed in muscle biopsy samples in which immune cell 
invasion is apparent. The inflammatory response in IIM can also include extramuscular 
organs and these characteristic patterns of organ involvement help define the clinical 
subtypes dermatomyositis (DM), polymyositis (PM), necrotizing autoimmune myopathy 
(NAM) and sporadic inclusion body myositis (sIBM) [85]. Frequently, autoantibodies 
directed against intracellular proteins can be detected in IIM patients. Among these, 
autoantibodies generated against aaRS enzymes are common. Autoantibodies against eight 
aaRS enzymes have been identified and associated with a distinct clinical IIM phenotype 
known as anti-Synthetase Syndrome (aSS). aSS clinical features include myositis 
(polymyositis or dermatomyositis), polyarthritis (non-destructive polyarthritis of knees, 
wrists, elbows and finger joints), Mechanic’s hands (cracked thin skin over tips and sides 
of fingers, interstitial lung disease, and Raynauld phenomenon, a symptom that causes 
areas of your body such as your fingers or toes to numb or cold in response to colder 
temperature or stress. 
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Patients with Jo-1 antibodies [86] were the first known aaRS antibody with 
immunoreactivity to HARS. Jo-1 antibodies are also the most commonly in patients with 
polymyositis or dermatomyositis, present in 20-25% of patients. Furthermore, HARS was 
shown to be have cytokine activity and causes immune cells to become activated [87]. Jo-
1 antibodies selectively target amino acid residues 60-90 of the HARS enzyme [88]. 
Additionally, mice immunizied with the HARS Jo-1 antibodies recapitulate all the 
symptoms of aSS as HARS can trigger both innate and adaptive immune responses[88]. 
Currently, autoantibodies against eight aaRS enzymes histidyl (Jo-1), threonyl (PL-
7), alanyl (PL-12), isoleucyl (OJ), glycyl (EJ), asparaginyl (KS), phenylalanyl (Zo) and 
tyrosyl (Ha) have been identified in aSS patients. 
 
1.6.2 Mitochondrial HARS2 mutations associated with Perrault Syndrome 
Perrault Syndrome is described clinically as an ovarian dysgenesis with sensory 
hearing loss. Genetic studies indicate that mutations in mitochondrial HARS2 and LARS2 
are both linked to Perrault Syndrome [79, 80]. In the HARS2 gene, a compound 
heterozygous mutation encoding both L200V and V368L is linked to Perrault Syndrome, 
and these substitutions alter highly conserved residues in the catalytic domain1. 
Pyrophosphate exchange assays demonstrated that the resulting mutant proteins exhibit 
decreased activity, implying that the phenotype is a straightforward loss of function effect 
likely arising from reduced respiratory chain complex activity. Given the limitations of this 
single assay, the mutant substitutions may have other structural and functional 
consequences. 
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1.6.3 Heterozygous mutations in HARS gene are associated with peripheral 
neuropathy. 
The first HARS mutation found in a patient with peripheral neuropathy was 
R137Q[89]. Recently, a genetic screening of patients suffering from peripheral neuropathy 
identified mutations in the HRS gene [89]. One of these mutations, R137Q, demonstrated 
a complete loss of function in a yeast complementation assay but in a C.elegans was shown 
to be neurotoxic. An analysis of the recently crystallized human histidyl-tRNA synthetase 
structure[61] shows this highly conserved arginine residue is involved in electrostatic 
interaction with Asp64 at the dimer interface. Other aaRS enzymes are related to Charcot-
Marie-Tooth (CMT) disease that also clinically presents as a peripheral neuropathy[90]. 
Glycyl-tRNA synthetase (GlyRS) is a well-studied aaRS related to CMT for which eight 
different mutations have been identified. To date, no correlations between aaRS 
aminoacylation activity and CMT have been clearly made. 
1.6.4 The first recessive HARS mutation associated with Usher Syndrome IIIB 
Cytoplasmic HARS has also been associated with a heterogeneous sensorineural 
disease that causes deaf-blindness, Usher Syndrome Type IIIB. Usher Syndrome is a 
polygenetic disease with at least 11 different loci identified. Most of the genes associated 
with Usher Syndrome are typically involved in inner ear hair cell morphology and 
development [91]. The three clinical subtypes are divided up by severity of the symptoms 
and age of onset that the phenotype presents. A homozygous mutation in HARS, Y454S, 
was discovered in patients with Usher Syndrome IIIB [92] and is the first cytoplasmic 
HARS mutation associated with disease. In these patients hearing and vision are severely 
impaired early in childhood, and fever induced hallucinations can occur. While peripheral 
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nerve function seems to be normal, there is some mild trunk ataxia. The Y454S mutation, 
which is localized specifically on the surface of the anticodon-binding domain (ABD), 
juxtaposes the catalytic domain of the second monomer. Y454 hydrogen-bonds with 
residue E439 within the anticodon binding domain, and E439 is positioned to interact with 
K148 from the catalytic domain of the second monomer to form a salt-bridge interaction 
[61]. Initial aminoacylation data employing wild type and mutant versions of the mouse 
enzyme demonstrates that the Y454S substitution is unlikely to be a simple loss of function.  
1.7 Questions remaining for Histidyl-tRNA synthetase 
To date there is no fundamental kinetic evaluation of the human HARS enzyme. 
Currently, there are few kinetic studies of other human AARS enzymes that have been fully 
characterized by multiple turnover kinetics and pre-steady state kinetics alongside 
associated disease mutations. We sought to rectify the lack of basic enzyme kinetics of the 
human enzyme to determine the functional consequences of these single point mutations 
linked to disease. Active site residues constitute the principal sequence elements conserved 
between E.coli and human HARS enzymes which only share 27% sequence identity. 
However, structural differences such as the larger insertion domain found in eukaryotes 
may contribute to subtle differences in catalytic activity. We have developed a purification 
protocol to isolate human WT and Usher-like syndrome Y454S HARS enzymes from a 
human cell line to eliminate cross species dimers for tRNAHis binding studies, there by 
permitting enzyme kinetic analysis, and thermal stability evaluation. 
As HARS is an essential component of the translation machinery, mutations that 
are associated with disease are unlikely to lead to a complete loss of function, as this would 
be embryonic lethal. However, understanding subtle defects in activity might provide 
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insights about disease progression. Furthermore, while a biochemical characterization of 
HARS disease variants is important, exploring how these mutations affect the intracellular 
environment must also be addressed. With this work I have advanced our understanding of 




1. Carter, C.W., Jr., Cognition, mechanism, and evolutionary relationships in 
aminoacyl-tRNA synthetases. Annu. Rev. Biochem., 1993. 62: p. 715-748. 
2. Ibba, M. and D. Soll, Aminoacyl-tRNAs: setting the limits of the genetic code. 
Genes Dev, 2004. 18(7): p. 731-8. 
3. Ibba, M. and D. Soll, The renaissance of aminoacyl-tRNA synthesis. EMBO Rep, 
2001. 2(5): p. 382-7. 
4. Eriani, G., et al., Partition of tRNA synthetases into two classes based on mutually 
exclusive sets of sequence motifs. Nature, 1990. 347(13 September): p. 203-206. 
5. Cusack, S., M. Härtlein, and R. Leberman, Sequence, structure and evolutionary 
relationships between class 2 aminoacyl-tRNA synthetases. Nucleic Acids 
Research, 1991. 19: p. 3489-3498. 
6. Yang, D.C.H., Mammalian aminoacyl-tRNA synthetases. Current Topics in Cell 
Regulation, 1996. 34: p. 101-135. 
7. Wolf, Y.I., et al., Evolution of aminoacyl-tRNA synthetases--analysis of unique 
domain architectures and phylogenetic trees reveals a complex history of 
horizontal gene transfer events. Genome Res, 1999. 9(8): p. 689-710. 
8. Tian, Q., et al., Structural basis for recognition of G-1-containing tRNA by histidyl-
tRNA synthetase. Nucleic Acids Res, 2015. 43(5): p. 2980-90. 
9. Merritt, E.A., et al., Crystal structures of trypanosomal histidyl-tRNA synthetase 
illuminate differences between eukaryotic and prokaryotic homologs. J Mol Biol, 
2010. 397(2): p. 481-94. 
10. Koh, C.Y., et al., Comparison of histidine recognition in human and 
trypanosomatid histidyl-tRNA synthetases. Biochimie, 2014. 106: p. 111-20. 
11. Qiu, X., et al., Cooperative structural dynamics and a novel fidelity mechanism in 
histidyl-tRNA synthetases. Biochemistry, 1999. 38(38): p. 12296-304. 
12. Francklyn, C., The Aminoacyl-tRNA Synthetases. Molecular Biology Intelligence 
Unit, ed. M. Ibba, C. Francklyn, and S. Cusack. 2005, Georgetown, Texas: Landes 
Bioscience. 
13. Arnez, J.G. and D. Moras, Structural and functional considerations of the 
aminoacylation reaction. Trends Biochem Sci, 1997. 22(6): p. 211-6. 
  32 
14. Arnez, J.G., et al., The first step of aminoacylation at the atomic level in histidyl-
tRNA synthetase. Proceedings of the National Academy of Sciences, U.S.A., 1997. 
94(14): p. 7144-9. 
15. Arnez, J.G., et al., Crystal structure of histidyl-tRNA synthetase from Escherichia 
coli complexed with histidyl-adenylate. EMBO J, 1995. 14(17): p. 4143-55. 
16. Cavarelli, J. and D. Moras, Recognition of tRNAs by aminoacyl-tRNA synthetases. 
FASEB Journal, 1993. 7(January): p. 79-86. 
17. Rould, M.A., J.J. Perona, and T.A. Steitz, Structural basis of anticodon loop 
recognition by glutaminyl-tRNA synthetase. Nature, 1991. 352: p. 213-218. 
18. Muramatsu, T., et al., Codon and amino-acid specificities of a transfer RNA are 
both converted by a single post-transcriptional modification. Nature, 1988. 336: p. 
179-181. 
19. Fromant, M., P. Plateau, and S. Blanquet, Function of the extra 5'-phosphate 
carried by histidine tRNA. Biochemistry, 2000. 39(14): p. 4062-7. 
20. Himeno, H., et al., Role of the extra G-C pair at the end of the acceptor stem of 
tRNA(His) in aminoacylation. Nucleic Acids Res, 1989. 17(19): p. 7855-63. 
21. Yan, W. and C. Francklyn, tRNA selection by a class II aminoacyl-tRNA 
synthetase: the role of accessory domains and inter-domain communication in RNA 
recognition. Nucleic Acids Symp Ser, 1995. 33: p. 167-9. 
22. Francklyn, C. and P. Schimmel, Enzymatic aminoacylation of an eight-base-pair 
microhelix with histidine. Proc. Natl. Acad. Sci. U.S.A., 1990. 87(November): p. 
8655-8659. 
23. Francklyn, C., K. Musier-Forsyth, and P. Schimmel, Small RNA helices as 
substrates for aminoacylation and their relationship to charging of transfer RNAs. 
Eur. J. Biochem., 1992. 206: p. 315-321. 
24. Francklyn, C., J.-P. Shi, and P. Schimmel, Overlapping nucleotide determinants for 
specific aminoacylation of RNA microhelices. Science, 1992. 255(28 February): p. 
1121-1125. 
25. Orellana, O., L. Cooley, and D. Söll, The Additional Guanylate at the 5' Terminus 
of Escherichia coli tRNAHis Is the Result of Unusual Processing by RNase P. Mol. 
Cell. Biol., 1986. 6(2): p. 525-529. 
26. Burkard, U. and D. Söll, The 5'-terminal guanylate of chloroplast histidine tRNA is 
encoded in its gene. J. Biol. Chem., 1988. 263(20, July 15): p. 9578-9581. 
27. Cooley, L., B. Appel, and D. Söll, Post-transcriptional nucleotide addition is 
responsible for the formation of the 5'terminus of histidine tRNA. Proc Natl Acad 
Sci U S A, 1982. 79(21): p. 6475-9. 
28. Nameki, N., et al., Identity elements of Saccharomyces cerevisiae tRNAHis. Nucl. 
Acids Res., 1995. 23(3): p. 389-394. 
29. Martinez, A., et al., Human BCDIN3D monomethylates cytoplasmic histidine 
transfer RNA. Nucleic Acids Res, 2017. 45(9): p. 5423-5436. 
30. Guth, E.C. and C.S. Francklyn, Kinetic discrimination of tRNA identity by the 
conserved motif 2 loop of a class II aminoacyl-tRNA synthetase. Molecular Cell, 
2007. 25(4): p. 531-42. 
  33 
31. Hawko, S.A. and C.S. Francklyn, Covariation of a specificity-determining 
structural motif in an aminoacyl-tRNA synthetase and a tRNA identity element. 
Biochemistry, 2001. 40(7): p. 1930-6. 
32. Belrhali, H., et al., The structural basis for seryl-adenylate and Ap4A synthesis by 
seryl-tRNA synthetase. Structure, 1995. 3(4): p. 341-52. 
33. Poterszman, A., et al., Synthesis and Recognition of Aspartyl-adenylate by Thermus 
thermophilus Aspartyl-tRNA Synthetase. J. Mol. Biol., 1994. 244: p. 158-167. 
34. Arnez, J.G., et al., Engineering a Mg2+ site to replace a structurally conserved 
arginine in the catalytic center of histidyl-tRNA synthetase by computer 
experiments. Proteins, 1998. 32(3): p. 362-80. 
35. Ruhlmann, A., F. Cramer, and U. Englisch, Isolation and analysis of mutated 
histidyl-tRNA synthetases from Escherichia coli. Biochem Biophys Res Commun, 
1997. 237(1): p. 192-201. 
36. Guth, E., et al., A substrate-assisted concerted mechanism for aminoacylation by a 
class II aminoacyl-tRNA synthetase. Biochemistry, 2005. 44(10): p. 3785-94. 
37. Guth, E., et al., Asymmetric amino acid activation by class II histidyl-tRNA 
synthetase from Escherichia coli. Journal of Biological Chemistry, 2009. 284(31): 
p. 20753-62. 
38. Brindefalk, B., et al., Origin and evolution of the mitochondrial aminoacyl-tRNA 
synthetases. Mol Biol Evol, 2007. 24(3): p. 743-56. 
39. Jia, J., et al., WHEP domains direct noncanonical function of glutamyl-Prolyl tRNA 
synthetase in translational control of gene expression. Mol Cell, 2008. 29(6): p. 
679-90. 
40. Rho, S.B., et al., Interaction between human tRNA synthetases involves repeated 
sequence elements. Proc Natl Acad Sci U S A, 1996. 93(19): p. 10128-33. 
41. Raben, N., et al., A motif in human histidyl-tRNA synthetase which is shared among 
several aminoacyl-tRNA synthetases is a coiled-coil that is essential for enzymatic 
activity and contains the major autoantigenic epitope. J Biol Chem, 1994. 269(39): 
p. 24277-83. 
42. Mathews, M.B. and R.M. Bernstein, Myositis autoantibody inhibits histidyl-tRNA 
synthetase : a model for autoimmunity. Nature, 1983. 304: p. 177-179. 
43. Yao, P. and P.L. Fox, Aminoacyl-tRNA synthetases in medicine and disease. 
EMBO Mol Med, 2013. 5(3): p. 332-43. 
44. Guo, M. and P. Schimmel, Essential nontranslational functions of tRNA 
synthetases. Nat Chem Biol, 2013. 9(3): p. 145-53. 
45. Arif, A., et al., Two-site phosphorylation of EPRS coordinates multimodal 
regulation of noncanonical translational control activity. Mol Cell, 2009. 35(2): p. 
164-80. 
46. Park, B.J., et al., The haploinsufficient tumor suppressor p18 upregulates p53 via 
interactions with ATM/ATR. Cell, 2005. 120(2): p. 209-21. 
47. Xu, X., et al., Unique domain appended to vertebrate tRNA synthetase is essential 
for vascular development. Nat Commun, 2012. 3: p. 681. 
48. Han, J.M., et al., Leucyl-tRNA synthetase is an intracellular leucine sensor for the 
mTORC1-signaling pathway. Cell, 2012. 149(2): p. 410-24. 
  34 
49. Wakasugi, K. and P. Schimmel, Two distinct cytokines released from a human 
aminoacyl-tRNA synthetase. Science, 1999. 284(5411): p. 147-51. 
50. Park, M.C., et al., Secreted human glycyl-tRNA synthetase implicated in defense 
against ERK-activated tumorigenesis. Proc Natl Acad Sci U S A, 2012. 109(11): p. 
E640-7. 
51. Williams, T.F., et al., Secreted Threonyl-tRNA synthetase stimulates endothelial 
cell migration and angiogenesis. Scientific Reports, 2013. 3: p. 1317. 
52. Wakasugi, K., et al., A human aminoacyl-tRNA synthetase as a regulator of 
angiogenesis. Proc Natl Acad Sci U S A, 2002. 99(1): p. 173-7. 
53. Yannay-Cohen, N., et al., LysRS serves as a key signaling molecule in the immune 
response by regulating gene expression. Mol Cell, 2009. 34(5): p. 603-11. 
54. Kang, T., et al., AIMP3/p18 controls translational initiation by mediating the 
delivery of charged initiator tRNA to initiation complex. J Mol Biol, 2012. 423(4): 
p. 475-81. 
55. Sampath, P., et al., Noncanonical function of glutamyl-prolyl-tRNA synthetase: 
gene-specific silencing of translation. Cell, 2004. 119(2): p. 195-208. 
56. Arif, A., et al., Phosphorylation of glutamyl-prolyl tRNA synthetase by cyclin-
dependent kinase 5 dictates transcript-selective translational control. Proc Natl 
Acad Sci U S A, 2011. 108(4): p. 1415-20. 
57. Mukhopadhyay, R., et al., The GAIT system: a gatekeeper of inflammatory gene 
expression. Trends Biochem Sci, 2009. 34(7): p. 324-31. 
58. Mirando, A.C., C.S. Francklyn, and K.M. Lounsbury, Regulation of angiogenesis 
by aminoacyl-tRNA synthetases. Int J Mol Sci, 2014. 15(12): p. 23725-48. 
59. Greenberg, Y., et al., The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, 
is secreted to induce an angiogenic response in endothelial cells. FASEB J, 2008. 
22(5): p. 1597-605. 
60. Mirando, A.C., et al., Aminoacyl-tRNA synthetase dependent angiogenesis revealed 
by a bioengineered macrolide inhibitor. Sci Rep, 2015. 5: p. 13160. 
61. Xu, Z., et al., Internally deleted human tRNA synthetase suggests evolutionary 
pressure for repurposing. Structure, 2012. 20(9): p. 1470-7. 
62. Zhou, J.J., et al., Secreted histidyl-tRNA synthetase splice variants elaborate major 
epitopes for autoantibodies in inflammatory myositis. J Biol Chem, 2014. 289(28): 
p. 19269-75. 
63. Becker, R., Beyond building proteins: tRNA synthetases outside of translation. Nat 
Med, 2016. 22(5): p. 452-3. 
64. Scheper, G.C., et al., Mitochondrial aspartyl-tRNA synthetase deficiency causes 
leukoencephalopathy with brain stem and spinal cord involvement and lactate 
elevation. Nat Genet, 2007. 39(4): p. 534-9. 
65. Antonellis, A., et al., Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth 
disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet, 2003. 
72(5): p. 1293-9. 
66. Schwenzer, H., et al., Released selective pressure on a structural domain gives new 
insights on the functional relaxation of mitochondrial aspartyl-tRNA synthetase. 
Biochimie, 2014. 100: p. 18-26. 
  35 
67. Taft, R.J., et al., Mutations in DARS cause hypomyelination with brain stem and 
spinal cord involvement and leg spasticity. Am J Hum Genet, 2013. 92(5): p. 774-
80. 
68. van Berge, L., et al., Leukoencephalopathy with brain stem and spinal cord 
involvement and lactate elevation is associated with cell-type-dependent splicing 
of mtAspRS mRNA. Biochem J, 2012. 441(3): p. 955-62. 
69. van Berge, L., et al., Pathogenic mutations causing LBSL affect mitochondrial 
aspartyl-tRNA synthetase in diverse ways. Biochem J, 2013. 450(2): p. 345-50. 
70. Steenweg, M.E., et al., Leukoencephalopathy with thalamus and brainstem 
involvement and high lactate 'LTBL' caused by EARS2 mutations. Brain, 2012. 
135(Pt 5): p. 1387-94. 
71. Frohlich, D., et al., In vivocharacterization of the aspartyl-tRNA synthetase DARS: 
Homing in on the leukodystrophy HBSL. Neurobiol Dis, 2017. 97(Pt A): p. 24-35. 
72. Edvardson, S., et al., Deleterious mutation in the mitochondrial arginyl-transfer 
RNA synthetase gene is associated with pontocerebellar hypoplasia. Am J Hum 
Genet, 2007. 81(4): p. 857-62. 
73. Glamuzina, E., et al., Further delineation of pontocerebellar hypoplasia type 6 due 
to mutations in the gene encoding mitochondrial arginyl-tRNA synthetase, RARS2. 
J Inherit Metab Dis, 2012. 35(3): p. 459-67. 
74. Kasher, P.R., et al., Impairment of the tRNA-splicing endonuclease subunit 54 
(tsen54) gene causes neurological abnormalities and larval death in zebrafish 
models of pontocerebellar hypoplasia. Hum Mol Genet, 2011. 20(8): p. 1574-84. 
75. Zhang, X., et al., Mutations in QARS, Encoding Glutaminyl-tRNA Synthetase, 
Cause Progressive Microcephaly, Cerebral-Cerebellar Atrophy, and Intractable 
Seizures. Am J Hum Genet, 2014. 
76. Novarino, G., et al., Exome sequencing links corticospinal motor neuron disease to 
common neurodegenerative disorders. Science, 2014. 343(6170): p. 506-11. 
77. Corti, O., et al., The p38 subunit of the aminoacyl-tRNA synthetase complex is a 
Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol 
Genet, 2003. 12(12): p. 1427-37. 
78. Ko, H.S., et al., Accumulation of the authentic parkin substrate aminoacyl-tRNA 
synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci, 
2005. 25(35): p. 7968-78. 
79. Pierce, S.B., et al., Mutations in mitochondrial histidyl tRNA synthetase HARS2 
cause ovarian dysgenesis and sensorineural hearing loss of Perrault syndrome. 
Proc Natl Acad Sci U S A, 2011. 108(16): p. 6543-8. 
80. Pierce, S.B., et al., Mutations in LARS2, encoding mitochondrial leucyl-tRNA 
synthetase, lead to premature ovarian failure and hearing loss in Perrault 
syndrome. Am J Hum Genet, 2013. 92(4): p. 614-20. 
81. Santos-Cortez, R.L., et al., Mutations in KARS, encoding lysyl-tRNA synthetase, 
cause autosomal-recessive nonsyndromic hearing impairment DFNB89. Am J 
Hum Genet, 2013. 93(1): p. 132-40. 
82. Timmerman, V., A.V. Strickland, and S. Zuchner, Genetics of Charcot-Marie-
Tooth (CMT) Disease within the Frame of the Human Genome Project Success. 
Genes (Basel), 2014. 5(1): p. 13-32. 
  36 
83. Wallen, R.C. and A. Antonellis, To charge or not to charge: mechanistic insights 
into neuropathy-associated tRNA synthetase mutations. Curr Opin Genet Dev, 
2013. 23(3): p. 302-9. 
84. Zong, M. and I.E. Lundberg, Pathogenesis, classification and treatment of 
inflammatory myopathies. Nat Rev Rheumatol, 2011. 7(5): p. 297-306. 
85. Rider, L.G., et al., The myositis autoantibody phenotypes of the juvenile idiopathic 
inflammatory myopathies. Medicine (Baltimore), 2013. 92(4): p. 223-43. 
86. Mathews, M.B. and R.M. Bernstein, Myositis autoantibody inhibits histidyl-tRNA 
synthetase: a model for autoimmunity. Nature, 1983. 304(5922): p. 177-9. 
87. Howard, O.M., et al., Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, 
autoantigens in myositis, activate chemokine receptors on T lymphocytes and 
immature dendritic cells. J Exp Med, 2002. 196(6): p. 781-91. 
88. Fernandez, I., et al., Functional redundancy of MyD88-dependent signaling 
pathways in a murine model of histidyl-transfer RNA synthetase-induced myositis. 
J Immunol, 2013. 191(4): p. 1865-72. 
89. Vester, A., et al., A loss-of-function variant in the human histidyl-tRNA synthetase 
(HARS) gene is neurotoxic in vivo. Hum Mutat, 2013. 34(1): p. 191-9. 
90. Nangle, L.A., et al., Charcot-Marie-Tooth disease-associated mutant tRNA 
synthetases linked to altered dimer interface and neurite distribution defect. Proc 
Natl Acad Sci U S A, 2007. 104(27): p. 11239-44. 
91. Yan, D. and X.Z. Liu, Genetics and pathological mechanisms of Usher syndrome. 
J Hum Genet, 2010. 55(6): p. 327-35. 
92. Puffenberger, E.G., et al., Genetic mapping and exome sequencing identify variants 
associated with five novel diseases. PLoS One, 2012. 7(1): p. e28936. 
 
  37 
CHAPTER 2: METHODS FOR EVALUATING AMINOACYL-TRNA 




As the discovery of HARS mutations associated with disease increases, methods to 
accurately determine the biochemical effects of single amino acid substitutions of the 
human enzyme should be readily available. This requires revisiting the current techniques 
and applications that are available for the study of aminoacyl-tRNA synthetases [1] while 
also developing new approaches. The goal of this thesis is to understand if disease 
associated mutations of the human HARS enzyme perturb primary aminoacylation 
function, substrate binding, thermal stability, dimerization, cellular morphology, or cellular 
stress. Techniques described here will aid in the execution of human HARS enzyme steady-
state amionacylation assays, determination of rate constants for amino acid activation and 
transfer, and evaluation of enzyme stability and substrate binding. Furthermore, we have 
developed methods to evaluate axonal outgrowth and cellular responses to endoplasmic 
reticulum (ER stress) of cells expressing HARS disease associated variants. Application of 
these methods will enable the comparison of disease-associated HARS mutations to the 
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2.2 Expression of human HARS enzyme in mammalian cell culture (HEK293 cells)  
Previously, expression and purification of human HARS enzymes were described 
and carried out using E.coli as an expression system [2]. Interestingly, human HARS 
purified from this system is susceptible to aggregation, in the absence of reducing agent. 
Additionally, our experience in purifying TARS from E.coli required multiple liters of 
media with special attention to induction and growth conditions to yield protein that had 
reduced activity [3]. 
Therefore, in an effort to purify human HARS as a folded and active enzyme we 
sought to use a mammalian cell line, human embryonic kidney cells (HEK293). HEK293 
cells were an ideal expression system because 1) they contain appropriate protein folding 
machinery, 2) can yield post-translational modifications that may be relevant, and 3) the 
relative ease and transfection efficiency is favorable for yielding target protein expression.  
 
2.2.1 Plasmid constructs, cell culture conditions and transfection 
For expression of human HARS in HEK293 cells we used plasmids 
(pCAG/FLAG/RFC/A) that contained a CAG promotor and N-terminal FLAG-tagged 
HARS from GateWay vector Reading Frame Cassette A. These plasmids bicistronically 
express green fluorescent protein (GFP) and provide a reliable check for transfection 
efficiency. HEK293 cells are typically grown in Dulbecco’s Modified Eagle Medium 
(DMEM) (Thermo) supplemented with 10% fetal bovine growth serum (FBS) (Gibco), 1% 
penicillin/streptomycin (Gibco), and 1% L-glutamine (Gibco) and maintained at 37 °C in 
a humidified incubator containing 5% CO2. Plasmids (pCAG/FLAG/RFC/A) containing 
the genes for WT N-terminal FLAG-tagged human HARS were a generous gift from Dr. 
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Robert Jinks (Franklin and Marshall College). This plasmid bicistronically expressed green 
fluorescent protein, to monitor transfection efficiency. Cells were transfected when 50% 
confluent using polyethyleneimine (PEI) at a 3:1 (µg) ratio of PEI:DNA diluted in serum-
free media, and incubated for 48h post transfection.  
Neuropathy-associated HARS R137Q, S356N, Y330C and V155G HARS 
containing plasmids were generated by QuickChange II Site-Directed Mutagensis (Qiagen) 
using the WT (pCAG/FLAG/RFC/A) plasmid as a template. The following forward and 
reverse primers were used in the mutagenesis reactions for S356N, forward 5’-
CCAGCAGCCACATTGCCC ACACCCAGG-3’ and reverse 5’-
CCTGGGTGTGGGCAATGTGGCTGCTGG-3’, for Y330C forward 5’-
TCACCCCAGTGTAGCAATCCAGCCCTCGAG-3’and reverse 5’ 
CTCGAGGGCTGGATTG CTACACTGGGGTGA-3’ reverse, for V155G 5-
GGTTATCCCGCCGATATCC CTTTGCTATGTGGTAG-3’ and reverse 5’-
CTACCACATAGCAAAGGGATATCGG CGGGATAACC-3’. Successful mutagenesis 
of the HARS gene was analyzed by Advanced Genome Technology Core sequencing 
facility at the University of Vermont and results were validated using Sequencher.  
 
2.2.2 Affinity purification and ion exchange – purity of final product  
 
To obtain purified human HARS enzyme, HEK293 cells that were transiently 
transfected with HARS-expressing plasmids were harvested and lysed in CelLytic M buffer 
(Sigma-Aldrich) containing mammalian protease inhibitor cocktail (Sigma-Aldrich) for 20 
min at 4 °C. The FLAG-tagged HARS was purified by binding to an anti-DYDDDDK resin 
per manufacturer protocol (GenScript) and eluted by competition with 3X-DYKDDDDK 
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peptide in buffer containing 50 mM Tris-HCl pH 7.4, and 150 mM NaCl. Isolated FLAG-
HARS is then further purified by HiTrapQ HP column (GE Healthcare) and eluted by a 
NaCl gradient to 150-500 mM. Individual fractions containing HARS are typically 
identified by SDS-PAGE, pooled, and dialyzed at 4 °C into a storage buffer containing 50 
mM HEPES pH 7.5, 150 mM KCl, 10 mM MgCl2, 5 mM b-mercaptoethanol (b-ME). After 
dialysis, samples are concentrated using Amicon Ultra-4 centrifugal filters (Millipore), 
then diluted by the addition of 80% glycerol for a final glycerol concentration of 40%. 
Protein concentrations are determined by A280 utilizing an extinction coefficient. 
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Figure 2.1. Purification and detection of human HARS from HEK293 cells. 
(A) Ion exchange chromatogram of affinity FLAG-tagged HARS purification. (B) SDS-
PAGE of fractions pooled for dialysis post ion exchange purification. (C) Western blot of 
two column purified HARS. Blots were probed with anti-FLAG antibody (left blot) and 
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2.2.3 Western blot analysis of purified HARS proteins 
A method to semi-quantitatively determine the amount of endogenous WT HARS 
dimerization with purified FLAG-tagged HARS proteins is by western blot. Purified 
FLAG-tagged HARS proteins from HEK293 cells were separated by a 12% SDS-PAGE 
and subjected to Western blot analysis. As our constructs are FLAG-tagged transfected 
HARS was visualized with anti-FLAG antibody (1:3000, Sigma), while both endogenously 
produced HARS and FLAG-tagged transfected HARS were visualized with anti-HARS 
antibody (1:3000 dilution, Abcam). The signal was developed by secondary antibody 
conjugated to horseradish peroxidase (HRP) (1:10000, Santa Cruz) and Super Signal West 
Femto (Thermo). Blots are then visualized by Versadoc and quantified by Quantity One 
(Bio-Rad) software. Endogenous HARS runs lower on an SDS-PAGE gel than FLAG-
tagged HARS, but less than 10% endogenous is typically detected in FLAG-tagged HARS 
preparations (Figure 2.1).  
 
2.3 Synthesis, purification, radioactively labeling of in vitro transcribed human 
tRNAHis 
 
2.3.2 In vitro tRNA transcription and purification  
An essential component to successfully monitoring aminoacylation activity is the 
ability to obtain reasonable yields of tRNAHis molecules. Human tRNAHis used for kinetic 
studies and gel shift assays were generated by enzymatic synthesis with T7 polymerase. In 
vitro translation is a commonly used method that enables the generation of high amounts 
of unmodified tRNAHis.  
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First, the human tRNAHis gene was constructed by overlap PCR incorporating 
EcoRI and BamHI sites cloned into a pUC19 derivative, pJA15 [1, 4]. The plasmid DNA 
was purified by giga prep (Qiagen) and subsequently restricted with FokI (New England 
Biolabs) to produce a linearized tRNAHis sequence with a T7 polymerase binding site.  
In vitro transcription reactions were performed as previously described [1, 5, 6]. 
After overnight incubation the tRNAHis transcripts were precipitated with ethanol and 
sodium acetate. The tRNAHis was then re-suspended in 1:1 mixture of 10 mM HEPES (pH 
6.0): formamide, and purified on 12% acrylamide (19:1 acrylamide:bis-acrylamide), 6M 
urea, Tris-borate-EDTA gel. Following gel purification tRNAHis molecules are 
electroeluted from gel slices with an Elutrap apparatus (Whatman/Schleicher & Schuell). 
After electroelution tRNA samples are precipitated with 1.5 times of the volume of 100% 
ethoanol and 1/10th the volume of sodium acetate. The purified tRNAHis pellet was 
resuspended in either 10 mM HEPES pH 7.0 or TE6 (Tris EDTA pH 6.0) buffer, and was 
then stored at −80 °C to avoid degradation.  
 
2.3.3 Generating 3’-[32P]-labeled human tRNAHis  
 
Approaches to detect aminoacylation activity can include the use of radioactive 
substrates, such as 3H or 14C-labled amino acids[1]. While this approach is relatively 
straightforward, limitations include low specific activity of the radioactive labeled amino 
acids at low concentrations (50 𝜇M). For these reasons it might be particularly challenging 
to determine elevated amino acid KM values. One assay that is helpful in remediating these 
issues is radio labeling 3’-tRNA with 32P-ATP. This reaction is catalyzed in two steps by 
the E.coli CCA adding enzyme (Figure 2.2) [7].   
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Briefly, purified tRNAHis is labelled at the A76 nucleotide with [32P]-α-ATP as 
previously described [8] with some modifications. These modifications included 
phenol:cholorform extraction to remove CCA adding enzyme, a Urea PAGE purification 
step to remove residual α-ATP [32P], and an overnight to 24 hr. soaking of gel pieces at 
37°C in TE6 buffer to extract α-ATP [32P]-labeled A76 tRNAHis, opposed to purification 
by spin columns.  
Figure 2.2. Radio labeling human 3’-tRNAHis with E.coli CCA adding enzyme. 
 
2.4 Electrophoretic mobility shift assay (EMSA) to monitor tRNAHis binding tRNA 
and data analysis  
These experiments employed radiolabeled tRNA, either 32P-tRNAHis transcripts 
prepared as above, or total RNA purified from human placental tissue [9]. The tRNAs, at 
concentrations (30 nM) much below enzyme concentration, was incubated with various 
concentrations (0.1-30 µM) of WT or Y454S HARS at room temperature. The binding 
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buffer for HARS enzymes includes 50 mM HEPES pH 7.5, 150 mM KCl, 10 mM MgCl2, 
5 mM b-ME, 0.0001% Triton-X. Binding reactions typically included 5 mM histidine and 
5 mM AMP to mimic adenylate while precluding aminoacylation of tRNAHis. Prior to its 
addition in binding reactions, tRNAHis can be folded by heating to 95 °C for two minutes 
in a water bath, adding MgCl2 to 5 mM, and cooling to room temperature. Following a ten-
minute incubation period, samples were brought to 25% glycerol with loading dye, and 
then loaded onto a native polyacrylamide gel (10% polyacrylamide, 50 mM Tris borate, 5 
mM MgCl2, 0.0001% Triton X-100). Gels were electrophoresed at 10 mA per gel for 3-4 
hours, dried, exposed to a phosphorimaging screen, and then scanned using a Pharos Bio-
Rad Molecular Imager FXä.  
Phosphor imaging data was analyzed using Prism from GraphPad Software, 
employing a one-site heterologous model with depletion for the competition assay, as 
described in [10]. Modelling of the competition assay determined that less than 1.25% of 
the binding sites were non-specific, so we used a one site-specific binding equation to 
measure binding of the transcribed tRNAHis to enzyme. 
2.5 Evaluating activity of human HARS enzyme and active tRNA preparations  
Protein purification methods may lead to misfolded or oxidized proteins that are 
inactive. Therefore, it is important to evaluate and determine the concentration of active 
enzyme from HEK293 purifications. By measuring the amount of AMP converted in the 
first step of catalysis by rapid chemical quench we can determine the number of active site 
residues from human HARS enzymes purified from HEK293 cells.    
Additionally, in vitro transcription reactions to generate tRNAHis can lead to 
incomplete transcripts or misfolded tRNA that can reduce the active tRNA population. 
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Therefore, it is equally important that we also evaluate the effective concentration of active 
tRNAHis by plateau charging experiments. 
 
2.5.1 Determination of active protein from HEK293 cells  
The activity of each enzyme preparation was determined by monitoring the 
appearance of a-labeled 32P-AMP in the presence of histidine under pre-steady state 
conditions with rapid chemical quench [1, 11]. Enzyme at 10 µM was incubated in one 
syringe with saturating histidine, 5 mM MgCl2 and 8 U/mL of PPiase in standard buffer 
conditions, while the second syringe contains 200 µM ATP. The reactions were quenched 
with 400 mM NaOAc, pH 4.5, 0.1% SDS. Then the products were analyzed by thin-layer 
chromatography in a mobile phase of 750 mM monobasic phosphate buffer. Radioactive 
products were detected by radioisotopic imaging on a phosphor screen (Bio-Rad Molecular 
Imager FXä) (Figure 2.3) 
Figure 2.3: Thin layer chromatography to monitor AMP formation in 




  47 
2.6 Monitoring aminoacylation with radio labeled tRNAHis with 3’-32P-ATP  
We monitored tRNAHis aminoacylation with a slightly modified version of the 
Uhlenbeck-Wolfson assay [8] (Figure 2.2). After 3’labling and gel extraction trace amounts 
of 3’labeled [32P]-tRNAHis are diluted to a final 1:10 of the total reaction volume 
(sufficient for detection) is combined with saturating histidine and ATP. Plateau charging 
reactions to determine the fraction of active tRNA typically includes excess enzyme 
combined with low enzyme concentrations and the reaction is allowed to proceed for an 
extended period of time, on the order of minutes. After completion of aminoacylation time 
courses, quenched time points with tRNAHis are subsequently digested for 40-60 minutes 
with 0.1 µg P1 nuclease (Thermo), that cleaves at the 5’-monophosphate, at ambient 
temperature. Radiolabeled aminoacylated A76 is separated from non-aminoacylated A76 
by thin layer chromatography on PEI cellulose plates (Scientific Adsorbents) using a 
mobile phase of 0.1M ammonium acetate and 5% acetic acid (Figure 2.4).  
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Figure 2.4. P1 nuclease digest of human tRNAHis. 
Separation of 32P-tRNAHis by thin layer chromatography. (A) Comparison of P1 nuclease 
digested reaction products with no HARS enzyme control and no P1 control. (B) A and B 
were digested with P1 prepared in standard buffer with lane C as a no P1 control, D and 
E were digested with P1 prepared in water and resolution of different preparations of 
RNase contaminated 32P-tRNAHis preparations (F-J). Samples were quenched in quench 
buffer of pH 7.0 to test P1 digestion. 
   
Initial protocols indicate that S1 and P1 nucleases are interchangeable, however 
little experimental evidence comparing the two nucleases has been shown. Under our 
experimental conditions we have noticed differences in digestion efficiency of tRNAHis 
when comparing P1 and S1 nuclease (Figure 2.5). There is also a clear difference in 32P -
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Figure 2.5. Quantification and validation of aminoacylated of 32P-tRNAHis 
aminoacylation assay. 
Aminoacylation time course data (A) Comparison of P1 nuclease digestion with S1 
digestion with E.coli HARS using just labeled 32P-tRNAHis  and digested with S1 (red 
squares), labeled 32P-tRNAHis and gel purified, digested S1 nuclease (blue circles) and 
labeled 32P-tRNAHis and gel purified digested P1 nuclease (black circles) (B) Human 
HARS aminoacylation with 10 nM enzyme and 1 uM tRNAHis with increasing glycerol 
concentrations- reactions were allowed to proceed for 2 min (black circles) or 1 min ( 
black x’s). (C) Plateau charging experiment of WT E.coli HARS with 100 nM enzyme 
and 2 uM tRNAHis. (D) Plateau charging experiment of WT human HARS with 1 uM 
enzyme and 100nM tRNAHis. 
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2.6.1 Aminoacylated tRNAHis product data analysis  
After imaging of radioactive products on a phosphor screen the concentration of 
aminoacylated tRNAHis was quantified by comparing the ratio of the relative amount of 
aminoacylated A76 (aa) (determined as counts * mm2) to total radiolabeled product (aa + 




Plateau charging assays of human tRNAHis by human HARS enzyme reveal that 
each tRNAHis preparation contains approximately 50-60% of active tRNA molecules 
relative to the total tRNAHis concentration by A260 readings.  
 
2.6.2 Application of multiple turnover and rapid chemical quench kinetics to 
monitor human HARS activity. 
Extensive multiple turnover (steady state) kinetics for aminoacylation and tRNA 
recognition functions of the E.coli HARS enzyme have been reported [4, 12, 13] but there 
have been relatively few studies focusing on the function of the human enzyme [14]. 
Multiple turnover kinetics have been reported for a number of other human AARS 
enzymes, including those associated with disease causing mutations [15] 
[16],[17],[18],[19], but few have been characterized by rapid state kinetics. In light of the 
lack in knowledge of human HARS enzymatic mechanism we chose to use Mechalis-
Menten kinetics to evaluate basic aminoacylation function and rapid chemical quench to 
monitor half-reactions. 
€ 
[AA − tRNAHis] = (AAcounts × mm
2)
(AAcounts × mm2) + (A76counts × mm2)
× [tRNAHis]
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The aminoacylation assays were carried out at 37 °C in a final reaction volume of 
20 µL with reaction buffer containing  50 mM HEPES pH 7.5, 150 mM KCl, 10 mM 
MgCl2, 5 mM (b-ME), and approximately 0.5 pM 32P-labeled tRNAHis [7]. Steady-state 
kinetic constants were determined by titrating a range of substrate concentrations from 1 
µM to 5 mM in histidine, 100 nM to 15 µM in tRNAHis and 5µM- 0.5 mM ATP for WT 
HARS. Reactions were initiated with the addition of 2 nM to 20 nM HARS enzyme, and 
are terminated by introducing 2 µL of the reaction mixture into 8 µL of a quenching buffer 
of (400 mM NaOAc pH 4.5, 0.1% SDS). These reaction conditions were suitable for 
monitoring WT HARS enzyme activity however, some HARS variants require higher 
concentrations of enzyme and or higher substrate titration ranges. 
 
2.7 Determing independent rate constants for adenylation/amino acid activation 
and transfer of histidine to tRNAHis by rapid chemical quench  
Rapid chemical quench assays have been previously applied in the study of 
prokaryote HARS aminoacylation half-reactions [4, 12, 13]. These experiments can be 
performed with the KinTek RQF-3 (KinTek, College Park, PA) instrument. The instrument 
contains three drive syringes and two ports for sample injections for samples and quench 
solution. With internal loops of varying lengths this machine can be programmed to sample 
reactions on a millisecond time scale.  
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Figure 2.6. Schematic of rapid chemical quench.  
Experimental set up to determine rate constants for adenylation (top reaction) and the 
contents of each syringe (top boxes with red text) and single turnover experiments for 
monitoring aminoacyl-transfer reaction (bottom reaction) and the contents of each 
syringe (bottom boxes with blue text). 
 
2.7.1 Pre-steady state kinetics to monitor the amino acid activation reaction 
Pre-steady state amino acid activation assays using a KinTek RQF-3 were set up 
and conducted essentially as described previously [4, 12] for E.coli HARS. A typical 
experimental set up (Figure 2.6), includes one syringe containing HARS enzyme, 8 U/mL 
inorganic pyrophosphatase (PPiase), a saturating concentration of histidine, and +/- 
tRNAHis in reaction buffer, while the second syringe contained 200 µM [a-32P] ATP in 
reaction buffer. The fractional conversion of ATP to AMP on the TLC plates was analyzed 
by radioisotopic imaging using K-screen and Bio-Rad Molecular Imager FXä. The pre-
steady state rate of amino acid activation was determined by fitting the first turnover to a 
single or double exponential equation [1].  
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2.7.2 Single turnover aminoacyl transfer kinetics by rapid chemical quench 
Single turnover aminoacylation (aminoacyl transfer) kinetics of HARS enzymes 
were also be determined with the KinTek RQF-3 chemical quench. In all single turnover 
reactions, the enzyme:histidyl-adenylate complex was generated in situ prior to the reaction 
by the incubation of HARS (2 µM), ATP (2.5 mM), histidine (10 mM), and PPiase (2 
U/mL) at 37 °C for 10 min. The enzyme adenylate reaction was loaded into one syringe, 
and then challenged with varying concentrations of tRNAHis in the opposing syringe 
(Figure 2.6). The reactions were quenched as described above. After P1 nuclease digestion, 
aminoacylated tRNAHis product was detected and quantified as described above.  
The single turnover aminoacyl transfer rate data were fit to a single exponential 
equation from which rate and amplitude parameters were extracted, as described previously 
[1]. The amount of aminoacylated tRNAHis product was plotted as a function of time and 
the single turnover aminoacyl transfer rate data was determined by use of equation (2):  
 
Where A1 represents the amplitude, C is the y offset, and ktrans is the rate of histidine transfer. 
 
2.8 Determining thermal stability by differential scanning fluorimetry 
Introduction:  Development of Differential Scanning Fluorimetry Assay   
 
Traditionally, biophysical techniques to measure aaRS enzyme stability and 
unfolding have included spectroscopic methods such as intrinsic tryptophan fluorescence 
in the presence of a denaturant like urea or guanidine-HCl, monitoring fluorescence with 
€ 
Y = A1 × (1− ektrans t+C ))
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1-anilino-8-naphthalene-sulfonic (ANS) dye, and circular dichroism [20-23]. For example, 
a classic method for determining a protein melting point without the use of exterior dyes is 
differential scanning calorimetry [24] [25]. Differential scanning calorimetry (DSC) 
calculates the amount of heat required to raise the temperature of a sample by a given 
number of degrees, computing the difference between the sample and a buffer reference 
cell. This approach has been employed to study protein stability in several aminoacyl-
tRNA synthetases systems [26, 27]. Isothermal titration calorimetry (ITC) has also proven 
useful for studying the interactions of small molecule ligands with aaRSs is [28-30]. In 
addition to providing binding constants and stoichiometry, ITC is a direct process that does 
not involve chemical alteration of either the enzyme or the substrate, can provide detailed 
thermodynamic parameters for a given interaction. The chief disadvantage of ITC is that it 
requires expensive instrumentation and, depending on the specific heat of a particular 
interaction, may require relatively high concentrations of the target protein in order derive 
adequate signal. Accordingly, both calorimetric approaches can provide valuable 
information, but typically require large quantities of protein, extensive analysis, and are 
low throughput. 
 
Differential Scanning Fluorimetry (DSF) is a method that enables researchers to 
monitor thermal denaturation of purified proteins with a fluorescent reporter. The DSF 
assay relies on the interactions of the fluorophore dye SYPRO Orange with the exposed 
regions of partially unfolded proteins rich in hydrophobic amino acids (Figure 2.7). The 
native folded structure of proteins sequesters these hydrophobic amino acid residues from 
water, burying them in the highly folded regions of the protein’s core domains. As the 
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solution temperature is increased incrementally, denaturation of the protein exposes 
increasing numbers of hydrophobic residues. This creates an opportunity for SYPRO 
Orange dye binding, which gives rise to an increase in fluorescence (excitation and 
emission of 490 and 575 nm, respectively).  
Figure 2.7. Differential scanning fluorimetery schematic.  
(1) Folded native protein is incubated in solution with SYPRO Orange dye. (2) 
Temperature increases and causes protein to unfold and SYPRO orange dye to bind 
exposed hydrophobic residues and increase in fluorescence signal is observed. (3) Protein 
is denatured and maximum SYPRO Orange dye binding is achieved. (4) Denatured 
protein begins to aggregate and SYPRO orange dye binding decreases. 
 
 
DSF was first developed as a drug screen for small molecule studies, but is also 
applicable as a screen to optimize stabilizing buffer conditions for aaRS crystallization [31] 
[32, 33] and ligand binding studies to obtain binding parameters [34]. Many examples of 
DSF have been reported for proteins such as Carbonic Anhydrase-II [35], cytoplasmic 
sulfotransferase 1C1 [36], cAMP-dependent protein kinase (PKA) [37], MAPK13 [38], 
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and pregnane xenobiotic receptor (PXR) [39] to name a few[40]. A particular advantage of 
the methods is that the experimental set up can be implemented in a high-throughput mode 
by use of a 96-well microtiter plate [41]. The measurements can be performed in a real-
time PCR instrument that is standard equipment for most molecular biology core facilities 
[42]. Fluorescence output is plotted against temperature to determine the melting 
temperature (Tm), by fitting fluorescent data to the Boltzmann equation [43].  
 
2.8.1 Differential scanning fluorimetry method 
 
All reagents used in the DSF assays are listed in Table 2.1. All buffers were pre-
made in sterile 0.22µM filtered deionized water. The dilution buffer used in our thermal 
shift experiments is identical to the standard reaction buffer typically used for 
aminoacylation assays: 20 mM HEPES pH 7.5, and 150 mM KCl. Final glycerol 
concentrations in our preparations varied between 1% to 10%, as this is a stabilizing agent 
for HisRS [44] glycerol was excluded by dialysis from the enzyme preparation to examine 
its effects on Tm.  
Table 2.1: Reagents for DSF experimental set up 
Reagent or supply Supplier Cat. number 
Ultrol grade HEPES buffer CalBioChem 391338 
KCl Fisher 138149 
SYPROrange Dye 5,000 X Molecular probes S6651 
MillexGV 0.22uM filter MerkMillipore 309603 
Sterile syringe 5mL BD Biosciences 309603 
Siliconized low retention 
micocentrifuge tubes 
Fisherbrand 02-681-311 
96 well PCR Plate non-warping Phenix Research MPS-3580-NW 
ThermalSeal RT2 Fi Phenix Research LMT-RT2-RR 
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A 10X stock of enzyme at a concentration of 100 µM was prepared and usually a 
useful starting point with respect to final aaRS concentration in an individual DSF reaction 
well was 10 µM. In our assay to determine Tm and the effect of bound ligand on protein 
Tm, approximately 0.5 mg of protein distributed over 48 wells was used. Based on the 
requirement of 10 µg of sample for each well, approximately 1 mg of enzyme would be 
needed to fill a 96 well microtiter plate. 
Typically, substrates to be evaluated for binding and stability are made as 10X 
concentrated stocks (ie. amino acid, nucleotide (ATP or AMP), and tRNA. In our 
experiments, typical 10X concentrated substrate stocks were 50 mM amino acid and 100 
µM for tRNA. These were diluted to final concentrations of 5 mM and 10 µM, respectively. 
SYPRO Orange (Molecular Probes #S6651- 5,000X concentrated solution) was diluted to 
a 20X stock in a dark Eppendorf tube (Sigma SIAL311AA2C). Typical reactions for 
determination of melting temperature and the effect of ligands on aaRS stability features 
25 µL reaction volumes. The final enzyme concentration that we routinely use was 10 µM. 
The sample mix is prepared by combining enzyme, ligand, buffer, and SYPRO Orange in 
an Eppendorf tube.  
Once samples are prepared, 20 µL of the sample mix is immediately transfered per 
well of a 96 well plate either individually or using a multichannel pipette.  Air bubbles in 
the sample well(s) should be avoided during this process. Following transfer to the 
microtiter plate, reactions containing SYPRO Orange should not be allowed to stand for 
longer than 15-20 min before reading in PCR instrument. Plates were covered with 
ThermalSeal as listed in Table1 and placed in a swinging bucket centrifuge configured with 
adapters for 96-well plates and subjected to centrifugation at 700-1000 x g to ensure that 
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the entire sample volume resides the bottom of the well before placing the plate in a PCR 
instrument. 
 
2.8.2 Melting temperature determination by use of qPCR device  
 
These studies used an Applied Biosystems 7500 fast real-time qPCR device and the 
basic program for dye-binding temperature scans is designated in the instructions for the 
ABI instrument as the “Protein Thermal Shift Solution” and has been described previously 
[32, 43]. Briefly, the ROX (carboxy-X-rhodamine) detector for the ABI 7500 fast 
instrument is selected with no passive dye reference to monitor SYPRO orange 
fluorescence emission. In a typical run, the scan is programmed to initiate at 26°C, followed 
by a temperature gradient in which the samples are heated at a scan rate of 1°C per minute 
until a final temperature of 95 °C is reached. During the heating process, fluorescence 
intensity is measured every 1 °C. Under these conditions, a complete scan of a 96 well 
plate can typically be completed in 1.5 hours.  
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Figure 2.8. DSF data analysis of Lysozyme. 
(A) Arbitrary fluorescence units for 6 well run with Lysozyme (empty circles) and buffer 
control incubated with SYPRO Orange (filled squares) obtained from ABI real-Fast PCR 
instrument plotted against temperature. (B) Data shown as relative fluorescence units 
plotted against temperature. (C and D) Both arbitrary and relative fluorescence data 
truncated and fit to Boltzmann equation to determine melting temperature (Tm).       
 
2.8.3 Data analysis 
 
Fluorescent data can be exported as component data from the ABI 7500 Fast 
instrument and annotated Excel sheet for Graphpad Prism 6 for Tm analysis. Fluorescent 
values are typically plotted on the Y-axis, while temperature is plotted on the X-axis 
(Figure 2.8A). The thermal shift data is typically truncated by excluding fluorescent values 
after maximum fluorescence intensity is achieved (before fluorescent values begin to 
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decrease as a result of protein aggregation) (Figure 2.8A). Relative fluorescence is 
calculated by dividing all fluorescence data in a given well by the maximum fluorescence 
value achieved during the run within the same well (Figure 2.8B and 2.8D). To determine 
the melting temperature (Tm) the the fluorescent data is fit to the Boltzmann equation:  
 
where F(T) is the fluorescence at a particular temperature, F(pre) is the fluorescence before 
the transition or melting at the start of the region of analysis (ROA), F(post) is the 
fluorescence after the transition or melting at the end of the ROA, Tm is the melting 
temperature, and C is a slope factor that corresponds to the enthalpy of the reaction. If the 
data is a monophasic curve Boltzmann will be an appropriate fit to determine Tm (Figure 
3C). ΔTm is substrate dependent and can be determined by the equation shown below: 
 
Here Tm represents the protein in the presence of ligand while T0 is the unbound 
protein. This will yield a positive ΔTm if binding ligand increases in stability (Tm>T0). A 
negative ΔTm values would imply a decrease in stability as a function of ligand binding. 
For samples that may have more then one transition of unfolding or bi-phasic melt curves, 
the Boltzmann equation cannot be used to reliably fit the data and determine Tm (Figure 
2.8C). However, the derivative method can be used to determine the Tm. By plotting the 
first derivative of fluorescence emission as a function of temperature (−dF/dT) each 




ΔTm = Tm −T0
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2.8.4 Replicates and controls 
 
Technical Replicates for each condition (sample mix) should minimally be done in 
triplicate within one 96-well plate run. The reactions shown in this protocol can be prepared 
in a single Eppendorf tube and are sufficient for a triplicate analysis based on three wells 
of a microtiter plate. A single set of technical replicates provides an indication of the 
variability between wells for the PCR instrumentation being used. We suggest repeating 
this step an additional one or two times for a total of 6-9 wells of three technical replicates. 
A 60 µL reaction containing 0.1 mg/mL lysozyme in 50mM HEPES pH 7.0, 100 mM KCl 
serves as a simple test experiment. In this standard DSF reaction, lysozyme exhibits an 
apparent published melting temperature transition (Tm) of 70.9 ± 0.7 °C [45]. In our 
apparatus and using these conditions, we determined a Tm of 69.4 ± 0.1 °C for lysozyme 
(Figure 2.3). Additionally, we have determined that SYPRO Orange does not bind tRNA 
and therefore tRNA substrates can be tested for binding with aminoacyl-tRNA synthetases.  
DSF was shown to reliably and reproducibly determine Tm values for two different 
HisRS preparations only varying by approximately 1°C. Similar studies examining the 
effects of disease related aaRS substitutions have been investigated by DSF for 
mitochondrial AspRS [46]. The experimental conditions described here to determine Tm 
represent useful initial conditions to initiate analysis of an AARS with an unknown 
apparent melting temperature. These conditions have been successfully used in the 
characterization of purified human AARS enzymes. Additionally, a negative Tm can be 
indicative of a positive hit for binding [43]. One possible explanation for a lower ΔTm value 
relative to Tm is that ligands or substrates bind the unfolded protein much more tightly [47].  
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As DSF was originally designed for small molecules studies, it can easily be applied 
to evaluate amino acid binding by aaRS enzymes, assuming a significant shift in Tm occurs 
upon binding [48]. By titrating increasing amounts of histidine while holding HARS 
enzyme concentration constant, the change in Tm (ΔTm) can be recorded as a function of 
amino acid concentration. In some cases, ligand dependent changes in Tm values 
determined by DSF have been shown to correlate with activity and calorimetrically 
determined binding measurements [49]. However, it appears that the concentration of 
histidine required to produce 50% of the ligand dependent increase in melting temperature 
is higher than the Kd determined by spectrofluorometric methods. In other systems, Tm 
shifts greater then 4°C have been shown to correlate to IC50 values less then 1µM [36]. In 
our experiments, a maximal apparent Tm increase of 4.4°C was observed upon titration of 
histidine to E.coli HARS; this required several orders of magnitude higher concentrations 
than the 35.4 µM KM determined kinetically [6].  
 
2.9 Determine dimerization of HARS in solution by analytical ultracentrifugation 
(AUC)  
There are a number of methods that can be used to rapidly evaluate the molecular 
weight of proteins including, size exclusion chromatography (SEC) and native gel 
electrophoresis [50]. However, SEC requires calibration while limitations of native gel 
electrophoresis hinge on the homogeneity of protein preparations.  
AUC is an accurate method for the characterization of protein molecular weight 
and oligomeric state in a biologically relevant solution[51]. The theory of AUC is centered 
on laws of gravitation and therefore sedimentation of proteins in solution allow for the 
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determination of mass, buoyancy, and shape. Protein oligomerization by AUC is 
determined in the absence of interactions with a solid support or acrylamide gel matrix. 
Furthermore, AUC can accurately and quantitatively determine not only molecular weight 
but also sample heterogeneity [52], purity, degree of aggregation, and hydrodynamic shape 
at a wide range of concentrations [53].  
There are two classical AUC experiments sedimentation velocity (SV) and 
sedimentation equilibrium. SV experiments of HARS enzymes characterize the solution 
behavior of macromolecules and observe the sedimentation and diffusion behavior of all 
species in a mixture, and report their partial concentrations, buoyant molar masses, and 
anisotropies. Sedimentation and diffusion transport in the ultracentrifugation cell are 
described by the Lamm equation, which can be solved using adaptive finite element 
methods [54, 55]. Therefore, we conducted the SV experiments at 230 nm where the 
extinction coefficient is significantly higher compared to the standard 280 nm absorbance, 
and allows us to monitor at lower concentration. Data quality at 230 nm is also higher due 
to the high light emission intensity of the Xenon lamp used in the ultracentrifuge. Whole 
boundary data obtained in SV experiments are fitted by linear combinations of such 
solutions using advanced optimization routines [56-58] that are typically implemented on 
a supercomputer [59]. 
Analytical centrifugation experiments were performed with purified HARS 
enzymes that were typically dialyzed into a buffer containing 10 mM potassium phosphate 
buffer, 50 mM KCl, and no reducing agents. All protein samples were concentrated to 0.3 
OD units/mL at 230 nm (0.7 µM). Sedimentation velocity experiments were performed by 
the Center for Analytical Ultracentrifugation of Macromolecular Assemblies at the 
  64 
University of Texas Health Science Center at San Antonio, and conducted at 20 ºC, 35 K 
rpm, in a Beckman Optima XLI analytical ultracentrifuge using an An60Ti rotor and 
standard 2-channel epon centerpieces (Beckman-Coulter) and measured by UV intensity. 
All data were examined with UltraScan-III ver. 3.5, release 2170 [54, 55] and 
hydrodynamic corrections for buffer density and viscosity was estimated to be 1.0019 g/ml 
and 0.998 cP, respectively. The partial specific volume of HARS (0.745 ml/g) was 
estimated by UltraScan from protein sequence analysis using methods outlined in Laue et 
al. [60]. Experimental sedimentation data were pre-processed by 2-dimensional spectrum 
analysis (2DSA) [56, 58, 61] and fitted by the parametrically constrained spectrum analysis 
(PCSA), using a straight-line parameterization coupled with a Monte Carlo approach[59, 
62]. The calculations [63] were performed on the Lonestar cluster at the Texas Advanced 
Computing Center at the University of Texas at Austin and on Comet and Gordon at San 
Diego Supercomputing Center.  
Experimental SV data were pre-processed by 2-dimensional spectrum analysis 
(2DSA) [56] with simultaneously removal of time- and radially-invariant noise 
contributions [64], and to fit the meniscus position as described in [64]. The resulting data 
were fitted by the parametrically constrained spectrum analysis (PCSA), using a straight-
line parameterization coupled with a Monte Carlo approach [59, 63]. The calculations are 
computationally intensive and are carried out on high-performance computing platforms 
[63]. All calculations were performed on the Lonestar cluster at the Texas Advanced 
Computing Center at the University of Texas at Austin and on Comet and Gordon at San 
Diego Supercomputing Center. 
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2.10 Evaluating cellular effects of HARS disease associated mutations in model cell 
systems 
 
The assays described thus far can provide essential information about the functional 
and structural biochemical consequences of HARS disease associated variants. However, 
a critical gap in knowledge as to what cellular consequences these mutations may have in 
neuronal cells, is still unknown. Notably, expression of various CMT mutations in animal 
models have presented with axonal phenotypes [65]. Additionally, intracellular 
perturbations by expression of disease associated mutant aaRS enzymes may involve 
activation of amino acid starvation response, accumulation of misfolded proteins, or non-
canonical functions yet to be discovered.  
 
2.10.1 Immunoprecipitation from HEK293 cells for HARS-protein interaction 
studies and identification of post-translational modifications. 
Immunoprecipitation experiments in preliminary studies to identify aaRS protein-
protein interactions as well as post-translation modifications are readily achieved using 
HEK293 cells. Immunoprecipitation reactions for human HARS enzymes were readily 
achieved with anti-FLAG (or anti-DYDDDK) resin used for the first step in protein 
purification. Briefly, transfected HEK293 cell lysates were incubated with agarose resin 
conjugated with anti-DYKDDDK antibody for 2 hours. After incubation with the resin 
samples were spun down at 6,000 x g for 30 seconds. After the initial spin supernatant was 
collected from the resin pellet and the resin was re-suspended and washed 3 times with 
TBS. The final elution of bound HARS-protein complexes was achieved with an acidic 
buffer, opposed to the peptide elution used for the purification. The eluted sample was 
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combined with 4X SDS PAGE loading dye and boiled for 10 min. at 95℃. The samples 
were then resolved by SDS PAGE and specific bands or whole lanes was cut from the gels 
after gel code blue staining. Gel pieces were then soaked and digested with Trypsin. Tryptic 
digested samples were then submitted for mass spectrometry analysis for either protein ID 
or post-translational modification. 
 
2.11 Cell models to evaluate axonal phenotypes of HARS disease associated 
variants  
 
While HEK293 cells are a useful line for generating active recombinant HARS 
protein, they are not particularly useful for evaluating defects HARS mutations may have 
in neuronal cells. While primary cell lines derived from a mouse model containing the 
HARS mutations would be the gold standard, these options are expensive and challenging 
to obtain. Previous studies have utilized an immortalized embryonic mouse motor neuron, 
neuroblastoma fusion cell line, known as MN-1, to identify GARS CMT mutations that 
lead to aberrant localization within the cell [66]. An alternative cell line that can exhibit 
neuronal morphology and properties upon nerve growth factor (NGF) treatment are known 
as pheochromocytoma (PC12) cells. We have utilized the latter of these two immortalized 
cells lines to evaluate phenotype, toxicity, and basic cellular biology of HARS disease 
mutations. Here we describe the methods and protocols for use of this cell line to evaluate 
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2.11.1 Pheocytochromotoma (PC12) cells for axonal phenotype 
 
PC12 cells are a tumor-derived cell line originally isolated from rat adrenal medulla 
pheochromocytoma [67]. A valuable property of these cells is their response to nerve 
growth factor (NGF) [68]. When PC12 cells are maintained in normal growth medium they 
exhibit a small round morphology that is slightly bi-polar and upon NGF treatment the cells 
begin to differentiate and form long processes [69]. Treatment of PC12 cells with NGF 
halts proliferation, promoting differentiation to non-dividing sympathetic neuron-like cells 
[70]. During this differentiation process the cells will extend processes reminiscent of 
axons and dendrites, collectively termed neurites. Differentiation is coupled to the 
increased expression of neurofilament (NF-L) [71] and GAP43 that aids in cytoskeletal 
rearrangement and growth cone formation, respectively. As PC12 cells have the cellular 
organization to synthesize and store neurotransmitters, NGF differentiation has been 
shown to prompt PC12 cells to become electrically active [72].     
PC12 cells are a valuable system to study axonal outgrowth. Differentiated PC12 
cells can then be used to evaluate normal neuronal homeostasis such as trafficking, effects 
of mitochondrial function, and receptor localization[73-75]. PC12 cells have been useful 
for disease research in Parkinson’s [76], Alzheimer’s [77], diabetic neuropathy [78] and 
even CMT [79]. Many pharmacology studies [80, 81] have also utilized PC12 cells to 
evaluate how compounds perturb axonal morophology. Our goal is to utilize these cells for 
evaluating HARS CMT variants cellular localization and perturbations to axonal outgrowth 
as previously observed in animal models.  
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2.12.2 PC12 cell maintenance and transfection. 
 
PC12 cells were typically maintained in a growth media of RPMI-1640 (Thermo) 
supplemented with 10% horse serum, 5% FBS, 1% penicillin/streptomycin, and 1% L-
glutamine and maintained at 37 °C in a humidified incubator containing 5% CO2. Cells 
were passaged as a ratio of 1:3 or 1:4. For successful transfection PC12 cells require a 
minimum confluence of 60-70% on poly-lysine coated plates. Prior to transfer of PC12 
cells for transfection, plates were coated for a minimum of 30 minutes with 0.5 mg/mL of 
poly-lysine and then thoroughly rinsed. Once PC12 cells reach optimal confluence (at least 
50-75% confluency) on poly-lysine treated plates they were pre-treated with OPTI-MEM 
media (Thermo) for 30 mins at 37 °C in a humidified incubator containing 5% CO2. While 
the cells were pre-treated with OPTI-MEM, 5 𝜇g of plasmid was added to 100 𝜇L OPTI-
MEM and separately 15 𝜇L of lipofectamine 2000 was combined with 200 𝜇L OPTI-MEM 
for 5 mins at room temperature. After a 5 min incubation the DNA:OPTI-MEM and 
Lipfectamine:OPTI-MEM mixtures were combined and incubated at room temperature for 
25-30 mins. After appropriate incubations the transfection mixture were added to the cells 
that have been incubating with OPTI-MEM media and placed back in the incubator for 5 
to 6 hours. After the 5 to 6-hour transfection the OPTI-MEM media was replaced with 
warm normal PC12 growth media.  
Plasmid (pCAG/FLAG/RFC/A) containing the genes for human N-terminal FLAG-
tagged HARS bicistronically expresses GFP, to identify transfected cells and effectively 
observe neurite outgrowth. 
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2.12.3 PC12 cell differentiation  
 
For evaluating neurite outgrowth 24 well plates were used to evaluate multiple 
CMT mutations or different treatments on PC12 cells. For NGF differentiation PC12 cells 
require both poly-lysine and laminin coated surfaces. First, poly-lysine was diluted to 0.5 
mg/mL from a 1 mg/mL stock in Dulbecco’s Phosphate Buffered Saline (DPBS) and 
incubated in wells (200-300 𝜇L/well) for 1 hour. After washing the wells with DPBS two 
times or sterile ddH2O, laminin (1mg/mL) diluted with DPBS to 0.02 mg/mL is added to 
the wells with (150 uL/well) for 1 hour. Again plates and/or coverslips are washed 2X with 
DPBS and once with media. After 24 hours that PC12 cells have been transfected they can 
be transferred into a 24 well plate at a desired density in differentiation media of RPMI-
1640 with 1% horse serum, 1% penicillin/streptomycin, and 1% L-glutamine, and B27 
supplement (Thermo). Three hours after transfected cells were plated they can be treated 
with NGF (50 ng/mL) for 1 to 4 days. 
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Figure 2.9. PC12 cell differentiation after NGF treatment and neurite tracing 




2.12.4 Imaging, neurite quantification and data analysis 
 
Images of transfected PC12 cells fixed on 24 well plates can be collected at 20X 
with an inverted fluorescence microscope such as Olympus IX71 and quantified with a 
simple measuring and tracing using SPOT microcopy imaging software (Figure 2.9). To 
evaluate localization of HARS in neurites images of transfected PC12 cells fixed onto 
coverslips were taken with a 40x objective on a Nikon Eclipse Ti inverted microscope. 
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Useful co-localization markers included were cytoskeletal proteins such as TUJIII (to stain 
microtubules) and phalloidin to mark actin filaments.   
To alleviate bias in the image processing multiple images are taken of each well 
and multiple wells of transfected PC12 cells for each variant per experiment are collected. 
From these images, parameters that can be measured include cell number, cell body width, 
number of neurites per cell [82], and neurite length. Experimental parameters to evaluate 
from this data include percent of differentiated cells as defined by cells that have at least 
one neurite twice the length of the cell diameter (approximately 10 to 20 microns) [83] . 
2.13 Conclusion 
Many researchers have contributed to our understanding of aaRS substrate binding, 
specificity, and editing catalytic activity over the past few years. However, as many 
different diseases have been linked to aaRS mutations it is essential to create new methods 
to evaluate different aspects of aaRS biology. Here, we describe kinetic assays to critically 
evaluate aminoacylation function of human HARS enzymes. Additionally, the application 
of DSF and AUC in structural studies are also described here. Finally, both HEK293 and 
PC12 cell methods were established in hopes to explore perturbations of the cellular 
environment and potential axonal phenotypes.  
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CHAPTER 3: CHARACTERIZATION OF HUMAN HARS MUTATIONS 
ASSOCIATED WITH INHERITED PERIPHERAL NEUROPATHY 
3.1 Introduction  
Peripheral neuropathy is a disease that describes damage or disease of the 
peripheral nervous system. Peripheral neuropathy can be either acquired or inherited [1] 
and symptoms include pain, weakness and or numbness of the hands and feet. Acquired 
peripheral neuropathies are associated with physical injury and disease related damage by 
diabetes [2], autoimmune disease, and infections. Acquired peripheral neuropathies can 
also result from exposure to toxins such as chemotherapeutics [3] and alcohol. Peripheral 
neuropathies can also be caused by inherited or de novo mutations as Charcot-Marie-Tooth 
(CMT) is a hereditary peripheral neuropathy that involves damage to both sensory and 
motor neurons.  
CMT manifests as progressive degeneration of distal motor and sensory neurons, 
leading ultimately to muscle weakness and atrophy of the legs and hands/arms. CMT 
typically presents in an axon-length dependent manner with the structures innervated by 
longer axons affected first [4]. CMT specifically affects the peripheral nerves of the 
extremities, causing a progressive muscle weakening and wasting, decreased sensation, 
and skeletal deformities. The onset and penetrance of CMT is quite variable, with many 
patients experiencing symptoms in the first two decades of life that become progressively 
worse over time. Subtypes of CMT can be further categorized into either demyelinating 
type 1 (CMT1), which features defects in the myelin sheath surrounding peripheral nerves, 
and axonal type 2 (CMT2), which results in abnormalities in the axon of the peripheral 
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nerve. Nerve conduction studies and electromyography (EMG) examination of patients 
with CMT are characteristically abnormal. Patients with CMT1, demyelination of Schwann 
cells, typically have decreased motor nerve conduction velocities (MNCVs). While 
patients with (CMT2) may have normal MNCVs but reduced muscle action potentials 
arising from axonal degeneration. There also exists an intermediate form that has 
characteristics of both CMT1 and CMT2 [5-8].  
3.1.1 Aminoacyl-tRNA synthetase mutations are associated with CMT 
Over 80 genes have been linked to CMT, distributed among diverse functional 
categories [9]. Four genes account for 96% of all CMT cases, consisting of peripheral 
myelin protein 22 (PMP22), myelin protein zero (MPZ), and gap junction beta-1 (GJB1), 
which are linked to CMT1, and mitofusin 2 (MFN2), which is linked to CMT2. In addition 
to myelin assembly, the diverse cellular processes affected by CMT include 
cytoskeleton/axonal transport, protein synthesis and quality control, endosomal sorting, 
mitochondrial functions, channel abnormalities, and mRNA/processing transcription. 
While the end result of genetic changes in these processes is likely to involve a degradation 
of Schwann cell function or axonal dysfunction, the precise mechanisms by which 
alterations of individual genes bring about these phenotypes are, for many genes, not well 
understood. At the current time, there are no effective treatments for CMT. Among the 
elements of the protein synthesis and protein quality control apparatus that are linked to 
CMT are the aminoacyl-tRNA synthetases (ARSs)[10].  
To date 30 gene mutations in aaRS genes are associated with the intermediate and 
axonal autosomal dominant and intermediate autosomal recessive forms of the disease 
[11]. In contrast to the relatively rare neurological diseases where a mutation or mutations 
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in a single aaRS gene is linked to the disease pathophysiology, at least six different aaRS 
genes are linked to inherited peripheral neuropathies, typically CMT [12, 13].  
The first aaRS associated with CMT was GARS, where mutations in the gene 
encoding  GARS were implicated in axonal CMT disease via positional cloning in families 
with an atypical disease presentation [14, 15]. Notably, the majority of patients presented 
with an upper limb predominant neuropathy that affected the intrinsic muscles of the hand 
(i.e., the thenar eminence and first dorsal interosseous) [14, 15]. Mutations in the GARS 
gene can cause both CMT2D and distal spinal muscular atrophy type V (DHMN5A) [14]. 
It is likely significant that the synthetase enzyme encoded by the GARS gene is obliged to 
function in both the cytoplasmic and mitochondrial compartments. Similar to other class II 
enzymes, GARS is an obligate dimer, and several of the mutant substitutions linked to 
CMT alter residues located at the dimer interface [16]. Some of these have been shown to 
either weaken or strengthen dimer formation [16]. Additionally, it may also be relevant 
that wild type protein forms punctate structures (granules) in neurite projections, a property 
lost in some of the GARS CMT mutants [17]. Other in vitro models of CMT GARS 
mutations also demonstrate a defect in localization to neurite-like projections in a 
transfected neuroblastoma cell line [18]. It is not clear whether the phenotype is related 
solely to the cytoplasmic or mitochondrial distribution of GARS, or both. However, 
cytoplasmic aaRS gene mutations associated with peripheral neuropathies [12] indicate 
that dysfunctional mitochondrial protein translation is not the primary cause of these 
phenotypes. 
A Drosophila model was created to examine the effects of the GARS CMT2D 
mutation on two different types of neurons, olfactory projection neurons and mushroom 
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body γ neurons [19] representing two CNS neuron populations that differ in development, 
morphology, and circuitry. The olfactory projection neurons showed severe defects in 
dendritic morphology but few axonal defects. However, mushroom body γ neurons had 
defects in both axon and dendritic morphology. Interestingly, as GARS is cytoplasmic and 
mitochondrial, individual disruption of cytoplasmic protein synthesis caused large defects 
in axonal and dendritic nerve end branching, while disruption of mitochondrial protein 
synthesis led to more dendritic nerve end branching than axonal. The Drosophila GARS 
mutations could be rescued by expression of human WT GARS. However, CMT2D 
mutations E71G and L129P could not rescue the defective neuronal projections and hence 
are loss of function mutations.    
Mouse models of GARS CMT mutations have shed some light on the possible 
pathological mechanism for which aaRSs can cause peripheral neuropathy. Interestingly, 
there did not appear to be significant mislocalization of GARS protein or change in GARS 
granule formation in the CMT2D mouse model, GARSNmf294/+ [20]. The GARSNmf294/+ 
mouse model of CMT2D also showed defects in the neuromuscular junction (NMJ), 
reduced axon diameter, and sensory and peripheral axonal loss but no myelination defects. 
Importantly, this mutation does not cause a substantial loss of primary aminoacylation 
function [21]. More recent studies of GARSNmf294/+ mice have shown that peripheral 
neuropathy is not caused by reduced neuronal connectivity to distal muscle fibers but that 
defects and denervation commonly observed at NMJs corresponds to inappropriate 
maturation process at distal muscle fibers [22].  
Subsequently, mutations in tyrosyl- (YARS) and alanyl-tRNA synthetase (AARS) 
genes were identified via linkage analysis of families with a more typical presentation of 
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CMT disease [23, 24]. In particular, the mutant YARS substitutions G41R and E196K, and 
deletion Δ153-156, are associated with dominant intermediate Charcot-Marie-Tooth C 
(DI-CMTC) (Jordanova et al., 2006). While the G41R and Δ153-156 mutations 
demonstrated severe catalytic defects, the E196 mutant was more active, suggesting that 
canonical activity defects are not responsible for the disease phenotype [25]. Furthermore, 
mutations are not found in domains responsible for previously reported non-canonical 
functions such as the cytokine activity of YARS [26], suggesting that the CMT pathogenic 
substitutions may not be associated with YARS non-canonical activities. The mutated 
YARS enzyme exhibits stability in vivo that is comparable to the wild type enzyme [25], 
but may be subject to a similar tendency to cellular mislocalization in neuroblastoma cells 
lines that was seen with GARS [23].  
Following these reports, a screen of a large cohort of CMT patients led to the 
identification of three variants of the KARS gene that are associated with a recessive 
intermediate form of CMT that exhibit additional neurological and non-neurological 
sequelae [27]. The bifunctional (cytoplasmic and mitochondrial) lysyl-tRNA synthetase 
(KARS) represents another targeted gene in CMT. One interesting CMT patient was found 
to be a compound heterozygote with mutations encoding both a L133H missense and a 
Y173SX7-frame shift mutation [27]. Both mutations localize to the anticodon-binding 
domain, however the Y173SX7-frame shift likely results in complete loss of the catalytic 
domain.  The L113H catalytic analysis results showed a reduction in aminoacylation to 
levels below 25% of wild type. In addition to peripheral neuropathy, a behavioral pathology 
was observed in this subject. KARS is also part of the multi-synthetase complex (MSC) 
and can exist as either a dimer or tetramer. KARS has additional non-canonical functions 
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involved in signaling, cell migration, and viral HIV infection, some of which are activated 
by post-translational modification [28]. Mitogen-activated kinase (MAPK) 
phosphorylation induces release of one dimer from the MSC for translocation into the 
nucleus, while the other dimer remains with the MSC to continue protein synthesis [29]. 
Another well characterized tRNA synthetase associated with hereditary motor 
neuropathy is the cytosolic AARS. In an earlier study, characterization of the mouse strain 
AARSsti (or “sticky” mouse) with uncharacteristic CMT phenotype, a progressive 
neurogeneration and a coat defect, suggested a link between these properties and an editing 
defect in AARS[24] [30]. Phenotypically, the AARSsti mice have significant Purkinje cell 
loss and ubiquitin inclusions suggestive of protein misfolding that are absent in 
GARSNmf294/+ mice [20]. Investigations of AARS CMT2N subjects in an Australian family 
showed additional symptoms that included sensorineural deafness [31]. An attractive 
hypothesis is that the protein misfolding is a direct consequence of mistranslation 
originating from the misacylation of tRNAAla with serine instead of alanine [32].  
Additionally, patients with late-onset CMT2 were identified to carry mutations in 
methionyl-tRNA synthetase (MARS) gene [33]. The mutation affects a highly conserved 
arginine residue, R618C, that forms a salt-bridge interaction at the catalytic and anticodon-
binding domain interface. The R618C MARS mutation phenotypically has a late-onset and 
does not show complete penetrance as a loss of function mutation in yeast models. 
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3.1.2  HARS variants associated with inherited peripheral neuropathy CMT 
Definitive evidence linking HARS mutations to CMT disease was developed by 
identification of multi-generational pedigrees with inherited peripheral neuropathies that 
segregated with missense mutations in HARS coding for substitutions in active site residues 
(e.g., T132I, P134H, D175E, and D364Y) [34]. All four missense mutations affected 
HARS protein function in a yeast complementation assay and over-expression of two of 
these mutations (R137Q and D364Y) in worm resulted in dominant toxicity to neurons[34] 
caused aberrant motor neuron axonal growth and a progressive loss of motor coordination. 
These data confirmed HARS as the fourth ARS locus implicated in CMT disease, but also 
demonstrate that different HARS mutations lead to distinct diseases, suggesting different 
pathophysiological mechanisms. 
Here, we report detailed functional analyses of three previously unreported HARS 
missense mutations derived from three distinct families. Each mutant protein was 
expressed, purified, and characterized biochemically. The mutations were also studied in 
yeast complementation assays to assess the ability of the mutants to support growth in 
yeast. The results of these analyses show that this set of HARS mutations lead to a clear 
reduction in HARS catalytic activity, typically manifesting as an increase in the Km for 
histidine, ATP, or both. None of the mutants exhibited an altered KM for the transfer RNA 
substrate, and none of the mutants led to a weakening of the HARS dimer stability. These 
data represent the first detailed biochemical analyses of HARS mutations associated with 
CMT, and our results are discussed in light of current models linking altered ARS activity 
to CMT pathophysiology. 
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3.2 Results and discussion 
3.2.1 Clinical and genetic analysis of patients with peripheral neuropathy 
Family 1. A three-generation family of Persian-Jewish descent (living in Israel) was 
identified with peripheral neuropathy (Figure 3.1A). Five affected individuals are present 
and the family displays an autosomal dominant inheritance pattern; please note the male-
to-male transmission. Age of onset is in the second decade of life for the two youngest 
individuals; age of onset is less clear for the older individuals but the affected status was 
clear upon examination. All individuals display a motor predominant to pure motor 
phenotype with clear pyramidal features as assessed by brisk reflexes and ankle 
clonus/Babinski signs. All patients—except for one—have normal sensory exams. At least 
two of the elder individuals have severe weakness necessitating the use of a cane or a 
wheelchair; however, the younger individuals are ambulatory. Nerve conduction studies 
are consistent with a motor predominant axonal neuropathy. There is some co-morbidity: 
the female patient from the second generation has systemic lupus and one of the males in 
the third generation has uveitis, hematuria, and proteinuria. 
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Figure 3.1. Histidyl-tRNA synthetase mutations identified in three pedigrees with 
peripheral neuropathy.  
(A-C) Genotyping was performed to determine if HARS variants segregate with disease 
status. The pedigree structures of Family 1 (A), Family 2 (B), and Family 3 (C) are 
shown. Circles represent female individuals and squares represent male individuals. 
Shaded symbols represent affected individuals and non-shaded symbols represent 
unaffected individuals. Diagonal lines indicate deceased individuals. Genotypes are 
indicated under each individual where DNA was available.  
 
Whole-exome sequencing was performed on one affected individual, which 
revealed common or non-segregating SLC5A7, SETX, and LAMA2 variants (the variant in 
LAMA2 was not consistent with a dominant neuropathy). This analysis also revealed 
V155G HARS, which fully segregated with the disease phenotype upon PCR and Sanger 
sequencing of additional individuals; however, DNA is not available for the unaffected 
individual in the third generation. V155G HARS affects an amino-acid residue that resides 
in the catalytic core of the HARS enzyme (Figure 3.2A and Figure 3.2B) and that is 
conserved from human to yeast (Figure 3.2A) V155G HARS has not been previously 
reported nor has it been detected in the gnomAD database (Table 3.1) [35]. 
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Wt / Wt Wt / p.V155G
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T132I Not detected None T131I (Safka Brozkova et al. 2015) 
P134H Not detected None P133H (Safka Brozkova et al. 2015) 
R137Q 20 / 246,154 rs191391414 R136Q (Vester et al. 2013) 
V155G Not detected None V154G This study 
D175E Not detected None D174E (Safka Brozkova et al. 2015) 
Y330C Not detected None Y330C This study 
S356N 5 / 277,222 rs144322728 S370N This study 
D364Y Not detected None D378Y (Safka Brozkova et al. 2015) 
aHuman amino acid positions are relative to GenBank Accession number NP_002100.2 
bhttp://gnomad.broadinstitute.org 
cYeast amino acid coordinates correspond to GenBank accession number EDN61168.1 
 
Family 2. A two-generation pedigree was identified with peripheral neuropathy 
(Figure 3.1B).The age of neuropathy onset for both patients was during childhood. Both 
individuals show a motor predominant phenotype, with distal motor deficit and atrophy, 
hammer toes, and pes cavus. Both affected patients have mild sensory symptoms in the 
toes, with reduced vibration sense at the knees. Tendon reflexes were brisk in both patients. 
The mother (patient 1) is restricted to a wheelchair while her son (patient 2) walks with 
difficulty but without aid. The CMT Neuropathy Score (CMTNS) for patient 1 is 22 and 9 
for patient 2. It has to be considered that phenotype of patient 1 is probably exacerbated by 
concomitant diseases (diabetes, chemotherapy for melanoma, radiculitis secondary to 
herpes zoster and Parkinson’s disease). Nerve conduction studies show axonal motor-
predominant neuropathy in both patients. 
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Targeted gene panel screening in Family 2 (Figure 3.1B) revealed two missense 
HARS variants in cis: S227A and Y330C; these variants were previously reported as part 
of a larger study on CMT disease [36] but the functional consequences of the mutations 
were not assessed. Both mutations segregate with the disease phenotype; however, S227A 
was deprioritized due to the number of alleles detected in gnomAD (37 alleles in 282,464 
alleles total) and the lack of conservation of the affected residue (see Figure 3.2A). Y330C 
HARS affects an amino-acid residue that resides in the catalytic core of the HARS enzyme 
(Figure 3.2A and Figure 3.2B) and that is conserved from human to bacteria (Figure 3.2A). 
Y330C has not been previously reported nor has it been detected in the gnomAD database 
(Table 3.1) [35].  
Family 3. A simplex pedigree was identified with two unaffected parents and a 
single daughter affected with peripheral neuropathy (Figure 3.1C). The affected daughter, 
at 15 years of age, was seen in consultation for difficulty with walking. Her early 
milestones were normal including walking with a normal gait at 12 months. She was 
physically active as a child and able to keep up with her peers until the age of 10. At 12 
years of age she noticed she could no longer walk on her heels. At ~13 years of age she 
developed difficulties with walking. This progressed and she had problems with other 
activities such as jumping and running by the age of 15. She had ankle weakness, a foot 
drop, and right knee pain. She began to wear foot orthotics bilaterally. No problems with 
hand function were reported, but a slight hand tremor was reported and observed. Her 
sensory exam was normal to pinprick, light touch, and joint position sense in all four 
extremities. Vibration sensation was also normal with the exception of a slight reduction 
at her toes. Her feet turned in bilaterally but could be brought to a neutral position. She had 
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high arches and atrophy noted in her hands and distal forearms. Her CMT Neuropathy 
Score (CMTNS) was a 10, which is in the high end of the mild range. Her CMT Pediatric 
Score (CMTPeds) was a 33, which is in the moderately impaired range. 
Whole-exome sequencing was performed on the affected daughter in Family 3 
(Figure 3.1C), which revealed S356N HARS as the only candidate disease-associated 
variant. Sanger sequencing revealed that this variant was inherited from the unaffected 
mother suggesting decreased penetrance or that this is a non-pathogenic variant. S356N 
HARS affects an amino-acid residue that resides in the catalytic core of the HARS enzyme 
(Figure 3.2B and C) and that is conserved from human to yeast (Figure 3.2A). S356N 
HARS has not been previously reported; however, it has been detected in the gnomAD 
database (5 alleles in 277,222 chromosomes; Table 3.1) [35]. 
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Figure 3.2. Neuropathy-associated HARS mutations are found in the active site of 
the dimeric enzyme.  
(A) Histidyl-tRNA synthetase forms a homodimer (first monomer yellow and second 
monomer blue). The neuropathy-associated HARS residues are shown in the 3D structure 
as red sticks of the HARS dimer bound to histidine (green spheres) (PDB 4PHC). (B) A 
close up of the HARS active site pocket (yellow) reveals that neuropathy-associated 
mutations face into the active site (shown as red sticks and spheres). (C) Modeling in 
HARS neuropathy-associated substitutions indicates that interference with substrate 
binding (histidine green sticks and ATP gray sticks) can occur. ATP was modeled into 
the active site of the human HisRS bound to histidine (PDB 4PHC) by aligning the 
HisRS E. coli structure bound to ATP (PDB 1KMN). (D) Complete amino acid sequence 
alignment of human, mouse, worm, yeast, and bacterial HARS enzymes annotated with 
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3.2.2 Identified HARS mutations affect viability in yeast complementation studies 
To test the functional consequences of the HARS missense variants described above 
(V155G, Y330C, and S356N), each variant was introduced into the yeast ortholog HTS1 
to model the effect of the mutation in the context of a eukaryotic cell (Table 3.1). Yeast 
complementation assays were then performed to independently test all three missense 
changes for the ability to support yeast cell growth as compared to wild-type HTS1 or an 
empty vector. A haploid yeast strain (with the endogenous HTS1 locus deleted and a 
maintenance vector to express wild-type HTS1 and URA3) was transformed with either a 
pRS315 vector with no insert (‘Empty’) or a pRS315 vector harboring wild-type HTS1, or 
a mutant version encoding one of the three missense mutations (V155G, Y330C, or 
S356N). Yeast cells were then selected on media containing 5-FOA, which is toxic to yeast 
carrying the URA3-bearing maintenance vector [37]. Thus, only yeast cells expressing a 
functional HTS1 allele from the pRS315 vector will grow in this assay. 
Yeast transformed with a wild-type HTS1 expression vector demonstrated 
significant growth, while those transformed with an empty vector did not (Figure 3.3A), 
consistent with HTS1 being an essential gene [38]. Yeast expressing Y330C or S356N 
HTS1 displayed severely depleted, but not ablated, yeast cell growth (Figure 3.3A), 
indicating that these are hypomorphic alleles. In contrast, V155G HTS1 supported yeast 
cell growth, but at levels less than wild-type HTS1 (Figure 3.3A). Growth at 37OC did not 
affect the cellular phenotype associated with above mutations, and over-expression of 
tRNAHIS or supplementation of histidine in the media did not improve the growth 
phenotypes associated with S365N or Y330C HTS1 (data not shown). In summary, our 
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previously employed in vivo yeast complementation assay demonstrated that V155G HTS1 
supports growth similar to wild-type HTS1, and that S365N and Y330C HTS1 are 
hypomorphic alleles in this assay. 
The lack of a cellular growth defect associated with V155G HTS1 was surprising 
given that this mutation segregates with disease in a three-generation family. One possible 
explanation for this discrepancy may be differential effects of V155G of the function of 
yeast HTS1 compared to human HARS. To explore this possibility, we attempted to rescue 
deletion of yeast HTS1 with the full-length human HARS protein. In yeast 
complementation assays similar to those described above, expressing human HARS 
rescued yeast cell growth while a vector with no HARS insert did not (Figure 3.3B); this is 
the first report that human HARS is functional in yeast cells. We next mutated the HARS 
expression construct to harbor the three missense mutations described here (V155G, 
Y330C, or S356N) and found that, consistent with our studies in HTS1, Y330C and S356N 
HARS did not support any yeast cell growth indicating that they are functional null alleles 
(Figure 3.3B). Interestingly, V155G HARS supported growth, but in a manner that is 
severely reduced compared to wild-type HARS (Figure 3.3B); these data indicate that 
V155G HARS is a hypomorphic allele. Combined, our in vivo functional analyses indicate 
that V155G, Y330C, and S356N HARS are loss-of-function alleles. 
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Figure 3.3. Neuropathy-associated HARS mutations result in loss-of-function in 
vivo.  
(A) Yeast complementation analysis of HARS variants. Haploid DHTS1 yeast strains were 
transformed with a vector containing no insert (‘Empty’) or an insert to express wild-
type, V155G, Y330C, or S356N HTS1. Two colonies (indicated by ‘A’ and ‘B’) from 
transformations with V155G, Y330C, or S356N HTS1 are shown. Resulting colonies 
(undiluted, diluted 1:10, or diluted 1:100) were grown on agar plates containing complete 
media with 0.1% 5-FOA. Note the severe depletion of growth associated with Y330C and 
S356N HTS1 in the 1:10 and 1:100 dilutions. (B) Similar yeast complementation assays 
as described in A using the human HARS open-reading frame. Haploid DHTS1 yeast 
strains were transformed with a vector containing no insert (‘Empty’) or an insert to 
express wild-type, V155G, Y330C, or S356N HARS. After transformations, colonies 
(undiluted, diluted 1:10, or diluted 1:100) were grown on agar plates containing complete 
media with 0.1% 5-FOA. Note the severe depletion of growth associated with V155G 
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3.2.3 Multiple-turnover kinetics identify specific catalytic defects of HARS 
mutations 
The results of the yeast complementation assays and the location of these 
neuropathy-associated mutations in the catalytic domain raised the possibility that these 
substitutions compromise catalytic function. As an initial characterization of catalytic 
function, the production of histidyl-tRNA by each mutant and a wild type control was 
monitored over a ten-minute time course in the presence of saturating concentrations of all 
three cognate substrates. In excellent agreement with the yeast complementation results, 
the two non-complementing mutants (S356N and V330C HARS) generated about 20% of 
the amount of charged tRNAHis generated by WT and V155G in ten minutes (Figure 3.4). 
Despite its near wild type level of product accumulation, the initial rate of product 
formation by the V155G mutant was approximately 50% of the wild type protein, 
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Figure 3.4. Catalytic defects are apparent for neuropathy-associated HARS 
mutations.  
Aminoacylation of tRNAHis with histidine by wild-type or mutant HARS enzymes [5 
nM]. Reaction conditions utlizing saturating substrates (10 mM ATP, 10 mM histidine, 
and 10 µM tRNAHis) by wild-type or mutant HARS enzymes was monitored with 
radioactive 32P-labled 3’-tRNAHis as a function of time (seconds) for the wild-type HARS 
enzyme (black diamonds) and the mutants V155G (green triangles), Y330C (red circles), 
and S356N (blue squares). Values represent the average of 3 independent experiments, 
and error bars indicate the standard error.  
 
In order to assess the effect of the mutant substitutions on the recognition of 
individual substrates, the 32P-tRNA aminoacylation experiments were repeated under 
multiple turnover conditions employing fixed nanomolar concentrations of enzyme and 
varying substrate concentrations. In the first set of kinetic experiments, aminoacylation was 
monitored in presence of varying concentrations of tRNA and saturating concentrations of 
histidine and ATP. This set of experiments showed that, while none of the mutants 
exhibited an elevated KM for tRNAHis, Y330C and S356N HARS exhibited 9-fold and 18-
fold reductions (0.6 s-1 and 0.3 s-1, versus 5.4 s-1 for WT) in the steady state kcat for 
aminoacylation, relative to wild type HARS (Figure 3.5A, Table 3.2). By comparison, the 
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V155G HARS mutant exhibited a modest two-fold reduction in kcat (Figure 3.5A, Table 
3.2). These results confirm and extend the previous yeast complementation and product 
formation assays. 
When histidine was the variable substrate and tRNA and ATP were the fixed 
concentration substrates, the turnover numbers for each of the mutants were similar to the 
values obtained in experiments where tRNA was the variable substrate (Figure 3.5B and 
Table 3.2). The most significant kinetic differences were seen with the Y330C and V155G 
HARS mutants. The KM for histidine was elevated 25-fold for Y330C HARS, and at least 
86-fold V155G HARS (Figure 3.5B and Table 3.2). These results illustrate that, despite 
the fact that Y330C and V155G HARS both exhibit deficits in histidine binding, the V155G 
HARS mutant alone is catalytically “rescuable” by elevated concentrations of histidine. 
Additionally, these results suggest that the diminished kcat associated with S356N HARS 
appears not be linked to a decrease in binding to histidine. 
  96 
 













































































































































  97 
Figure 3.5. Multiple turnover (steady state) kinetics pinpoint catalytic deficiencies 
of neuropathy-associated HARS mutations.  
Steady-state kinetics by wild-type or mutant HARS enzymes were monitored for each 
substrate. Initial velocity of product formed vs. varying substrate concentrations are 
shown for (A) tRNAHis, (B) Histidine and (C) ATP. Plots in (A), (B) and for WT (black 
diamonds in C) were fit to Michaelis-Menten equation to determine kcat, KM, and VMax. 
Mutant HARS enzymes saturation was not achieved at 5mM ATP and were fit linearly to 
determine an estimate for kcat/KM. Values represent the average of 3 independent 





Table 3.2A: Steady state kinetics of tRNAHis aminoacylation for human 
neuropathy-associated mutations of HARS with tRNAHis as the variable substrate 
tRNAHis 
 Km (µM) kcat  (s-1) kcat/Km 
(µM-1 s-1) 
WT 
HARS 0.782 ± 0.101 5.4 ± 0.2 6.9 
S356N 
HARS 0.199 ± 0.059 0.30 ± 0.02 1.5 
Y330C 
HARS 0.330 ±0.072 0.56 ± 0.03 1.7 
V155G
HARS 0.979±0.159 3.05 ± 0.14 3.1 
E. coli 
HisRS 0.34 ±0.05 1.71 ± 0.06 5.0 
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Table 3.2B.  Steady state kinetics of tRNAHis aminoacylation for human 
neuropathy-associated mutations of HARS with histidine as the variable substrate 
Histidine 
 Km (µM) kcat  (s-1) kcat/Km 
(µM-1 s-1) 
WT 
HARS 8.0 ± 4.0 4.1 ± 0.4 0.5 ± 0.4 
S356N 
HARS 10.8 ± 9.1 0.39 ± 0.04 0.04 
Y330C 
HARS 202.9 ± 83.23 0.74 ± 0.10 0.004 
V155G
HARS 687.2 ± 200.0 2.08 ± 0.16 0.003 
E. coli 
HisRS 35.4 ± 3.7§ 133 ± 2.2§ 3.8§ 
Values reported are the mean ± standard error of three independent experiments. 
 
Table 3.2C.  Steady state kinetics of tRNAHis aminoacylation for human 
neuropathy-associated mutations of HARS with ATP as the variable substrate 
 
 ATP 
 Km (µM) kcat  (s-1) kcat/Km (µM-1 s-1) 
WT 
HARS 44.2 ± 5.5 5.8 ± 0.2 0.13 
S356N 
HARS ND ND 1.5x10
-4 ± 1.2x10-5 
Y330C 
HARS 1,763 ± 544 0.48 0.000272 
V155G
HARS ND ND 3.8x10
-4 ± 2.7x10-5 
E. coli 
HisRS 380 [39] ND ND 
 
The final set of steady state kinetic experiments investigated the kinetics of 
aminoacylation under conditions of variable ATP concentrations and saturating histidine 
(10 mM) and tRNAHis (5 µM). Kinetic experiments for the wild type enzyme indicate that, 
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under these substrate conditions, the KM value for ATP in the aminoacylation reaction is 
44.2 µM (Table 3.2C). This is comparable to the value of 140 µM determined for the 
S.typhiumurium WT HisRS catalyzed aminoacylation reaction [40]. Initial pilot 
experiments conducted with the mutants indicated that substantially higher titration ranges 
had to be to employed in order to accurately determine parameters. Even under these 
conditions, saturating velocities were not obtained with any of the mutants. However, 
plotting the velocities to the concentration of [ATP] yielded straight lines from which 
estimates of the second order rate constant Vmax/ KM could be estimated (Figure 3.5C). 
Relative to wild type HARS, all three mutants showed significant decreases in Vmax/ KM 
for ATP, corresponding to 342-fold for V155G HARS, 866-fold for S356N HARS, and 
2549-fold for Y330C HARS (Table 3.2). Based on these results, we conclude that, for all 
three mutants, a major component of the attenuated catalytic activity originates from a 
significant increase in KM, for ATP. It is noteworthy that while we were unable to achieve 
saturation at 5mM ATP we were able to reproduce kcat results with 10 mM ATP in both the 
tRNA and histidine titration (Figure 3.5A and Figure 3.5B). In summary, we conclude that 
the HARS neuropathy-associated mutations lead to significant decreases in catalytic 
activity. Similar defects in kcat and ATP binding are observed for all three HARS 
neuropathy mutations and minor issues with tRNA and histidine binding.  
3.2.4 Differential scanning fluorimetery reveals only one out of three mutations 
are unstable and two have apparent substrate binding defects 
Differential scanning fluorimetry (DSF) is a useful technique that can be used to 
assess the melting temperature stabilizing effect of a substrate with respect to an enzyme, 
as well as aid in the evaluation of the effect of a potential pathogenic amino acid on protein 
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structure [41]. Previously, incubation of HARS with saturating concentrations of the 
histidine amino acid ligand raised the thermal shift transition temperature by seven degrees 
[42]. On the basis of the kinetic results indicating weaker binding of both histidine and 
ATP, we predicted that one or more the mutants would show altered thermal shift behavior. 
Thermal shift assays were performed for each combination of mutant enzyme and 
substrate. Consistent with the previous kinetic data, there was an inverse relationship 
between the KM for histidine of a given mutant protein and the extent of temperature 
stability provided by incubation with histidine in the assay. As seen in Figure 3.6 and Table 
3.3, S356N HARS exhibited the same extent of stabilization by histidine (8.3 vs 7.03°) as 
WT HARS, consistent with its essentially equivalent KM in aminoacylation. By contrast, 
Y330C HARS and V155G HARS exhibited smaller histidine mediated temperature shift 
(4.23 and 1.3°, respectively) closely tracking their substantially increased histidine 










  101 
Table 3.3. Thermal stability of neuropathy-associated HARS variants and 
substrate complexes 
Enzyme Tm °C  Δ Tm °C # Δ Tm °C ## 
WT  51.72 ± 0.44*** - - 
WT + histidine 58.75 ± 0.41 7.03 - 
WT + ATP 53.76 ± 0.21 2.04 - 
WT + tRNAHis 53.43 ± 0.41 1.71 - 
    
S356N 50.87 ± 0.33 - -0.85 
S356N + histidine 59.17 ± 0.31 8.30 0.42 
S356N + ATP 53.12 ± 0.11 2.25 0.64 
S356N + tRNAHis 55.16 ± 0.20 4.29 NA 
    
Y330C 51.72 ± 0.36 - 0 
Y330C + histidine 55.95 ± 0.32 4.23 -2.8 
Y330C + ATP 53.85 ± 0.12 2.13 0.09 
Y330C + tRNAHis 55.88 ± 0.29 4.16 NA 
    
V155G 48.05 ± 0.39*** - -3.67 
V155G + histidine 49.35 ± 0.67 1.30 -9.4 
V155G + ATP 51.09 ± 0.16 3.04 -2.67 
V155G + tRNAHis 53.91 ± 0.26 5.86 NA 
Bold values were previously determined [42]. # Relative to the apo form of the same enzyme. ## Relative 
to the same form of WT HARS enzyme. Values reported are the mean ± standard error of 2 independent 
experiments in triplicate. Values that are significantly different WT to V155G are indicated as *** 
p<0.0001 (extra sum-of-squares F test). 
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For wild type HARS, the ATP and tRNA mediated temperature shifts are much 
smaller (2.04 and 1.7°, respectively) than that provided by histidine (Figure 3.6 and Table 
3.3). In the presence of saturating ATP (5 mM) all three neuropathy-associated mutations 
had slightly increased ∆Tm values, corresponding to least 2 ºC for Y330C and S356N, and 
3 ºC for V155G (Table 3.3). In the presence of 20 µM tRNAHis, all three mutants exhibited 
1 ºC in ∆Tm increases in stability (Table 3.3). Notably, none of the three mutants showed a 
significantly altered melting temperature in the presence of either ATP or tRNA, despite 
the fact that all three show substantially reduced apparent second order rate constants 
associated with ATP binding (Table 3.3).  
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Figure 3.6. Differential scanning fluorimetry reveals melting temperatures of 
neuropathy-associated HARS enzymes and indicate issues in substrate binding.  
Melting temperature of apo wild-type or mutant HARS enzymes were determined at a 
concentration of 10 µM enzyme (A-C) WT (black diamonds), S356N (blue squares), 
V155G (green triangles), and Y330C (red circles). Stabilization by histidine was 
monitored by incubation of mutant HARS enzymes with 5 mM histidine (D-F) Empty 
symbols represent APO enzymes while filled symbols represent histidine bound enzymes 
(D) S356N, (E) V155G and (F) Y330C. Thermal shift curves are representations of 
neuropathy-associated HARS mutants measured in duplicate and WT once. 
 
3.2.5 Analytical ultra-centrifugation confirms that HARS neuropathy-associated 
mutations do not disrupt enzyme dimerization.  
Previous studies investigating mutations in the GARS gene linked to CMT have 
reported that for a subset of these mutants the mutant substitutions lead to weaker tertiary 
interactions and thus reduced dimer stability [18]. Given the location of the HARS mutants 
in the active site, we considered the possibility that the decreased activity of these mutants 
might be a consequence of reduced dimer stability. To address this hypothesis, we 
subjected highly purified preparations of each of the mutant proteins and a wild type 
control to sedimentation velocity experiments at various loading concentrations. In these 
experiments, we monitored protein absorbance at 230 nm, allowing the experiments to be 
performed at concentrations that would be in the range of the equilibrium dissociation 
constant (Kd) for the dimer. As shown in Figure 3.7, the molar mass distributions of the 
wild type and mutant proteins were similar. For each mutant, a major species was observed 
that had a molar mass that was in excellent agreement with the dimer form of HARS (Table 
3.4). In none of the mutants was there a detectable amount of material corresponding to the 
monomeric form of the enzyme. On the basis of these results, we conclude that the 
pathophysiology of these mutants is unlikely to be the result of a weakened dimer. This is 
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a key result as the lower melting temperature of the V155G mutation is not a consequence 
of increased monomers in solution. 
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Figure 3.7. Dimerization of HARS enzyme is not disrupted by neuropathy-
associated mutations.  
A. Molar mass distributions determined by sedimentation velocity, showing the PCSA-
Monte Carlo distributions for HARS WT (black), HARS V155G (red), HARS Y330C 
(blue), and S356N (green). A minor contaminant (< 2%) of unknown identity is visible in 
the Y330C preparation. Molar masses are in excellent agreement with a dimer of each 
species. B. Frictional ratio anisotropies for HARS WT (black), HARS V155G (red), 
HARS Y330C (blue), and S356N (green), as a function of the sedimentation coefficient 
(WT (black) is congruent with HARS Y330C and therefore hardly visible). Pseudo-3D 
plots derived from PCSA-Monte Carlo analyses of sedimentation velocity experiments. 
The right vertical axis indicates the partial concentration in terms of color density. All 
four samples show remarkable similarity. 
 
Table 3.4. PCSA – Monte Carlo results (straight-line parameterization) from the SV 
experiment. 
 
Species Molar mass 
(kDa) 
D(x 10-7 cm/sec2) s (x 10-13 sec) f/f0 RMSD 





































Values in parenthesis are 95% confidence intervals from the Monte Carlo analysis. The 
theoretical molar mass of HARS WT dimer is 114.9 kDa, indicating the observed species 
is a dimer. The residual mean square deviation (RMSD) of the fit is shown in units of 
absorbance at 230 nm. 
 
3.2.6 Results and discussion for Y330C, S356N, and V155G HARS CMT 
variants 
All three of the amino acid substitutions analyzed here alter amino acids located in 
the catalytic domain, consistent with their pronounced effect on aminoacylation. 
Visualization of these substitutions in the context of available X-ray structure of human 
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HARS provides insights into potential structural and functional consequences. S356 does 
not appear to be involved directly in substrate binding interactions. Ser356 may be 
important for positioning other amino acid residues within the active site that are critical 
for binding of the ATP substrate. ATP binding in the active site of HARS requires 
coordinated interactions from conserved arginines in motif 2 and motif 3, as well as 
interactions from conserved magnesium ions coordinated to one or more coordinated 
glutamates. In the human HARS histidine complex (no ATP), Ser356 is within 2.5 Å of 
Arg 388 (Figure 3.8A), the conserved motif 3 arginine that (based on the E. coli complex) 
is predicted to interact with the gamma phosphate of ATP (Figure 3.8B). Important caveats 
regarding the likely effects of S356N are that, firstly, a complex with ATP is not available, 
and secondly, that much of the loop between strands B9 and B10 in which the Ser356 
residue resides is disordered in the various human HARS structures, and has different 
conformations in the different subunits of the asymmetric unit. Hence, it is difficult to make 
definitive conclusions about the potential role of Ser356 in stabilizing interactions in the 
bound complex, and about the consequences of substitution with asparagine. However, the 
elevated KM for ATP for S356N could be interpreted as a likely outcome of a local 
disruption of contacts to the gamma phosphate.  
The one HARS mutant that is predicted to have the most dire consequence for 
function is Y330C, which substitutes a highly conserved tyrosine, in the His A motif, 
constitutes part of the binding site for histidine (Figure 3.2A). Notably, this residue has 
different conformations in the apo versus histidine bound complex. In the apo complex 
without substrates (4X5O), Y330 adopts a conformation directed away from the active site, 
pointing towards solvent and donating a hydrogen bond to the main chain carbonyl of 
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Gly108 (Figure 3.8C). In the complex of HARS with its amino acid substrate, Y330 moves 
some 8 Å to approach within 3.1Å of the alpha-carbon of histidine (Figure 3.8D). In this 
bound conformation, Y330 may further stabilize the histidine binding pocket by engaging 
in a stacking interaction with the neighboring tyrosine in position 331.  
A similar effect may underlie the effect of V155G on HARS function. Analysis of 
the human HARS-histidine complex and comparison to the E. coli HisRS-histidinol ATP 
complex suggests that V155G is unlikely to substitute a residue that interacts directly with 
ATP (Figure 3.8E). However, Val155 is in the region of the active site near where ATP 
binds, and the valine can potentially make a CH-p interaction with the neighboring 
hydrophobic Phe171 in the active site (Figure 3.8E). Phe171 in human HARS corresponds 
to Phe125 in the E. coli enzyme[43], which makes a critical stacking interaction with the 
adenine ring (Figure 3.8F). The substitution of glycine for valine at position 155 may allow 
greater conformational flexibility on the part of Phe 171, reducing its ability to generate 
stable binding pocket for ATP. The effects of this disruption are apparent in the elevated 
KM value for ATP observed for V155G. Additionally, a glycine substitution would permit 
greater conformational freedom in the accessible phi si angles within the peptide backbone 
of the beta sheet, potentially accounting for the lower melting temperature in the absence 
of substrate. Furthermore, a “loose” beta sheet created by the glycine substitution could 
directly impact helix 3, which contains the ‘TXE’ motif for histidine binding. This provides 
a structural rationale for the decreased Tm of the V155G apo enzyme, the dramatically 
reduced Tm in the presence of histidine (Table 3.3), and the elevated KM for histidine (Table 
3.2).  
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Figure 3.8. Structural analysis of HARS enzyme reveal how substitutions 
compromise enzyme structure and substrate binding.  
Molecular interactions of HARS neuropathy-associated amino acid residues in the active 
site. (A) S356 is positioned in the active cite to coordinate a critical arginine residue 
R388 in motif III. (B) R388 is highly conserved and corresponds to R311 in E.coli HisRS 
structure (cyan) that is responsible for positioning the gamma phosphate of ATP with 
R121. (C) Y330 faces 2.5 Å from the alpha carbon of histidine and no immidate 
interactions with modeled ATP (gray sticks and spheres). (D) Y330 and Y331 facilitate 
hydrogen bonding interactions with histidine. Y330 in the apo enzyme (shown as purple 
sticks) can flip away from the active site and swing 8 Å upon histidine binding (shown as 
red sticks) to facilitate hydrogen bonding interactions. (E) V155G is buried in the active 
site and does not mediate any direction interactions with either substrate histidine or ATP 
but in the apo enzyme forms a CH-Pi interaction with the aromatic ring of Phe 171 within 
the active site. (F) Phe 171 forms a stacking interaction with the ribose ring of ATP (as 
modelled in to active site as grey sticks and spheres).  
 
 
3.2.7 R137Q HARS as a periphearal neuropathy variant at the dimer interface  
A candidate gene screen on 363 patients with CMT disease and no known disease-
causing mutations had previously identified the first HARS missense mutation (R137Q) in 
a 65 year old patient with a 15 year history of motor and sensory peripheral neuropathy 
[38]. While functional studies suggested that R137Q HARS was pathogenic, the genetic 
data was not sufficient to implicate HARS as a bona fide CMT disease gene [38].  
In a fashion reminiscent of the some of the GARS-linked CMT mutants, the R137Q 
substitution eliminates a salt bridge at the dimer interface with D64 of the opposite 
monomer [44] (Figure 3.9). This provides one scenario by which the R137Q substitution 
could bring about a loss of function, and promote the peripheral neuropathy phenotype. 
However, the existence of a heterozygous asymptomatic carrier with the same mutation 
suggests that the genetics of the system are not straightforward, and may be confounded 
by incomplete penetrance effects. To determine if R137Q shares similar catalytic or 
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structural defects with S346N, V155G, and Y330C we used similar kinetic, DSF, and AUC 
studies to make comparisons. 
 
 
Figure 3.9. R137Q mutation disrupts an essential electrostatic interaction at the 
dimer interface.  
R137Q substitution alters a highly conserved dimer stabilizing interaction at the dimer 
interface and opposed to the USH3B Y454S HARS mutation in the anti-codon binding 
domain-catalytic domain interface. R137 forms a salt-bridge with D64 at the dimer 
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3.2.8 R137Q CMT variant is catalytically compromised for the adenylation 
reaction but can still aminoacylate  
Initial experiments were carried out to evaluate if the R137Q HARS variant had 
catalytic activity by monitoring AMP formation. While AMP production by R137Q 
relative to WT was not extensive, the requirement for histidine confirms that any AMP 
formed was the result of catalysis by R137Q HARS and was not produced by a 
contaminating protein (Figure 3.10).  
Figure 3.10. TLC analysis of AMP formation by WT and R137Q HARS enzymes. 
(A)WT and (B) R137Q HARS were evaluated for activity as a function of AMP 
formation. Enzyme concentrations evaluated were (1𝜇M for WT and R137Q 
respectively).  
 
Notably, turnover of ATP to AMP was improved in the presence of tRNA (Figure 
3.11). As these initial experiments were done using relatively low concentrations of ATP 
(10𝜇M) we sought to evaluate the adenylation reaction of R137Q by rapid chemical 
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quench. Under these conditions much higher ATP concentrations (100𝜇M) are used to 
evaluate amino acid activation (Figure 3. 11).  
Figure 3.11. Quantification of WT and R137Q AMP production as a function of 
time. 
Formation of AMP was quantified from TLC time course results. (A) AMP production of 
WT 1 uM and R137Q 1uM in the presence and absence of tRNAHis 2uM) evaluated for 
30 mins. with 10 uM ATP 5 mM histidine (B) Data from the first 5 mins of the reaction 
time course.  
 
Pre-steady state adenylation revealed as that R137Q is defective in the adenylation 
reaction and has a significantly slower rate, 0.014 ± 0.02 s-1. Interestingly, the rate 
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improves with the addition of tRNAHis and this improvement is apparent in the first 5 
second of the amino acid activation reaction, 0.4 ± 0.01 s-1 (Figure 3.12). As a comparison 
to the first test for activity (Figure 3.11) the rapid quench pre-steady state assay seems to 
provide a more accurate analysis for activity of R137Q with the presence of tRNAHis. This 
is likely the result of the increased ATP concentration and the presence of tRNAHis. These 
results are very interesting and potentially indicate issues with ATP binding. This data 
would be further supported by a complete Michaelis menten kinetic analysis titrating ATP 
as the variable substrate. Without a complete histidine titration, it is also unclear if R137Q 
also has catalytic defects when histidine is the variable substrate. 
 
Figure 3.12. Pre-steady state amino acid activation reaction for WT and R137Q in 
the presence and absence of tRNAHis.  
Rapid quench was utilized to measure rate of adenylation in the presence of tRNAHis. 
Conditions of the reactions were as follows: 5µM hHARS and 25µM of in vitro generated 
tRNAHis transcript.  Data was fit to a single exponential to determine the rate of 
adenylation. 
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As the R137Q variant had severely compromised rate for the adenylation reaction 
we sought to determine how this affects aminoacylation. Surprisingly, in the presence of 
saturating histidine (10 mM) and ATP (5mM) R137Q seems to have comparable 
aminoacylation activity similar to WT for low and high concentrations of tRNA (Figure 
3.13). This data suggests that under conditions of saturating ATP and histidine R137Q is 
very active and may not be defective in tRNAHis binding. However, to be certain, a 
complete titration with tRNAHis as the variable substrate would be required to make this 
observation complete.  
 
Figure 3.13. R137Q HARS aminoacylation of tRNAHis.  
(A)Aminoacylation with 1µM tRNA with10nM enzyme (WT black filled circles) 
(R137Q purple filled squares) and 100nM tRNAHis and 0.9µM enzyme (WT empty black 
squares)(R137Q purple empty squares). (B) Thin layer chromatography plates of R137Q 
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3.2.8 R137Q is thermally unstable and slight formation of monomer is apparent 
by AUC  
R137Q is the only known HARS CMT variant that forms a direct dimer interface 
contact. As this substitution may disrupt a critical salt bridge at the dimer interface we 
evaluated its DSF profile in the presence of substrates and its ability to form dimers by 
AUC. DSF data indicated that R137Q is indeed thermally unstable (Figure 3.14) with a Tm 
values of 46.1 ºC. R137Q is not readily stabilized by the addition of histidine or ATP, 
yielding ΔTm values of 0.8 ºC and 1.2 ºC respectively. Notably, the most stabilizing 
substrate was tRNA, and this data corresponds with the apparent improvement of 
adenylation activity upon the addition of tRNA with a ΔTm value of 4.7 ºC. Furthermore, 
as histidine did not have a stabalizing effect for R137Q, this may support evidence for 
histidine binding defects. As mentioned previously, these findings might become more 
apparent by multiple turnoever kinetic analysis titrating in histidine as the variable 
substrate (Table 3.5). 
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Figure 3.14. Thermal shift data of R137Q HARS.  
Comparison of WT HARS thermal shift data with WT (black) (A). Tm as a function of 
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Table 3.5. Differential Scanning Fluorimetery Tm values for CMT Variant 
R137Q HARS 
Enzyme  Substrate Tm S.E. ΔTm 
R137Q 
NA 46.12 0.70 ----- 
5mM Histidine 46.88 0.60 0.76 
5mM ATP 47.35 1.04 1.23 
10uM tRNA 50.86 0.603 4.74 
 
WT 
NA 50.37 0.64 ------ 
5mM Histidine 58.95 0.58 8.58 
5mM ATP 52.91 0.33 2.54 
ATP + Histidine 59.65 0.44 9.28 
 
While R137Q is also thermally unstable it can form stable dimers in solution 
(Figure 15). This particular construct is the first example where the appearance of monomer 
in solution is observed, otherwise, R137Q is comparable with WT with respect to 
dimerization.  
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Figure 3.15. Analytical ultra centrifugation analysis of R137Q HARS 
dimerization.  
(A) Molar mass distributions determined by sedimentation velocity, showing the PCSA-
Monte Carlo distributions for HARS WT (black), HARS R137Q (red). A minor fraction 
of monomer is apparent (< 5%) in the R137Q preparation. Molar masses are in excellent 
agreement with a dimer of each species. B. Frictional ratio anisotropies for HARS WT 
(black), HARS R137Q (red), HARS, as a function of the sedimentation coefficient. 
Pseudo-3D plots derived from PCSA-Monte Carlo analyses of sedimentation velocity 
experiments. The right vertical axis indicates the partial concentration in terms of color 
density. These two samples show remarkable similarity. 
	
3.3 PC12 cells as a model for axonal defects caused by HARS CMT variants  
3.3.1 Results and discussion of PC12 cell neurite analysis and cellular localization 
of HARS 
PC12 cells were transfected with four HARS CMT variants, V155G, S356N, 
Y330C, and R137Q. After differentiation with NGF for two days the cells were fixed to 24 
well plates and imaged at a 20X magnification using an epifluorescent microscope. 
Multiple images from each well and multiple wells transfected with the same HARS CMT 
variant were collected and GFP positive cells were analyzed and neurites were measured 
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(Figure 3.16A). Additionally, the number of cells bearing neurites is not different across 
the experiment (Figure 3.16B). A preliminary analysis of the length of the all the neurites 
counted indicated that the average neurite length for all the HARS CMT variants tested 
was lower relative to WT. From the neurite data analysis there is no difference in the 
percent of cells that undergo differentiation (having at least one neurite twice the length of 
the average cell body diameter) (Figure 3.16C). However, the number of neurites greater 
than 30 microns per cell are lower for CMT HARS variants relative to WT (Figure 3.16D). 
This would suggest that while all the HARS CMT variants do not affect initial neurite 
outgrowth or the number of neurites that the cell can form, the ability to form long neurites 
is affected, and this variable is likely the component driving down the average neurite 
length. 
Furthermore, with transfected PC12 cells the cellular localization of HARS CMT 
variants were evaluated. PC12 cells were transfected with C-terminally GFP-tagged HARS 
CMT variants and differentiated for two days on coverslips. Antibodies against GFP and 
other cytoskeletal markers (beta tubulin 3) were used in these assays. What was clear and 
consistently observed for WT and all HARS CMT variants was the appearance of GFP-
tagged HARS proteins to the most distal regions of neurites.  
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Figure 3.16. CMT variants reduce the average neurite length of differentaited 
PC12 cells 
Quantification of differentiated PC12 cell neurites were analyzed. Number of cells 
counted for each CMT vatiant (WT = 216, Y330C = 122, R137Q = 227, V155G =117, 
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Figure 3.17. Localization of GFP HARS to neurites. 
Localization of WT and CMT-associated HARS variants in differentiated PC12 cells. 
GFP-tagged HARS enzymes were transfected in PC12 cells and visualized with anti-GFP 
antibody and co-stained with Dapi and neuronal beta tublin III. 
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3.4 Conclusions  
The detailed characterization of these mutants showed that they all displayed losses 
in catalytic activity when assessed in vivo and in vitro. Notably, the extent of decrease in 
catalytic activity was well correlated with the loss of ability to support yeast growth. The 
most active of the three mutants (V155G HARS) was the only one of the three mutants that 
retained some ability to support yeast growth when studied in the HARS open-reading 
frame. In contrast to most of the previous work analyzing aaRS mutants linked to CMT, 
each of the HARS mutants was fully characterized with respect to defects associated with 
recognition of each substrate. The novel finding emerging from this analysis is that all three 
mutants Y330C, S356N, and V155G displayed substantially elevated Michaelis constants 
for ATP, and two of the three (Y330C and V155G) displayed an elevated KM for histidine. 
Notably, none of the three exhibited an altered KM for tRNA. While the full kinetic analysis 
has not been performed for R137Q, preliminary DSF and amino activation experiments are 
indicative of catalytic defects. Thus, for these families, like HARS, the linkage to CMT 
appears to be associated with a loss of aminoacylation function. 
The work reported here on HARS suggests that, in the absence of detailed studies 
where substrate dependence is examined in detail, conclusions about the functional impact 
of mutations should be taken cum grano salis. Collectively, these mutants represent some 
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3.5 Supplemental Methods 
Clinical and Genetic analysis of patients with peripheral neuropathy 
Family 1: We applied whole-exome sequencing in a cohort of index patients from 
82 families with genetically undefined distal hereditary motor neuropathy, mutations in the 
known pathogenic genes had previously been excluded. The Ethical Review Boards of the 
participating institutions approved this study. All patients or their legal representatives 
signed informed consent prior to enrolment. Blood sampling and DNA extraction was 
performed according to standard methods. The Nextera Rapid Capture Expanded Exome 
kit (62Mb) (Illumina) was used for exome enrichment. Subsequently, the libraries were 
sequenced on a HiSeq 2500 platform (Illumina). The Burrows-Wheeler Aligner (BWA) 
tool was used to perform the sequence alignment to the reference genome (hg19, UCSC 
Genome Browser). Variant calling was done with Genome Analysis Toolkit (GATK) 
Unified Genotyper. For the annotation and filtering we used the Clinical Sequence 
Analyzer and Miner (Wuxi NextCODE). For further filtering of the data, the following 
criteria were applied: no occurrence or a frequency ≤ 0.5% of the variants in public exome 
variant repositories (Exome Aggregation Consortium, 1000 Genomes Project, Exome 
Variant Server, in-house data); variants with impact on the encoded protein (missense, 
nonsense, frame shift, inframe indels and splice site variants); read depth ≥ 7; minimal 
heterozygous call percentage ≥ 20%, minimal homozygous call percentage ≥ 66%. In 
addition, all data were imported and re-annotated into the GENESIS (gem.app) platform, 
a web-based tool for next generation sequencing data analysis 
(http://thegenesisprojectfoundation.org/) [45]. Patients were evaluated by clinical 
examination in combination with nerve conduction studies according to standard methods.  
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Family 2: All family members were studied at Bellvitge’s University Hospital. 
Detailed neurological evaluation was performed on patients and unaffected subjects. 
Electrophysiological studies were performed using standard methods in all subjects. We 
classified the severity of neuropathy symptoms according to the CMT neuropathy score 
(CMTNS). Blood samples were obtained from all family members once informed consent 
had been given. Genomic DNA was extracted from peripheral blood leukocytes. PMP22, 
MPZ, MFN and GJB1 mutations were previously excluded in index case.  
Family 3: The family was evaluated in the University of Iowa CMT Clinic. 
Informed consent was obtained from all individuals and the study has been approved by 
the Institutional Review Board at the University of Iowa. Neurological examination and 
neurophysiological studies were performed. The second version of the CMT Neuropathy 
Score (CMTNSv2) and CMT Exam Score (CMTESv2) [1] were employed to evaluate 
neuropathy. The SureSelect Human All Exon 50 MB Kit (Agilent) was used for in-solution 
enrichment, and the HiSeq 2500 instrument (Illumina) was used to produce 100 bp paired-
end sequence reads. The Burrows-Wheeler aligner, Picard, and the Genome Analysis Tool- 
kit were used to align sequence reads and call variants. These data were imported into 
GENESIS (GEM.app) [45]for further analysis and filtering of variants. 
Yeast complementation assays 
Yeast complementation assays to study the functional consequences of HARS 
mutations were generated and performed as previously described (Vester et al. 2013). Each 
indicated missense variant was modeled in the yeast HARS ortholog HTS1 or in the human 
HARS open-reading frame (primers available upon request). After mutagenesis, wild-type 
or mutant HARS or HTS1 were cloned into pRS316 or pYY1, respectively, using the 
  126 
QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene). Resulting expression 
clones were purified and fully sequenced to confirm successful mutagenesis and rule out 
PCR-induced errors. A haploid ΔHTS1 strain (harboring a maintenance vector to express 
wild-type HTS1 and URA3) was transformed with an empty vector (‘Empty’ in Fig. 2A 
and B) or the appropriate wild-type or mutant HTS1 or HARS in a LEU2-bearing vector 
and selected on medium lacking uracil and leucine (Teknova). For each transformation, at 
least two independent plasmid preparations were used and at least two colonies from each 
plasmid were selected for additional analysis and grown to saturation for 2 days at 37°C in 
liquid media lacking uracil and leucine. A 10 µl aliquot of each culture was spotted 
undiluted or diluted 1:10 or 1:100 in H2O onto plates containing 0.1% 5-FOA (Teknova) 
or medium lacking uracil and leucine and incubated at 30°C for 48-72 hours. Survival was 
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CHAPTER 4: CHARACTERIZATION OF A RECESSIVE HARS MUTATION 
ASSOCIATED WITH USHER SYNDROME IIIB  
4.1 Introduction  
4.1.1 Usher Syndrome  
Usher syndrome is the most common recessively inherited neurological disorder 
that results in deafness and vision loss. Charles Usher, a Scottish ophthalmologist, first 
described this inherited neurological disorder in 1914. He noted characteristic symptoms 
of this disease included sensory impairment of the audio, vestibular, and visual systems. 
The onset of blindness in Usher patients is caused by retinitis pigmentosa (RP), a 
progressive degradation of photoreceptors in the retina. RP symptoms include peripheral 
vision loss, night blindness, visual field constriction, and abnormal retinal pigmentation[1].  
Usher syndrome is divided into three clinical categories, USH1, USH2, and USH3, 
which are differentiated by the severity and progression of hearing loss and by the degree 
of vestibular dysfunction although, visual impairment caused by RP is common to all three 
subtypes [2]. USH1 is the most severe form as patients are either born completely deaf or 
experience hearing impairment within the first year of life and usually do not develop 
speech [1]. Vestibular dysfunction is evident from birth as children experience a delay in 
sitting independently and walking later than usual. Evidence of retinitis pigmentosa occurs 
during childhood, presenting as progressive constriction of the visual field and impaired 
visual acuity followed by complete blindness. USH2 patients usually develop retinitis 
pigmentosa symptoms later compared to their USH1 counterparts. Hearing impairment 
with USH2 is congenital and usually detected at later stages when it hinders 
communication. Hearing impairment increases from moderate to low frequencies to severe 
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in high frequencies [1]. Curiously, vestibular function in USH2 patients appears not to be 
affected. The onset of RP symptoms is variable for USH3 patients and usually occurs by 
the second decade of life. Sensorineural hearing loss is progressive and can appear between 
the first and third decade of life [1]. Initially hearing loss symptoms are similar to that of 
USH2 patients, with a major hearing impairment seen in high frequencies. The rate of 
hearing loss in USH3 patients is variable but in most cases becomes profound. However, 
during the first stages of development hearing is good enough to permit development of 
speech. Vestibular dysfunction is also variable, with 50% of cases experiencing impairment 
[1]. 
Usher syndrome is an inherited polygenetic disorder and encompasses a group of 
autosomal recessive genes.  Interestingly, Usher syndrome is more common in regions with 
small isolated, often consangious populations such as in Israel (Samarthians), Pakistan 
(Hutterities), France (Poitou-Charentes region), Northern Sweden, Finland and the 
Accadian population of Louisiana, United States [2]. Presently, twelve loci have been 
linked to Usher syndrome, nine of which have an identified protein product (Table 1). 
Seven loci have been mapped for clinical type I Usher syndrome and five causative Usher 
genes have been cloned: MYO7a, USH1C, CDH23, PCDH15, and USH1G, implicated in 
USH1B, USH1C, USH1D, USH1F, and USH1G, respectively [1]. Three loci are 
associated with clinical type II Usher syndrome; and these genes have been identified as: 
USH2A, GPR98 (USH2C), and DFNB31 (USH2D). Usher type III is the least common 





4.1.2 Molecular components of Usher syndrome. 
The inner ear contains a spiral shaped structure called the cochlea, which is 
responsible for auditory transduction of sound. The cochlea contains a specialized unit 
termed the organ of Corti that contains highly specialized neurosensory cells. These 
neurosensory cells are the inner and outer cochlear hair cells that consist of ciliary 
structures, stereocilia and kinoclilium. Stereocilia are tethered together by fibrous 
connections along their length and highly organized into bundles. The unique structure of 
stereocilia is supported by the internal cytoskeleton composed of F-actin. Deflection of 
stereocilia results in mechanical opening of potassium channels allowing for influx of 
potassium ions, which consequently leads to the depolarization of the membrane and 
release of neurotransmitters. The mechanosensory channels are connected via protein-
protein interactions with the actin filaments.  
Many genes responsible for Usher syndrome affect molecular components that are 
present in both the inner ear and retina (Table 4.1). The main site of colocalization for 
Usher proteins are in the stereocilia of hair cells. Additionally, occurrences of many of the 
Usher proteins in the synapse of hair cells suggest that they also play a functional role in 
the neurotransmission and likely the reason they contribute to the pathological 
development of sensorineural hearing loss. Usher proteins, such as cadherin 23, are 
involved in the proper development and cohesion of hair cell bundles in the organ of Corti. 
Cadherin 23 and protocadherin 15 as well as transmembrane proteins usherin and VLGR1 
are part of inter-stereocilia fibrous links that are essential in hair cell cohesion. These 
proteins are anchored to the intracellular scaffolding proteins harmonin and/or whirlin, 
which connect, via myosin VIIa and possibly other proteins, to the actin core of stereocilia 
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[2]. Of note, unconventional myosins are motor molecules with structurally conserved 
heads, which move along actin filaments using their actin-activated ATPase activity [3]. 
Mutations in the gene encoding an unconventional myosin involved in Usher syndrome 
type I, myosin VIIA, are located at the N-terminal motor domain of the protein [3]. 
Table 4.1. Genetic classifications of Usher syndrome.  
Clinical subtype/locus Gene/protein Function/Inner ear and/or retina 
USH1B/DFNB2/DFNA1 MYO7A/myosin VIIA Transport –inner ear and retina 
USH1C/DFNB18 USH1C/harmonin Scaffolding-inner ear and retina 
USH1D/DFNB12 CDH23/cadherin 23 Tip link formation in inner ear and pre-ciliary maintenance in retina 
USH1E Unknown Unknown 
USH1F PCDH15/protocadherin 15 
Tip link formation in inner ear and 
pre-ciliary maintenance in retina 
USH1G USH1G/SANS Scaffolding and protein trafficking –inner ear and retina 
USH1H Unknown Unknown 
USH2A USH2A/usherin Formation of ankle links  and 
cochlear development for inner ear 
and pre-ciliary maintenance in retina USH2C GRP98/VLGR1 
USH2D DFNB31/whirlin Scaffolding –inner ear and retina 
USH3A USH3A/clarin-1 Probably role in synaptic transport- inner ear and retina 
USH3B HARS/histidyl-tRNA synthetase Protein translation - unknown 
Genes and proteins identified are listed with corresponding proteins and protein function. 
 
Usher proteins, cadherins, constitute a superfamily of glycosylated transmembrane 
proteins, that mediate cell-cell adhesion, compaction and cellular rearrangement during 
development [4]. Octocadherin or cadherin 23 (Cdh23 and USH1D) and protocadherin 15 
(pcdh15 and USH1F) are cadherin related proteins (Table 4.1). Cdh23 expression is 
restricted to inner and outer hair cells. Hair cells of a mouse model for USH1D 
demonstrated that mutations in Cdh23 cause stereocilia to be disorganized rather than in a 
crescent shape [4]. Stereocilia disorganization appears to be the primary defect and thus 
identifies otocadherin as a critical component for proper hair bundle formation [4].  
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Harmonin as an usher protein is thought to act as a scaffold protein in both the 
retina and cochlea that integrates all known USH1 molecules in an USH1-protein network 
[5]. In the retinal photoreceptor cells, harmonin co-localizes with other USH1 proteins 
(myosin VIIa, cadherin 23, and pcdh15) at the synaptic terminals, whereas in the inner ear, 
the harmonin organized USH1-protein network is found in the stereocilia of hair cells [6]. 
Binding studies indicate that usher proteins Usherin (USH2A) and very large G-coupled 
protein receptor (VLGR1) bind to harmonin’s PDZ1 domain [2]. The “Goliath” usher 
syndrome molecule VLGR1 is a cell surface receptor and similar to cadherins function in 
cell adhesion of synaptic membranes and therefore participates in cell adhesion of inner 
ear hair cells [2],[6]. Harmonin is the first molecular link between USH types, USH1 and 
USH2, via its functions as a potent scaffold protein [6].  
Pathogenic mutations in the SANS gene are associated with USH1G. SANS was 
identified from an analysis of 39 sporadic and familial USH1G cases from Germany, 
France, Israel, Iran and Morocco that had no mutations in myosin VIIA or in the gene 
encoding harmonin. Two patients with a frame shift deletions in the SANS gene were 
identified and predicted to form a truncated version of the SANS protein. It has been shown 
that SANS interacts with harmonin by binding to the first PDZ domain [3]. SANS produced 
in sensory hair cells, may be connected to the actin cytoskeleton via its interaction with 
harmonin b, an isoform largely restricted to the inner ear [3]. Being that harmonin interacts 
with myosin VIIa and cadherin 23 these results suggest that SANS is involved in the 
functional network that is required for cohesion of the growing hair bundle [7].  
Finally, the DFNB31 gene encodes whirlin, a PDZ scaffold protein with expression 
in both hair cell stereocilia and retinal photoreceptors cells. Whirlin represents an excellent 
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candidate for USH2 because it co-localizes and binds to usherin (USH2A) and VLGR1b 
(USH2C), in both hair cell stereocilia and retinal photoreceptor cells [8]. Both whirlin and 
myosin-15a, play a crucial role for the development and differential elongation of hair cell 
stereocilia [8]. There is evidence that harmonin and whirlin can bind other components of 
the USH network, including CDH23, PCDH15, Usherin, VLGR1 and myosin VIIa [2].  
 
4.1.3 Usher Syndrome IIIB mutation in the gene for histidyl-tRNA synthetase. 
The genetic mutation in human HARS linked to Usher Syndrome IIIB was 
identified in children of an Old Order Amish population in Lancaster, Pennsylvania [9]. 
Autozygosity mapping indicated that a large homozygous block on chromosome 5q31 was 
shared in three patients and exome data from two patients revealed 80 homozygous variants 
within the mapped interval. Only one variant, HARS c.1361A.C (p.Tyr454Ser) (Figure 
1A), was novel. Three carriers among 203 Old Order Amish controls (1.5%) were detected 
[9]. Further evidence for pathogenicity was provided by an Old Order Amish patient who 
was from an unrelated deme in Ontario, Canada. This Amish settlement arose from a 
separate migration event from Europe than the Lancaster County settlement. The patient 
had an identical phenotype to patients in PA and was homozygous for the HARS 
c.1361A.C variant. 
The Y454S HARS substitution associated with USH3B (OMIM #614504) 
represents a striking example of a simple Mendelian trait encoding a single missense 
substitution that presents as a complex human disorder [9]. Patients with USH3B exhibit 
normal growth during infancy, but experience progressive loss of hearing and sight in the 
first and second decades of life, respectively. For most patients, acute viral infections of 
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febrile illness induce vivid hallucinations. USH3B patients also exhibit mild truncal ataxia, 
wide based gait, and delayed motor development. No difference in either intracellular 
levels of expression or cytoplasmic distribution was observed between the wild type (WT) 
and the Y454S HARS enzyme [9]. While this disorder is rare in Lancaster County it is 
common in the Amish Community of Northern Ontario with 12 afflicted individuals. 
Typically, cochlear implants are done early and language development is essentialy 
normal. Our recent communications with clinicians at the Children’s Health Research 
Institute Ontario, Canada have divulged that several affected children from this population 
have died with acute pulmonary edema during illnesses and the pathology of the lungs is 
that of Adult Respiratory Distress Syndrome (ARDS). It was originally thought these were 




Figure 4.1. Y454S mutation disrupts hydrogen bonding interaction with E439.  
A) The Y454S mutation is located in the anticodon binding domain beneath the floor of 
the catalytic domain of the opposing monomer. B) Modeling the serine at Y454 position 
in the anticodon binding domain creates a 6 Å gap between E439 and S454.  
 
Previously, we collaborated with the clinic for Special Children in Lancaster PA to 
study the catalytic defects of the Y454S HARS mutation found in the Amish community, 
Y454S. Conclusions drawn from this study reported less than a two-fold difference in 
aminoacylation function observed using murine WT and Y454S enzymes with whole 
tRNA isolated from human placenta as a substrate [9]. Furthermore, no difference in either 
intracellular levels of expression or cytoplasmic distribution was observed between the 
wild type (WT) and the Y454S HARS enzyme [9]. 
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These current studies were undertaken to comprehensively examine the chemical 
steps in catalysis for human WT HARS as a reference point in understanding in Y454S 
mutation.  We carried out kinetic studies of the human WT and Y454S HARS enzymes to 
expand upon our earlier work analyzing not only multiple turnover kinetics for tRNAHis 
but also for histidine. Furthermore, we measured the half reactions for amino acid 
activation and aminoacylation of WT and Y454S HARS. Additionally, we explored the 
hypothesis that WT and Y454S HARS differ with respect to thermal stability and 
dimerization.  
We carried out these studies to critically evaluate whether the USH3B phenotype 
could be ascribed to a loss in the canonical aminoacylation function. The impact of the 
Y454S USH3B substitution may not be a simple loss of aminoacylation function, but a 












4.2.1 Purified wild type and Y454S enzymes prepared from human cell culture are 
active.  
Figure 4.2: Purification yields FLAG-tagged HARS.  
Lysates (3ug total protein) from HEK293 cells transfected with FLAG-tagged WT HARS 
or Y454S HARS were separated by 12% SDS-PAGE. HARS purified by FLAG resin and 
ion exchange (0.1ug) was run adjacent. The gels were western-blotted using anti-FLAG 
antibody (A) or anti-HARS antibody (B). Two different MW markers were run on each 
gel.  
 
In order to compare the kinetics of WT and Y454S HARS, we expressed and 
purified human FLAG-tagged WT and Y454S HARS from human embryonic kidney 
(HEK293) cells. The successful purification sequence included affinity and ion exchange 
chromatography. A Western blot analysis showed that FLAG-HARS constituted 93% of 
the purified protein, and less than 7% represented the endogenous untagged WT HARS 
(Figure 4.2). On the basis of active site titration (described in Experimental Procedures), 
purified enzymes contain at least 75% active protein on the basis of the maximum 
amplitudes, a concentration of 3.4 µM and 4 µM AMP formation per active site was 





Figure 4.3. Monitoring AMP formation to determine human WT and Y454S 
HARS activity  
Rapid chemical quench was used to evaluate enzyme active sites. 5uM of WT HARS (A) 
or Y454S (B) enzymes was mixed with 100 uM ATP in the presence of saturating 
histidine (10 mM). 
 
4.2.2 Wild type and Y454S HARS bind tRNA with comparable affinities. 
 Within the protein structure the USH3B Y454S substitution is located on helix 15 
on the surface of the anticodon-binding domain, which is located proximal to the dimer 
surface of the catalytic domain of the opposing monomer. Based on structure 4G85 [10], 
Tyr454 hydrogen bonds with Glu439, a  residue in a nearby β-sheet that forms a salt bridge 











































with K148 across the interdomain interface to the catalytic domain of the opposing 
monomer (Figure 4.1A). While the hydrogen bond may be disrupted by the substitution of 
serine for Tyr454 (Figure 4.1B) the change in hydrophobic character of the position is also 
lost. Y454 is conserved among eukaryotic species extending from the human to 
Caenorhabditis elegans and the Trypanosoma (Figure 4.4A) [11]. In bacterial species (such 
as Escherichia coli, Thermus thermophilus, and Staphylococcus aureus) however, the 454 
position is occupied by a charged residue (Figure 4.4A). We tested this hypothesis by the 









































Figure 4.4. tRNAHis and total tRNA binding are unaffected by Y454S.  
(A)Alignment and modeling of Thermus Thermophilius HARS bound to tRNA with 
human HARS.  tTHARS E372 and hsHARS Y454 do not mediate the same interactions 
but both may impact tRNAHis binding and discrimination by the anti-codon binding 
domain. Y454 (red) and E372 (dark blue) mediate different interactions in the anti-codon 
binding domain. Y454 forms a hydrogen bond with E439 across the anticodon binding 
domain akin to the salt bridge interaction between R376 (dark blue) and E358 (dark 
blue). 
(B) Y454S and HARS tRNAHis binding forward curve. HARS (circles) and Y454S 
(triangles) varied from 0.1 to 30 µM. 32P-tRNAHis concentration was 30 nM. (C) 
Competition Plot where transcribed tRNAHis bound to either HARS or Y454S was 
competed by increasing concentrations of total tRNA purified from human placenta. 32P-
tRNAHis concentration was 30 nM, enzyme (HARS (circles) and Y454S (triangles)) was 
5 µM and placental tRNA varied from 0 to 100 µM. Values reported are the mean ± 
standard error of two independent experiments. 
 
 
Binding reactions were conducted under conditions of excess protein with the 
tRNA at a limiting concentration. Under the conditions reported, WT and Y454S HARS 
exhibited identical apparent Kds of 7.9 ± 1.1 µM (Figure 4.4B). These apparent Kds were 
dependent on assay conditions, most notably the percent of acrylamide gel used in the 
electrophoresis (data not shown). Therefore, we can use this method only to determine an 
upper limit of the Kd, and to compare the Kd of enzymes analyzed similarly. 
In the cell, each ARS must select its correct tRNA from a pool including high 
concentrations of non-cognate tRNAs. In addition, tRNAHis produced in vivo is modified 
by conversion of the first guanosine in the anticodon to queuosine, relative to transcribed 
tRNAHis [12]. In order to test whether WT and Y454S differ with respect to non-cognate 
tRNAs, we carried out a binding competition experiment using 32P-labeled tRNAHis 
transcript as the primary ligand and total human placental tRNA as competitor. (A caveat 
in the design of this experiment is that total tRNA contains ~1.4% native tRNAHis [9].) As 
shown in Figure 4C, WT and Y454S responded in an identical fashion to the presence of 
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increasing concentrations of unlabeled competitor tRNA. Thus, under the conditions 
explored, differences in tRNA binding or tRNA binding specificity that could account for 
the phenotype of Y454S were not observed. 
 
4.2.3 Multiple turnover kinetics indicates the Y454S HARS mutant has 
comparable kinetic parameters with wild type HARS.  
The binding experiments suggested that the Y454S substitution does not 
significantly affect tRNA recognition at the binding step. To more fully investigate the 
effect of the substitution on aminoacylation function directly, steady state kinetic 
parameters were determined for the tRNAHis transcript and histidine substrates. Under 
steady state conditions where tRNA was the variable substrate, we observed that WT and 
Y454S HARS had essentially equivalent Km values (WT, 1.2 ± 0.5 µM vs. Y454S, 0.9 ± 
0.2 µM) and kcat values (WT, 3.9 ± 0.5 s-1 vs. Y454S, 4.4 ± 0.3 s-1) (Table 1). When histidine 
was titrated as the variable substrate, the value of Km for Y454S was 1.7-fold decreased 
relative to WT, and the value of kcat for Y454S was 1.4-fold greater than WT (Table 4.1). 
In the previous comparison of mouse WT and Y454S enzymes with bulk human tRNA, 
the ratio of relative kcat/Km for WT and Y454S HARS was approximately 1.5. Here, with 
purified human enzymes and substrates, the ratios of kcat/Km for tRNA and for histidine 






Table 4.2. Steady state aminoacylation kinetics of tRNAHis by human and 
bacterial histidyl-tRNA synthetases 
 Variable Substrate 
  tRNA   histidine  
Enzyme Km (μM) kcat (s-1) kcat/Km (μM-1 s-1) Km (μM) kcat (s
-1) kcat/Km (μM-1 s-1) 
WT 
HARS 1.2 ± 0.5 3.9 ± 0.6 3.2 ± 1.0 8.0 ± 4.0 4.1 ± 0.4
a 0.5 ± 0.4 
Y454S 
HARS 0.9 ± 0.2 4.4 ± 0.3 5.1 ± 1.0 4.7 ± 2.5 5.9 ± 0.5
a 1.2 ± 0.4 
E. coli 
HisRS 0.34 ± 0.05 1.71 ± 0.06 5.0 35 ± 4
b 133 ± 2b 3.8b 
Values reported are the mean ± standard error of three independent experiments. 
aSignificantly different (extra sum-of-squares F test) p<0.05. bData are for histidine in the 
pyrophosphate exchange reaction. 
 
4.2.4 The Y454S variant has similar rates of amino acid activation and aminoacyl 
transfer relative to wild type.   
While not large, these differences prompted us to examine the adenylation and 
aminoacylation half reactions separately. First, we examined the production of AMP under 
pre-steady state conditions where ATP was the limiting substrate, but still in excess over 
enzyme. As seen in Figure 4.3A and 4.3B, WT and Y454S HARS produced 3.4 µM ± 0.2 
and 3.6 µM± 0.1 of AMP respectively in the first five seconds of the reaction. Based on a 
concentration of 2.5 µM HARS dimers or 5 µM monomers in these reactions, this suggests 
a product stoichiometry of  0.75 molecules of AMP formed per active site. At the end of 
five seconds, the slopes of the progress curves approached zero suggesting that further 
production of AMP had ceased. Prior to this plateau period, the rates of product formation 
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were derived by fitting the progress curves in the first 500-800 milliseconds to a single 
exponential followed by a linear phase. (Other equations, such as an isolated single 
exponential or a double exponential, produced substantially poorer fits.) These fits 
provided rates of 18.9 ± 15 s-1 and 18.2 ± 6 s-1, in the exponential phases for WT and Y454S 
respectively, followed by rates of 2.8 ± 1.2 s-1 and 2.9 ± 0.7 s-1 for the respective linear 
phases (Table 4.2). The values of the exponential phases for WT and Y454S were 
essentially equivalent to the kobs1 for the first exponential for the rate of adenylate formed 
by the E.coli enzyme under pre-steady state conditions [13]. This value is thought to 
represent the rate of activation in the first subunit of the dimer, with the second 
considerably slower. Consistent with the conclusions from the steady state analysis, these 
measurements confirm that WT and Y454S catalyze the activation of histidine in the 
absence of tRNA at the same rate. In the presence of tRNA, the rates of the exponential 
and linear phases are increased by 2.5 -3 fold for WT and 1.2 -2.6 fold for Y454 (Figure 
4.5A and 4.5B and Table 4.2).  
Owing to the fact that the experiments were performed under conditions where the 
ATP concentration (100 µM) was below Km, the rates reported are unlikely to represent the 
maximal rate of amino acid activation. Values for the Km for ATP in aminoacylation 
reactions previously reported in the literature include a value of 380 µM for rat HARS[14] 
and 80 µM for rabbit HARS[15]. As the HARS sequence has high identity across 
mammalian species, we expect these values to be a good estimate for human HARS. 
 147 
Accordingly, the maximal possible rates of amino acid activation catalyzed by both the 
WT and the mutant are likely to be higher than reported here[13]. 
 
Figure 4.5. Amino acid activation and the rate of histidine transfer is unaffected 
by the Y454S mutation even in the presence of tRNAHis.  
Amino acid activation (WT: panel A; Y454S: panel B) was monitored by mixing 5 µM 
monomer HARS enzyme (WT: filled circles; Y454S: filled triangles) with 100 µM ATP 
and saturating histidine. tRNAHis (25 µM) addition (empty circles and empty triangles, 
insets: note 0.5 s time scale) increased the rate of amino acid activation, which was 
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Table 4.3: Pre-steady state rate for amino acid activation 
 Rate of amino acid activation 
Reactants Rate of exponential phase 
(s-1) 
Rate of linear phase k1 
(s-1) 
WT HARS (n=3) 19 ± 15 3 ± 1a 
WT HARS + tRNAHis (n=2) 47 ± 21 9.1 ± 0.7a 
Y454S (n=2) 18 ± 6 2.8 ± 0.7b 
Y454S HARS + tRNAHis (n=2) 21 ± 5 6.4 ± 0.6b 
Values reported are the mean ± standard error of n independent experiments. a 
Significantly different at p<0.05. b Significantly different at p<0.01 (extra sum-of-
squares F test). 
 
In order to address whether the WT and mutant enzymes differ with respect to the 
rate of aminoacyl transfer, a single turnover experiment was performed. As described in 
Methods, WT and Y454S HARS were each pre-incubated with ATP and histidine to pre-
form the enzyme-adenylate complex in situ. Using rapid chemical quench techniques, rates 
of 30 ± 6 s-1 and 30 ± 4 s-1 were determined (Table 4.3, Figure 4.6A and 4.3B). Notably, 
the single turnover rates of both human enzymes were essentially equivalent, further 
supporting the kinetic equivalence of WT and Y454S HARS. It is also potentially of 
interest that these rates were both considerably faster than the 18.1 s-1 previously reported 
for E. coli HisRS[16, 17]. In summary, the small increase in Y454S steady state kcat is not 
accounted for by differences in either isolated pre-steady state amino acid activation or 
aminoacyl transfer partial reactions. 
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Figure 4.6. Aminoacyl transfer of WT and Y454S 
The rate constant for histidine transfer ktrans (WT: panel A Y454S: panel B) was 
determined by single turnover with 2 µM enzyme, preformed with histidyl-adenylate, and 
mixed with 100 nM tRNAHis. ktrans was determined by fit to a single exponential. The 




















































Table 4.4. ktrans for Y454S and WT HARS 
Single turnover aminoacyl transfer 
Enzyme ktrans (s-1) References 
WT HARS (n=4) 30 ± 6 This work 
Y454S (n=6)  30 ± 4 This work 
E.coli HARS 18.8 ± 2.5 [16] 
Values reported are the mean ± standard error of n independent experiments. No 
difference by extra sum-of-squares F test. 
 
4.2.5 The Y454S substitution reduces the thermal stability of HARS but not 
dimerization. 
The observations reported above suggested that the Y454S substitution has minimal 
consequences for HARS function as determined in the standard assays for aminoacylation. 
Inspection of the human HARS structure leaves open the possibility that the substitution 
nevertheless influences protein stability by weakening inter-domain dimeric interactions. 
To further assess the dimer stability of Y454S HARS, we performed sedimentation velocity 
experiments (SV) and compared the results to those obtained from WT. As an additional 
comparison, we also evaluated the SV of a temperature sensitive (ts) version of HARS 
originally isolated in BHK21 cells (tsBN250) that encodes an R362H substitution[18]. We 
hypothesized that if a mutant dimer were less stable than the WT, it would exhibit an 
increased Kd concentration and display a shift in the sedimentation coefficient distribution 
when it more readily dissociates into monomer. This effect would be enhanced at low 
concentration. Therefore, we measured the SV experiments at 230 nm where the extinction 
coefficient is significantly higher compared to the standard 280 nm absorbance, which 
allowed us to monitor at lower concentration. Data quality at 230 nm is also higher due to 
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the high light emission intensity of the Xenon lamp used in the ultracentrifuge.
 
Figure 4.7. Molar mass distributions determined by sedimentation velocity.  
Showing the PCSA-Monte Carlo distributions for HARS WT (black), HARS Y454S 
(red), and HARS R362H (blue). Molar masses are in excellent agreement with a dimer of 
each species. B. Frictional ratio anisotropies for HARS WT (black), HARS Y454S (red), 
and HARS R362H (blue) as a function of the sedimentation coefficient. Pseudo-3D plots 
derived from PCSA-Monte Carlo analyses of sedimentation velocity experiments. The 
right vertical axis indicates the partial concentration in terms of color density.  
 
Molar mass distributions from HARS mutants and WT are shown in Table 4.4, 
demonstrating remarkable similarity between WT and HARS mutants. The molar mass of 
the major species observed for each sample is in excellent agreement with the dimer form 
of HARS (Figure 4.7A). Detailed integration results for the Monte Carlo analysis are 
reported in Table 4.4. Pseudo-3D overlays of the anisotropy vs. sedimentation coefficient 
for each species are shown in Figure 4.7B. These results conclusively show that the mutant 




Table 4.5. PSCA- Monte Carlo results (straight-line parameterization) from 
HARS sedimentation velocity experiment.  
Values in parenthesis are 95% confidence intervals from the Monte Carlo analysis. The theoretical molar 
mass of HARS WT dimer is 114.9 kDa, indicating the observed species is a dimer. The residual mean 
square deviation (RMSD) of the fit is shown in units of absorbance at 230 nm. 
 
The work described thus far suggests that the Y454S substitution has minimal effect 
on substrate recognition (when assessed kinetically) and overall dimer formation. 
However, these prior analyses might not be able to detect subtler structural effects, such as 
those associated with localized protein unfolding. To test this hypothesis, we used 
differential scanning fluorimetry (DSF) to measure the transition temperature for molten 
globular formation, which will be referred to herein as Tm. Melting profiles were initially 
performed in the absence of substrates, yielding Tm’s of 50.7 ± 0.4 °C and 45.5 ± 0.7 °C for 
WT and Y454S HARS, respectively (Figure 4.8B, summarized in Table 4.5). The 5 °C 
temperature decrease observed with the mutant relative to WT provided the first evidence 
in temperature instability for Y454S. The unliganded melting profile for Y454S was only 
2°C higher than the value determined for ts R362H (44.1 ± 0.2 °C), a bonafide temperature 
sensitive mutant in HARS described earlier[18]. The close Tm values for Y454S and 
R362H support the conclusion that the Y454S substitution destabilizes the HARS enzyme 
structure in a manner similar to R362H and in fact confers temperature sensitivity. 
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Figure 4.8. Y454S mutation is thermally less stable relative to WT HARS. 
10 µM enzyme (WT black circles, Y454S red triangles and R362H blue squares) was 
incubated with Sypro Orange dye in the absence (filled symbols) of substrate, or presence 
of 5 mM histidine (empty symbols). A) Wild type ± histidine. B) Wild type vs. Y454S. C) 
Y454S ± histidine. D) R362H ± histidine. Thermal shift results are from two preparations 
of WT and Y454S enzymes each measured in triplicate. 
 
Previously, it has been shown that histidine is a stabilizing substrate for HARS[19]. 
We therefore evaluated the effect of all three HARS substrates on the apparent melting 
transition of the enzymes. Consistent with the conclusions that histidine stabilizes the 
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HARS active site, the addition of 5 mM histidine increased the Tm for all three enzymes by 
6.3 - 8 °C. By contrast, ATP and tRNAHis showed less pronounced stabilizing effects on 
Tm, providing increases in the Tm in the range of 1 - 2 °C for both WT and Y454S mutant 
enzymes. Interestingly, the R362H substitution exhibited larger stabilizing effects for these 
substrates, corresponding to 4.1 and 7.2 °C for ATP and tRNA, respectively. In summary, 
both Y454S and R362H HARS displayed significant decreases in thermal stability relative 
to the WT protein, in the presence and absence of substrates. While both substitutions could 
be described as conferring temperature sensitivity, the two mutations were distinguished 
by different responses to individual substrates, with R362H exhibiting substantially 
increased stability with binding all three substrates, and Y454S responding only to histidine 
















Table 4.6: Thermal stability of HARS enzymes with substrates  
Enzyme Tm °C  Δ Tm °Ca Δ Tm °Cb 
WT  51.7 ± 0.4c  - 
WT + histidine 58.8 ± 0.4 7.0 - 
WT + ATP 53.8 ± 0.2 2.0 - 
WT + tRNAHis 53.4 ± 0.4 1.7 - 
Y454S 46.3 ± 0.7c - -5.4 
Y454S + histidine 54.4 ± 0.5 8.1 -4.4 
Y454 + ATP 47.0 ± 0.5 0.7 -6.8 
Y454S + tRNAHis 48.5 ± 0.4 2.2 -4.9 
R362H 44.1 ± 0.2c - -7.7 
R362H + histidine 50.4 ± 0.4 6.3 -8.4 
R362H + ATP 48.2 ± 0.5 4.1 -5.6 
R362H + tRNAHis 51.3 ± 0.3 7.2 -2.1 
 
aRelative to the apo form of the same enzyme. bRelative to the same form of WT HARS enzyme. Values 
reported are the mean ± standard error of 2 independent experiments in triplicate (1 experiment in triplicate 
for R362H). cValues that are significantly different WT to Y454S or R362H, p<0.0001 (extra sum-of-squares 
F test). #Concentaration of tRNAHis tested was 10 uM *Concentration of tRNAHis tested was 20uM.  
 
4.2.6 Elevated temperature results in lowered de novo protein synthesis in patient 
fibroblasts.  
The observed reduced thermal stability of the Y454S substituted HARS and the 
clinical association of acute illnesses including hallucinations and interstitial lung disease 
with febrile events in USH3B patients prompted us to assess the incorporation of 3H–
histidine into total protein, a measure of cellular protein translation, in cultured WT and 
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Y454S human primary fibroblasts. WT and Y454S fibroblasts incorporated 3H–histidine 
into cultured fibroblasts at the same rate at 37 °C. However, when the fibroblasts were 
cultured at 43 °C, the incorporation of 3H –histidine into total cellular protein in the WT 
fibroblasts was about 7 –fold greater than in the Y454S fibroblasts. (Figure 4.9).  Thus, the 
temperature sensitivity of Y454S detected in vitro has consequences for protein synthesis 
in vivo. 
 
Figure 4.9. Human fibroblasts from patients with the Y454S mutation 
demonstrate less de novo protein synthesis at elevated temperatures than wild type 
cells.  
Scatter plot showing 3H-histidine incorporation into total cellular protein (values 
normalized to cellular DNA), Y454S cells (circles) and wild type cells (squares). Values 
shown include three replicates each for three Y454S cell lines and three replicates each 
for six wild type cell lines (culture temperature 37 °C solid symbols, 43 °C open 





In this study, we critically evaluated the hypotheses that USH3B results from a 
decrease in canonical HARS catalyzed aminoacylation function. Rates were determined 
for both partial reactions, including the amino acid activation and aminoacyl transfer steps, 
and the overall rate of aminoacylation. The main conclusion from these studies is that, 
under the conditions examined, no significant differences in aminoacylation could be 
observed in a comparison of WT and Y454S. At the gross structural level, sedimentation 
velocity experiments revealed no difference in the strength of dimer formation. By contrast, 
the DSF assay indicated that the two proteins exhibited significant differences in the Tm. 
In addition, translation was significantly impaired in USH3B patient fibroblasts at elevated 
temperatures. These results provide a new context to rationalize the linkage of the Y454S 
HARS mutant to USH3B. 
4.3.1 Structural context of the Y454S substitution, and its apparent minimal effect 
on aminoacylation.  
The USH3B Y454S substitution is located on helix 15 on the surface of the 
anticodon-binding domain, which is located proximal to the dimer surface of the catalytic 
domain of the opposing monomer [10]. The substitution of serine for Tyr454 (Figure 4.1B) 
changes the hydrophobic character of this position, while also removing a likely hydrogen 
bond with Glu 439. Tyr454 is conserved among eukaryotic species extending from the 
human to yeast (Saccharomyces) [19]. In bacterial species (such as Escherichia coli and 
Staphylococcus aureus) however, the residue corresponding to Y454 positions is a charged 
residue, and in the case of Thermus thermophilus, hydrophobic. The helix harboring the 
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Y454S substitution in the anticodon-binding domain is predicted to make direct or indirect 
contacts to the phosphodiester backbone of the tRNA anticodon arm[20]. While initial 
expectations were that the mutation might affect binding affinity to tRNA, our results 
indicate that tRNA binding specificity of Y454S was not disrupted (Figure 4.4). Previously, 
an Escherichia coli HisRS mutant with the double substitution of G96D and R104H was 
uncovered in a genetic selection for altered tRNA binding specificity[21]. Kinetic 
characterization of the mutant protein showed that it exhibits reduced discrimination for 
the specific sequence of the tRNAHis anticodon [21]. While the similar location of R104 
and Y454 in the catalytic:anticodon-binding domain interface encourages one to speculate 
about similar functional effects, the E. coli mutant enzyme with the single R104H mutation 
remains to be characterized. Modeling studies of the human HARS:tRNAHis complex (not 
shown) suggest that Y454 is likely to have at most only an indirect effect on tRNA binding 
through perturbations of contacts to the phosphodiester backbone, which is in agreement 
with our results. 
A detailed analysis of human HARS kinetics showed that with respect to the 
individual half reactions of amionacylation and with respect to all parameters examined, 
WT and Y454S were virtually equivalent. Key parameters that were essentially equivalent 
for the two enzymes included the Km for tRNA and the overall kcat for aminoacylation when 
tRNA was the variable substrate. When histidine was the variable substrate in the presence 
of saturating tRNA Y454S HARS was slightly more active, as reflected in a higher kcat and 
slightly lower Km.  
The discrepancy in values of kcat between conditions where tRNA was saturating 
and conditions where histidine was saturating could arise from several sources. One 
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possibility is that there is a discrepancy in the calculation of active sites for different 
preparations, which would affect the values of kcat. Alternatively, the Y454S mutant could 
have a bona fide differential interaction with tRNA, leading to either an increased 
percentage of correctly folded protein in the presence of saturating tRNA, or a faster 
dissociation of aminoacylated product. Either scenario highlights the fact that kcat measures 
the limiting rate in the overall catalytic cycle, and incorporates all elementary steps 
including product release. Clearly, not all of these features nor the full catalytic 
contribution of the dimeric structure (e.g. potential alternating catalysis in the two active 
sites of the dimer [17] are captured in the pre-steady state experiments. In any event, the 
increase in kcat seen with Y454S HARS is relatively slight, and supports the conclusion that 
the effect of the mutant in Usher syndrome is unlikely to be due to a loss in catalytic 
efficiency, as measured in a purified system.  
These findings support the conclusions of an earlier study that reported less than a 
two-fold difference in aminoacylation functions of the WT and Y454S enzymes [9]. 
Notably, the values of Km for tRNAHis determined in the two studies were virtually 
identical, despite the fact that the earlier study employed murine enzyme preparations and 
total human tRNA as substrate. 
Adenylation kinetics determined in the presence of tRNA highlighted a potential 
difference from the E. coli enzyme. In the E.coli enzyme, the progress curve for the 
formation of AMP in the absence of tRNA is best described as a double exponential 
followed by a linear rate [13]. In the presence of tRNA, these complex kinetics reduce to a 
linear progress curve over multiple turnovers [16]. This was interpreted to suggest that the 
presence of tRNA inhibits the rate of amino acid activation in the first subunit of the dimer, 
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while increasing the same rate in the second subunit. The equalization of rates is thought 
to reflect the coupling of activities of the two active sites in the dimer and the linkage of 
dissociation of product from subunit one to formation of product in subunit two [13]. The 
rate of adenylation in the human HARS enzyme did not show the same attenuation by the 
presence of tRNA, suggesting a potential mechanistic difference between these structurally 
similar enzymes. This difference remains to be explored further in additional experiments. 
4.3.2 The Y454S substitution is less thermally stable compared to wild type HARS.  
While the results of standard aminoacylation assays argue strongly against the 
model that the USH3B phenotype arises from an aminoacylation defect, the potential 
structural changes (Figure 4.1B) suggest a possible decrease in protein stability by virtue 
of the weakening intra- or inter-domain interactions. Here, we used sedimentation velocity 
analysis to assess the dimer status of the mutant, and saw no apparent weakening of dimeric 
structure (Figure 4.7). SV experiments characterize the solution behavior of 
macromolecules and report on the sedimentation and diffusion behavior of all species in a 
mixture. Information is also provided about the partial concentrations of various species, 
buoyant molar masses, and anisotropies. Even at low concentrations, HARS and the 
temperature sensitive mutants maintained their dimeric structure, indicating the mutation 
alone does not alter enzyme dimerization, consistent with the binding and kinetic analyses. 
Originally developed as a high throughput method for quantitatively assessing the 
strength of small molecule protein interactions, the DSF assay has proven useful in other 
contexts, such as profiling protein constructs for their suitability in crystallographic studies. 
Here, DSF assays were used to indirectly compare the Tm of WT and Y454S HARS, and 
the effects of substrates on protein stability. The clear result was that the Y454S 
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substitution decreases the Tm for HARS in the range of 5-6 °C. Moreover, as evidenced by 
the gain in Tm, each of the three canonical substrates (His, ATP and tRNAHis) provided the 
same enhancement of protein stability as seen with WT HARS. This supports the earlier 
conclusion that Y45S has minimal effect on the recognition of any of individual substrates, 
versus overall stability. By contrast, the R362H mutant showed increased Tm in the 
presence of ATP and tRNA relative to the other proteins, suggesting a greater propensity 
to stabilization by these substrates. It will be of interest to determine whether this signature 
holds true for other bona fide temperature sensitive mutants. 
The inability of fibroblast cultures from patients with the HARS Y454S mutation 
to incorporate [3H]-histidine into total cellular protein at elevated temperature, when 
compared to control fibroblasts, is a key finding. Notably, there was no difference in 
incorporation at 37 °C, but only when the cell was stressed at 43 °C. Although the 
temperature used in the cell culture experiments cannot be directly compared with febrile 
conditions in patients or with the DSF results, this finding comports with the clinical 
observation that febrile illnesses evoke the USH3B phenotype [9], 
These observations and the qualitatively similar results obtained with R362H 
HARS strongly suggest that decreased temperature stability underlies the molecular basis 
of the USH3B syndrome. This interpretation is supported by the direct experimental 
comparison of Y454S HARS to the R362H substitution (Figure 4.8D). The latter mutant 
was derived from the tsBN250 BHK cell line, which was isolated in an unbiased screen for 
cell cycle arrest mutants [18, 22]. Consistent with a temperature sensitive phenotype, 
tsBN250 cells exhibited decreased cell growth and increased apoptosis at elevated 
temperatures. In both the tsBN250 and related tsBN269 BHK cells (which carry a ts LysRS 
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allele), cell cycle arrest was attributed to decreased cyclin D1 production, which resulted 
from decreased 3H incorporation into the total protein pool. Growth defects could be 
overcome by supplementation of high concentrations of histidine or inducing expression 
of cyclin D1[18]. Given that Y454S and R362H HARS are accompanied by similar 
decreases in protein stability, we can hypothesize that elevated temperatures (or other 
physiological stresses) might cause reduced protein synthesis in the mutant cells, leading 
to cell cycle arrest and apoptosis. In a specific G296D ValRS mutant isolated in C. elegans, 
altered editing domain function is predicted to reduce global translation by inappropriately 
deacylating Val-tRNAVal at high temperatures. The reduction in aminoacylated Val-
tRNAVal subsequently results in mitotic cell arrest of stem cells within the organism[23]. 
This hypothesis might at first glance appear to contradict some observed features 
of Y454S HARS, including the lack of an apparent effect on intracellular protein levels[9] 
and a lack of an effect on primary aminoacylation function (this work). Of note, the 
intracellular protein levels were determined in unstressed cells cultured at normal 
temperature [9]. Again, the comparison with R362H HARS is instructive. Notably, no 
apparent degradation of the R362H enzyme was observed in tsBN250 BHK at increased 
temperatures[18, 22]. Further, thermal sensitive aminoacyl-tRNA synthetase mutations 
were originally described as mutations that disrupt normal cellular growth and division, 
and sensitivity to increased temperature in CHO cell lines with ARS defects could be 
alleviated by high concentrations of cognate amino acid[24]. These CHO cell lines are His-
1, with a temperature sensitive mutation in HisRS, and Arg-1, with a temperature and 
arginine-sensitive mutation in arginyl-tRNA synthetase[24]. Curiously, while His-1 and 
Arg-1 CHO cell lines showed decreased 3H incorporation into the total protein pool, there 
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was not a clear impairment of aminoacylation activity in vivo[24]. Accordingly, our 
inability to detect decreased aminoacylation function with Y454S HARS under specified 
in vitro conditions may not rule out the possibility of decreased function in vivo, 
particularly at elevated temperatures. Along these lines, it should prove instructive to 
conduct a kinetic characterization of the R362H enzyme, and determine whether or not it 
too exhibits relatively robust aminoacylation function in vitro.  
4.3.3 Comparison to other ARS linked diseases.  
Our study adds to a growing body of literature in which mutations encoding 
missense substitutions in aminoacyl-tRNA synthetases have been linked to a variety of 
neurological disorders, most notably CMT syndrome [25, 26]. Among the tRNA 
synthetases implicated in this way are GlyRS[26-28], AlaRS[29, 30], GlnRS[31], 
LysRS[32], and TyrRS[33]. While for many of these examples a significant loss in 
aminoacylation function has been documented[26-28], there are also a few notable reports 
where retention of aminoacylation activity has been claimed[34, 35]. These latter examples 
raise the possibility that, at least for some ARS-linked diseases, the molecular basis of 
pathophysiology may arise from features that are distinct from a loss of primary function 










Here, we have shown that perturbation of the primary aminoacylation function is 
unlikely to fully account for the basis of disease for the Y454S mutation, as compared to 
other ARS mutants linked to CMT that exhibit a clear loss of aminoacylation function when 
measured in vitro[28]. Further work will be necessary to determine how the thermal 
instability of the Y454S HARS enzyme plays a role in USH3B disease progression in the 
context of the cellular environment. A multi-factorial approach will be required, with 
investigations into the role of Y454S in the cellular stress response and Y454S HARS 
interactions with other proteins, which may entail HARS secondary functions, yet to be 
identified. 






1. Millan, J.M., et al., An update on the genetics of usher syndrome. J Ophthalmol, 
2011. 2011: p. 417217. 
2. Yan, D. and X.Z. Liu, Genetics and pathological mechanisms of Usher syndrome. 
J Hum Genet, 2010. 55(6): p. 327-35. 
3. Weil, D., et al., Usher syndrome type I G (USH1G) is caused by mutations in the 
gene encoding SANS, a protein that associates with the USH1C protein, harmonin. 
Hum Mol Genet, 2003. 12(5): p. 463-71. 
4. Di Palma, F., et al., Mutations in Cdh23, encoding a new type of cadherin, cause 
stereocilia disorganization in waltzer, the mouse model for Usher syndrome type 
1D. Nat Genet, 2001. 27(1): p. 103-7. 
5. Reiners, J., et al., Molecular basis of human Usher syndrome: deciphering the 
meshes of the Usher protein network provides insights into the pathomechanisms 
of the Usher disease. Exp Eye Res, 2006. 83(1): p. 97-119. 
6. Reiners, J. and U. Wolfrum, Molecular analysis of the supramolecular usher 
protein complex in the retina. Harmonin as the key protein of the Usher syndrome. 
Adv Exp Med Biol, 2006. 572: p. 349-53. 
7. Weil, D., et al., Defective myosin VIIA gene responsible for Usher syndrome type 
1B. Nature, 1995. 374(6517): p. 60-1. 
8. Ebermann, I., et al., A novel gene for Usher syndrome type 2: mutations in the long 
isoform of whirlin are associated with retinitis pigmentosa and sensorineural 
hearing loss. Hum Genet, 2007. 121(2): p. 203-11. 
9. Puffenberger, E.G., et al., Genetic mapping and exome sequencing identify variants 
associated with five novel diseases. PLoS One, 2012. 7(1): p. e28936. 
10. Xu, Z., et al., Internally deleted human tRNA synthetase suggests evolutionary 
pressure for repurposing. Structure, 2012. 20(9): p. 1470-7. 
11. Koh, C.Y., et al., Comparison of histidine recognition in human and 
trypanosomatid histidyl-tRNA synthetases. Biochimie, 2014. 106: p. 111-20. 
12. Katze, J.R. and W.R. Farkas, A factor in serum and amniotic fluid is a substrate for 
the tRNA-modifying enzyme tRNA-guanine transferase. Proc Natl Acad Sci U S A, 
1979. 76(7): p. 3271-5. 
13. Guth, E., et al., Asymmetric amino acid activation by class II histidyl-tRNA 
synthetase from Escherichia coli. J. Biol. Chem., 2009. 284(31): p. 20753-62. 
14. Fahoum, S.K. and D.C. Yang, Purification of mammalian histidyl-tRNA synthetase 
and its interaction with myositis-specific anti-Jo-1 antibodies. Biochemistry, 1987. 
26(18): p. 5871-7. 
15. Kane, S.M., et al., Purification and some properties of the histidyl-tRNA synthetase 
from the cytosol of rabbit reticulocytes. Biochemistry, 1978. 17(8): p. 1509-14. 
16. Guth, E., et al., A substrate-assisted concerted mechanism for aminoacylation by a 
class II aminoacyl-tRNA synthetase. Biochemistry, 2005. 44(10): p. 3785-94. 
 166 
17. Guth, E.C. and C.S. Francklyn, Kinetic discrimination of tRNA identity by the 
conserved motif 2 loop of a class II aminoacyl-tRNA synthetase. Mol Cell, 2007. 
25(4): p. 531-42. 
18. Motomura, S., et al., A hamster temperature-sensitive G1 mutant, tsBN250 has a 
single point mutation in histidyl-tRNA synthetase that inhibits an accumulation of 
cyclin D1. Genes Cells, 1996. 1(12): p. 1101-12. 
19. Koh, C.Y., et al., Comparison of histidine recognition in human and 
trypanosomatid histidyl-tRNA synthetases. Biochimie, 2014. 106C: p. 111-120. 
20. Tian, Q., et al., Structural basis for recognition of G-1-containing tRNA by histidyl-
tRNA synthetase. Nucleic Acids Res, 2015. 
21. Yan, W., J. Augustine, and C. Francklyn, A tRNA identity switch mediated by the 
binding interaction between a tRNA anticodon and the accessory domain of a class 
II aminoacyl-tRNA synthetase. Biochemistry, 1996. 35(21): p. 6559-6568. 
22. Fukushima, K., et al., A single point mutation of hamster aminoacyl-tRNA 
synthetase causes apoptosis by deprivation of cognate amino acid residue. Genes 
Cells, 1996. 1(12): p. 1087-99. 
23. Rastogi, S., et al., Caenorhabditis elegans glp-4 Encodes a Valyl Aminoacyl tRNA 
Synthetase. G3 (Bethesda), 2015. 5(12): p. 2719-28. 
24. Thompson, L.H., D.J. Lofgren, and G.M. Adair, CHO cell mutants for arginyl-, 
asparagyl-, glutaminyl-, histidyl- and methionyl-transfer RNA synthetases: 
identification and initial characterization. Cell, 1977. 11(1): p. 157-68. 
25. Sivakumar, K., et al., Phenotypic spectrum of disorders associated with glycyl-
tRNA synthetase mutations. Brain, 2005. 128(Pt 10): p. 2304-14. 
26. Antonellis, A., et al., Functional analyses of glycyl-tRNA synthetase mutations 
suggest a key role for tRNA-charging enzymes in peripheral axons. J Neurosci, 
2006. 26(41): p. 10397-406. 
27. Deng, X., et al., Large Conformational Changes of Insertion 3 in Human Glycyl-
tRNA Synthetase (hGlyRS) during Catalysis. J Biol Chem, 2016. 291(11): p. 5740-
52. 
28. Griffin, L.B., et al., Impaired function is a common feature of neuropathy-
associated glycyl-tRNA synthetase mutations. Hum Mutat, 2014. 35(11): p. 1363-
71. 
29. Simons, C., et al., Loss-of-function alanyl-tRNA synthetase mutations cause an 
autosomal-recessive early-onset epileptic encephalopathy with persistent 
myelination defect. Am J Hum Genet, 2015. 96(4): p. 675-81. 
30. McLaughlin, H.M., et al., A recurrent loss-of-function alanyl-tRNA synthetase 
(AARS) mutation in patients with Charcot-Marie-Tooth disease type 2N (CMT2N). 
Hum Mutat, 2012. 33(1): p. 244-53. 
31. Zhang, X., et al., Mutations in QARS, encoding glutaminyl-tRNA synthetase, cause 
progressive microcephaly, cerebral-cerebellar atrophy, and intractable seizures. 
Am J Hum Genet, 2014. 94(4): p. 547-58. 
32. McLaughlin, H.M., et al., Compound heterozygosity for loss-of-function lysyl-tRNA 
synthetase mutations in a patient with peripheral neuropathy. Am J Hum Genet, 
2010. 87(4): p. 560-6. 
 167 
33. Jordanova, A., et al., Disrupted function and axonal distribution of mutant tyrosyl-
tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat 
Genet, 2006. 38(2): p. 197-202. 
34. Froelich, C.A. and E.A. First, Dominant Intermediate Charcot-Marie-Tooth 
disorder is not due to a catalytic defect in tyrosyl-tRNA synthetase. Biochemistry, 
2011. 50(33): p. 7132-45. 
35. van Berge, L., et al., Pathogenic mutations causing LBSL affect mitochondrial 
aspartyl-tRNA synthetase in diverse ways. Biochem J, 2013. 450(2): p. 345-50. 
 168 
 
5.0 DISCUSSION AND FUTURE DIRECTIONS  
The HARS system represents a notable example in which two different complex 
human diseases arise from distinct mutations in the same parent gene. Results from kinetic 
assays described demonstrated that all of the HARS CMT variants have catalytic defects. 
From these studies the structural integrity of only two mutations were compromised 
V155G and R137Q. However, all CMT variants can form stable dimers. Additionally, 
assays utilizing neuronal PC12 cells have established that CMT variants can reduce the 
average neurite length. Furthermore, CMT HARS variants were localized out to the distal 
most end of processes in PC12 cells.  
By contrast, the recessive HARS USH3B variant, Y454S, was shown to be 
kinetically indistinguishable from WT for the independent catalytic steps as well as for the 
overall aminoacylation reaction. Interestingly, the Y454S variant also formed stable dimers 
but is thermally unstable. This single biochemical characteristic reduces aminoacylation at 
elevated temperatures, and likely accounts for the pathogenicity of Y454S. Data in this 
thesis emphasizes that while some dominant variants have catalytic defects, one cannot 
always assume that variants are going to be a clear loss of aminoacylation function. 
 
5.1 The structural locations of pathogenic variants 
In the case of HARS, the different disease variants are restricted to different 
domains – CMT variants are localized to the catalytic domain, while the USH3B and 
R362H variants are restricted to the anticodon binding domain. Previously, four additional 
HARS variants identified in patients with peripheral neuropathy [1], were found to also 
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localize to the catalytic domain (Figure 1) [2]. These four variants (T132I, D175E, P134H, 
and D365Y) can be found in motifs that have essential functions in the amino acylation 
reaction. T132I is found in a histidine binding motif ‘TXE’ within the catalytic domain, 
P134H is located in the same helix as R137Q (although it does not mediate cross dimer 
interactions), D175E is localized to motif loop 2 and D364Y is found in the HARS family 
conserved His B motif (Figure 5.1). While two of these substitutions do not apparently 
alter direct contacts with substrate, they may indirectly alter enzyme structure and perturb 
aminoacylation activity, as was the case for V155G. To date, all known HARS CMT 
mutations are located in the catalytic domain. 
By comparison, the 12 GARS variants that have been associated with CMT disease 
are distributed over all major domains of the protein, including the WHEP domain, 
catalytic domain, anticodon binding domain, and in the relatively unstructured insertion 
loops [2]. Initial attempts to map many of the original GARS CMT variants to an 
unliganded structure of GARS led to the proposal that, instead of loss of aminoacylation, 











Figure 5.1. Four additional HARS CMT variants that are localized to the catalytic 
domain.  
Variants are shown as red sticks with histidine bound and shown as green sticks. 
 
For at least some of the variants, this hypothesis was supported by the results of 
sedimentation equilibrium experiments, which indicated that several (e.g, L129P, G240R) 
displayed increased Kd for dimer dissociation, and two (G526R and G598A) exhibited 
reduced dissociation constants for dimerization. The recent X-ray structure of the GARS-
tRNAGly complex provides an opportunity to re-examine the question of how GARS CMT 
variants might exert their effects on GARS structure and function [4]. The results of that 
re-examination suggest that CMT-associated GARS variants proteins can be broken into 
three groups: (1) those variants that specifically disrupt the dimeric interface (L129P, 
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G240R, and potentially H418R); (2) those mutants that likely disrupt interactions with ATP 
or tRNA (P244L, I280F, G526R, and G598A); and (3) those variants which are located 
away from substrate binding regions, or are located in loop regions not defined in the 
existing structures (A57V, E71G, D146N, C157R, D500N). Of note, the variants that lack 
aminoacylation function fall into Groups 1+2, while the partially active mutants fall into 
Group 3. Hence, in GARS, as in other aaRSs, loss of aminoacylation appears to correlate 
with disruption of either interaction with substrates and/or the opposing monomer. 
Conversely, variants (e.g., E71G and D500N) that do not appear to affect aminoacylation 
(i.e., based on the in vitro assays used) are either distal to interactions with substrates or 
are located in unstructured regions of the enzyme. 
As earlier studies attributed disruptions in dimerization as the pathogenic variable 
for many of the GARS mutations this is clearly not the case for HARS. Hence, 
perturbations to the dimeric nature of aaRS enzymes are unlikely to completely satisfy the 
requirement for pathogenesis. However, a notable characteristic that many aaRS variants 
share is their high level of evolutionary conservation [2]. Hence, it is likely that either 
variants perturb aminoacylation activity or disrupt structure and leads to disease 
progression [2]. 
 
5.2 Pathology is linked to a reduction in protein synthesis  
As aaRS enzymes are essential for protein synthesis, it raises the question as to how 
perturbations in protein synthesis contribute to disease without conferring lethality. Results 
of the enzyme assays described in this thesis emphasize that CMT HARS variants localized 
to the catalytic domain do disrupt the process of aminoacylation to varying extents. The 
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four HARS mutations linked to CMT described here have defects in aminoacylation 
activity. While HARS CMT variants clearly have catalytic defects, similar observations 
have been made previously for other CMT-associated aaRS enzymes. Notably, GARS 
CMT variants have been characterized with respect to aminoacylation at varying degrees 
of completeness. Some have been characterized with respect to Michaelis–Menten 
parameters as a function of tRNA concentration [5] while others have only been 
characterized as either single end-point assays or a single-product progress curve at one 
concentration of enzyme and substrates [3]. Further, KARS [6], AARS, HARS [1], and 
MARS [7] biochemical analysis suggests that the CMT-linked mutations in each case 
confer at least a partial loss of aminoacylation function.  
While GARS and YARS enzymes also contain multiple CMT-linked variants, 
many of which have defective aminoacylation, there are some that appear to retain 
significant activity. In the case of YARS, the G41R and 153-156DVKQV variants are 
reported to have significantly reduced activity [8] but the E196K variant appears to be 
much more active, or even unaffected [9]. However, the E196K variant and another CMT-
associated variant at the same codon (E196Q) were unable to fully support yeast cell 
growth in complementation studies [8, 10]. Studies employing a D. melanogaster model 
of CMT showed that, despite its near wild type activity in vitro, the E196K YARS variant 
leads to decreased protein synthesis rates in flies [11]. In the Drosophila system, over-
expression of selected GARS and YARS variants (E71G and E196K, respectively) led to 
defects in motor neuron performance, shortened lifespan, and were highly correlated with 
reduced protein synthesis. Notably, the variants exhibited aminoacylation activity in vitro 
and produced high levels of aminoacylated tRNA in vivo. Based on these results, the 
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authors concluded that the variants exhibit a dominant negative effect on protein synthesis 
that could not be reversed by over expression of the wild type protein. The mechanism that 
leads to the cellular inhibition of protein translation was not determined.  
In our studies of Type IIIB Usher Syndrome, we have also observed that, despite 
the essentially wild type levels of aminoacylation activity in vivo, patient fibroblasts 
homozygous for the mutation exhibit reduced protein synthesis at the an elevated 
temperature [12]. Increasing the temperature for in vitro aminoacylation assays did not 
reduce the enzyme activity of either WT or Y454S HARS (Figure 5.2). Again, in vitro 
aminoacylation assays fail to recapitulate the observations from the patient cells. By 
contrast, the temperature sensitive R362H HARS variant did not appear to have activity 
equivalent to WT under these conditions. Preliminary multiple turnover kinetics titrating 
tRNAHis as the variable substrate indicated that R362H has activity comparable to WT 
HARS when measure at 37℃ (Figure 5.3). However, definitive conclusions regarding the 
catalytic activity of R362H HARS awaits further replicates and additional assays with 
varying histidine and ATP concentrations. When this information is in hand, a more 




Figure 5.2. Aminoacylation as a function of increasing temperature.  
Time course of aminoacylation activity for 1 nM WT (black circles) and Y454S (red 
triangles) HARS at 40℃ with low histidine (2𝜇𝑀) with saturating ATP (10 mM) and 
1𝜇𝑀 tRNAHis (n=3) (B) Aminoacylation as a function of increasing temperature 
(37℃, 40℃, 41℃	) with saturating histidine and ATP (10 mM) and 5	𝜇𝑀 tRNAHis for 5 
nM WT (black circles), Y454S (red triangles) and R362H (blue squares) (n=3). 
 




















































Figure 5.3. R362H multiple turnover aminoacylation kinetics.  
Aminoacylation by R362H (10nM) with tRNAHis as the variable substrate (n=3) 
 
The observations that patient fibroblasts display significantly reduced incorporation 
of histidine into the total protein pool raises questions regarding in vitro conditions and the 
link between the mutant protein activtity with the phenotype. This observation could 
indicate that the enzyme activity within the context of the cell is reduced. An additional 
control using a different amino acid, such as 14C-Thr or 14C-Leu, might help indicate if 
under heat shock conditions the reduction in translation is global, rather than being specific 
to histidine and HARS activity. Additionally, detection of reduced aminoacylated tRNAHis 
from patient cell lysates could also indicate if reduced histidine incorporation is specifically 
linked to reduced HARS aminoacylation activity. Interestingly, this type of global 
reduction in translation activity has been described in a GARS Drosophila model of CMT, 
utilizing click-chemistry to visualize protein translation [11]. Similar methods to visualize 
global translation of USH3B patient cells during heat shock could be informative, and 
validate our initial observations.  
























One plausible mechanism for reduced protein translation by Y454S during heat 
shock involves the structural instability revealed by DSF. While in vitro aminoacylation 
reactions have demonstrated that the enzyme can aminoacylate tRNAHis even at elevated 
temperature although these assays do not truly reflect translational events occurring in the 
cellular environment. After aminoacylation of tRNAHis, elongation factor 1 alpha (eEf1a) 
is responsible for the transportation of aminoacylated tRNA to the ribosome. Previously, it 
was demonstrated that, as eEf1a is a GTPase, increasing GTP levels can directly increase 
HARS activity. The addition of an antibody against eEF1a in these assays dampened the 
affect [13]. If during heat shock Y454S is structurally altered such that it disrupts the hand-
off of aminoacylated tRNAHis to eEF1a, then a reduction in histidine incorporation might 
be apparent. This point reiterates the need to address protein synthesis in the context of the 
cell from patient cells in response to heat shock conditions.  
A key question that emanates from these analyses is how the translational defects 
we observe preferentially affect certain tissues. The peripheral nerves and the sciatic nerve 
in particular, is the largest and has the longest axonal processes in the body. Localized 
translation in remodeling the synaptic proteome and along axons has become increasingly 
recognized as an important process for neuronal homeostasis [14]. How aaRS enzymes and 
other essential components of the protein translational machinery in these distal regions of 
neurons are regulated remain to be investigated. Given that the average neurite length of 
CMT transfected PC12 cells was observed to be shorter, experiments utilizing Click-
chemistry might be useful to address the issues of whether or not localized protein synthesis 
is disrupted along the axon and/or at the synapse. The concept that reduction in translation 
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can lead to tissue specific pathology is supported by a recent mouse model which revealed 
that reduction of a brain specific tRNAArg molecule, increased ribosomal stalling, leading 
to neurodegeneration of the cerebellum. This phenotype is exacerbated by the absence of 
GTP binding protein 2 (Gtpbp2) protein that aids in resolving ribosomal stalling [15].  
A systematic characterization for each CMT variant utilizing the biochemical 
studies described in this thesis are instrumental in determining the extent to which 
aminoacylation activity is affected. However, in light of the points discussed here new 
methods should be used to connect the loss of aminoacylation function to the cellular 
biology of disease. 
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5.3 ER stress as the pathological mechanism  
As noted above, a key observation is that under elevated temperatures, 
incorporation of histidine into total proteins was reduced. Accordingly, we suspect that ER 
stress may be activated. If histidine incorporation into the total protein pool is significantly 
reduced, then ribosomal stalling would likely increase, and lead to an increase of misfolded 
proteins. Misfolded proteins in the ER would then activate the unfolded protein response 
(UPR). UPR is mediated by three resident ER proteins; PRKR-like ER kinase (PREK), 
activating transcription factor 6α (AFT6a) and inositol-requiring protein 1α (IRE1a) 
signaling branches. When unfolded proteins build up in the ER, chaperone Binding 
immunoglobulin protein (Bip) dissociates from ATF6a. ATF6a then subsequently gets 
processed in the Golgi to short ATF6 (sATF6). As a transcription factor, sATF6 targets ER 
protein 57 (ERp57) and glucose-regulated protein (GRP) 94, proteins that serve as ER 
chaperones and aid in protein folding [16]. Additionally, IRE-1a released via disruption of 
Bip binding becomes phosphorylated activating its RNase activity to splice X-box binding 
protein 1 (XBP1) mRNA. The spliced and translated short XBP1 (sXBP1) translocates to 
the nucleus where it serves as a transcription factor and induces the expression of ER stress 
chaperones and genes responsible for ER-associated protein degradation (ERAD). In the 
final parallel UPR pathway, ER resident protein PERK also serves as a sensor to increased 
ER stress via BIP binding. The UPR initiated by PERK dimerization and 
autophosphorylation leads to phosphorylation of eukaryotic translation initiation factor 2α 
(eIF2a) which directly inhibits protein translation. Furthermore, chronic induction of 
apoptosis typically occurs through C/EBP homologous protein (CHOP) [16].  
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A central question that emerges here is the degree to which ER stress is a direct 
consequence of a loss of canonical aaRS function, or the destabilized of aaRS proteins 
themselves. Preliminary qRt-PCR experiments with patient fibroblast cells, following heat 
shock treatment, indicated that downstream targets of ER stress are upregulated compared 
to normal fibroblasts (Figure 5.4). The DNAJB9 transcript levels are regulated by IRE1a 
and is a Hsp40 family ERAD co-chaperon with protein folding chaperone Hsp70. While 
HSPA5 is regulated by ATF6 and interacts with multiple ER-associated proteins required 
to facilitate protein folding and degradation of misfolded proteins. Patient fibroblasts seem 
to be exceptionally sensitive not only to the four-hour heat shock but also histidinol 
mediated inhibition of HARS.   
 
Figure 5.4. Monitoring ER stress of patient fibroblasts by qRT-PCR.  
Data was kindly provided by Dr. Susan Robey Bond. 
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As mentioned previously, if HARS activity is reduced in the USH3B patient cells 
and a large pool of un-aminoacylated tRNA is present, the amino acid starvation response 
would likely be activated. The amino acid starvation response is a cellular response that 
converges on the unfolded response pathway through eIF2a. GCN2 kinase serves as a 
sensor to amino acid starvation by detection of un-aminoacylated tRNA. High levels of un-
aminoacylated tRNA molecules cause the GCN2 kinase to dimerize and phosphorylate its 
primary target eIF2a𝛼 which serves to down regulate translation.  
In the case of the Y454S variant, another reason histidine incorporation might be 
decreased in the patient cells is that levels of the enzyme itself are reduced. From DSF 
experiments, Y454S is less thermally stable than WT but maintains its dimeric structure. 
However, the cellular environment during heat shock may increase the structural instability 
of Y454S, such as reduced chaperone binding. Therefore, Y454S maybe more sensitive or 
unstable during physiologically relevant febrile temperatures of 101	º𝐹 to 104	º𝐹 or 
38.3	º𝐶 to 40	º𝐶. 
Previously, experiments involving treatment of HEK293 cells expressing either 
HARS WT, with proteasome inhibitor (MG132), failed to show the appearance of high 
molecular weight species during heat shock corresponding to increased ubiquitination. 
(Figure 5.5). However, this experiment was done using a cell line not physiologically 
relevant, with a plasmid that drives over expression, and only a 4-hour heat shock 
treatment, for which increased proteasome processing may not be apparent. It may be 
worthwhile to determine if during heat shock of USH3B patient cells, HARS levels are 




Figure 5.5. Heat shock of HEK293 cells in the presence of MG132. 
Data were generously provided by Dr. Susan Robey-Bond. HEK 293 cells were exposed 
to heat shock for 4 hours in the presence of MG132. Lysates were resolved by SDS-
PAGE and western-blotted for the presence of GFP and HARS. 
 
ER stress continues to be identified as a critical mediator in many disease states 
[17]. As the Y454S HARS variant is currently described as Usher syndrome, there are some 
key clinical differences that are not typical of Usher syndrome patients. The two most 
distinct presentations that make this variant as an Usher variant unique are the 
hallucinations patients experience during illness and the severe pulmonary phenotype. 
Other pulmonary diseases such as asthma [18] and cystic fibrosis [19, 20] can lead to 
specifically increased ER stress of these tissues. These diseases represent examples of ER 
stress activation in a tissue-specific nature and may explain the complexity of HARS 
disease associated variants. Moreover, ER stress is elevated in demyelinating CMT [21] 
and may present a common pathogenic mechanism that may be shared by the USH3B 
variant and CMT variants. 
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5.4 Perturbations of neuronal processes as a potential pathogenic mechanism  
Previous studies examining the links between mutations in aaRS genes and CMT 
have attempted to address the question of whether mutations lead to a change in the 
neuronal cell localization [3]. As human peripheral nerve axons can extend more than a 
meter in length, and transport of essential proteins to the cell periphery is likely to be 
essential for maintaining axonal function [22]. Evidence of local protein translation along 
axons and at synapses is ever increasing yet not well understood [14, 23]. It will be 
important to investigate if the HARS mutations described here also lead to local reductions 
in protein synthesis in vivo.  
Previously, investigations into the cellular localization of GARS CMT variants 
demonstrated that these variants do not localize to the synapse for local translation. 
Contrary to these results, our PC12 cell data shows that unlike some GARS variants that 
cannot localize the distal most regions of neurites – all of the HARS CMT variants 
examined here exhibited localization in distal regions. Despite these contradictory results, 
effects on local translation may not be ruled out. The absence of GARS protein would 
reduce levels of translation in the same capacity as trafficking out non-functional HARS 
protein. It will be interesting to evaluate with Click-chemistry and high resolution 
microscopy if changes in synapse translation are reduced by the presence of non-functional 
HARS proteins. In addition to our PC12 model we hope to validate the preliminary axonal 
shortening, with transgenic zebrafish that highlight the peripheral nervous system GFP and 
motor nervous system RFP.   
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In addition to a loss-of-function mechanism, multiple gain-of-function hypotheses 
have also been proposed, specifically for GARS mutations [24]. For example, a mouse 
model involving the ability of mutant monomeric GARS that alters neuronal signaling via 
binding to the VEGF receptor neuropilin-1 has been described [25]. As yet, this model has 
not yet been tested in the context of human diseases-causing alleles in GARS or in the 
genes of other ARSs linked to CMT disease. While the findings reported here do not 
explicitly address the neuropilin-1 hypothesis, our characterization of HARS mutant 
proteins indicates a loss of canonical catalytic function rather than weakened dimerization 
(Figure 5.5). Previously it was argued that the propensity of mutant GARS to bind to 
neuropilin-1 was linked to weakened dimer formation [26]. It is also striking that, despite 
the linkage of over 80 loci to CMT disease, neither mutations in neuropilin-1 nor in its 















Table 5.1. Protein interaction partners identified from SILAC.  
Experiments and data analyzed by Dr. Susan Robey-Bond. 
 
The USH3B variant instability may be indicative that Y454S likely has localized 
unfolded regions or has a somewhat structurally dissimilar anti-codon binding domain 
compared to WT HARS. As described above, an altered structure may encourage the 
association of new protein binding partners. Initial, stable isotope labeling with amino acids 
in cell culture (SILAC) experiments coupled with mass spectrometry of Y454S and WT 
transfected mouse otocyst cells (embryonic inner ear hair cells) highlight that under normal 
growth conditions, some protein-interaction partners differentially bind to Y454S 
compared with WT (Table 5.1). Interestingly, many of these proteins are involved in 
vesicular transport. Furthermore, the Y454S variant also preferentially binds endosomal 
trafficking protein Ras-related protein (Rab7) (SRB results). Curiously, mutations in Rab7 
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proteins are also associated with CMT [27]. We had hoped from these proteomic 
investigations, to identify Usher proteins, as potential binding partners, and the association 
of HARS with vesicular trafficking proteins maybe significant. Previous studies in 
zebrafish have indicated that if Usher proteins do not pre-assemble for trafficking to the 
stereocilia in the ER, chronic activation of ER stress will lead to apoptosis and inner ear 
hair cell death [28]. Yet again we come across another potential link between USH3B and 
CMT HARS variants to ER stress. 
5.5 Closing remarks  
This thesis has presented data that further supports a loss-of-function molecular 
pathology for CMT variants and provides key data, newly applied methods, and novel 
reagents for studying the pathological mechanism of aaRS-associated human disease. 
Additionally, the complex nature of the USH3B HARS variant results demonstrate that a 
loss-of-function may not be apparent in vitro. However, a key feature shared by these 
diseases associated variants is a reduction in activity. This thesis summarizes that ER stress 
is also a plausible disease mechanism that may be shared by these two distinct disease 
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